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RNA Interference for Improving the Outcome of Islet Transplantation and
Polymeric Micelle‑based
Micelle based Nanomedicine for Cancer Therapy
Abstract
Ex vivo gene transfer has been used to improve the outcome of islet transplantation for treating type I
diabetes. RNA interference is an effective approach for reducing gene expressions at the mRNA level. The
application of RNA interference to improve the outcome of islet transplantation was reviewed in Chapter
2, where I summarized biological obstacles to islet transplantation, various types of RNAi techniques,
combinatorial RNAi in islet transplantation, and different delivery strategies.
Upregulation of inducible nitric oxide synthase (iNOS) and subsequent product of radical nitric oxide (NO)
impair islet β cell function. Therefore, we hypothesized that iNOS gene silencing could prevent β cell
death. In Chapter 3, we designed and used siRNA to silence iNOS gene in a rat β cell line and human
islets. We found that siRNA inhibited rat iNOS gene expression and NO production in rat β cells in a dose
and sequence dependent manner. iNOS gene silencing also protected these β cells from inflammatory
cytokine‑induced apoptosis and increased their capacity to secret insulin. Although there was also dose
and sequence dependent iNOS gene silencing and NO production in human islets, the effect of iNOS gene
on apoptosis of islets was only moderate, as evidenced by 25‑30% reduction in caspase 3 activity and in
the percentage of apoptotic cells. Since an islet is a cluster of 20‑1000 cells, the transfection efficiency of
lipid/siRNA complexes into human islets was only 21‑28%, compared to effective transfection efficiency
(> 90%) in β cells.
Gene delivery vectors which can express a growth factor gene to promote revascularization and silence of
proapoptotic genes might be good for ex vivo genetic modification of islet prior to transplantation. Thus,
in Chapter 4, we constructed bipartite plasmid vectors to co‑express a vascular endothelial growth factor
(VEGF) cDNA and shRNA targeting iNOS gene. Firstly, shRNA sequences against human iNOS gene were
screened. Then, we determined the effect of different promoters and shRNA backbones on gene
silencing. The shRNA with H1, U6 and CMV promoters showed similar efficiency in iNOS gene silencing.
In addition, a conventional shRNA showed better silencing of iNOS gene, compared to shRNA containing
mir375 and mir30 backbones. A bipartite plasmid was also constructed with mir30‑shRNA and a VEGF
cDNA controlled by a single CMV promoter. This plasmid showed a better silencing effect compared with
plasmid without VEGF cDNA. In conclusion, we have successfully constructed bipartite vectors
co‑expressing a VEGF cDNA and a shRNA against iNOS gene. These vectors could be an attractive
candidate to improve the survival of transplanted islets.
The second part of research was focused on the study of polymeric micelle formulations for treating
cancers. Two key elements were integrated in my research projects: development of polymeric micelle
delivery systems; discovery of new therapeutics for better treatment of cancers.
The project described in Chapter 5 was carried out in collaboration with Dr. Miller's group at The University
of Tennessee Health Science Center. In this study, we showed that SMART‑100 effectively inhibited
HepG2 cell proliferation and was able to circumvent multiple drug resistance (MDR) in cancer cells.
SMART‑100 inhibited P‑gp activity, which may be responsible for its ability to overcome MDR. Since
SMART‑100 is poorly soluble in water, it was formulated in poly(ethylene glycol)‑b‑poly(D, L‑lactide)
(PEG‑PLA) micelles. The solubility of SMART‑100 was increased by more than 1.1x105folds. SMART‑100
loaded PEG‑PLA micelles could effectively inhibit HepG2 cell growth and arrest cell cycle progression at
G2/M phase, followed by cell apoptosis. Increased caspase 3 activity was also observed when HepG2
cells were treated with SMART‑100. The anticancer activity of SMART‑100 loaded PEG‑PLA micelles was
also evaluated on luciferase expressing C4‑2‑Luc cell lines by IVIS imaging. Our results suggest that
SMART‑100 has the potential to treat resistant cancers and PEG‑PLA micelles can be used to formulate

SMART‑100.
We are not only interested in using commercial polymers but also interested in designing new polymers
for micellar drug delivery. Therefore, the objective of study described in Chapter 6 was to design
lipopolymers for hydrophobic drug delivery. In this study, poly(ethylene
glycol)‑block‑poly(2‑methyl‑2‑carboxyl‑propylene carbonate‑graft‑dodecanol) (PEG-PCD) lipopolymers
were synthesized and characterized by 1H NMR, FTIR, GPC, and DSC. The critical micelle concentration
(CMC) of PEG‑PCD micelles was around 10-8 M and decreased with increasing length of hydrophobic
block. PEG‑PCD micelles could efficiently load a model drug embelin into its hydrophobic core and
significantly improve its solubility. The drug loading capacity was dependent on the polymer core
structure, but the length of hydrophobic core had little effect. PEG‑PCD formed both spherical and
cylindrical micelles, which were dependent on the copolymer structure and composition. Lipopolymers
PEG‑PCD with various hydrophobic core lengths showed similar drug release profiles, which were slower
than that of poly(ethylene glycol)‑block‑poly(2‑methyl‑2‑benzoxycarbonyl‑propylene carbonate)
(PEG‑PBC) micelles. Embelin loaded PEG‑PCD micelles showed significant inhibition of C4‑2 prostate
cancer cell proliferation, while no obvious cellular toxicity was observed for blank micelles.
In Chapter 7, we studied the use of paclitaxel and lapatinib loaded lipopolymer micelles for treating MDR
prostate cancers. Although paclitaxel remains effective in treating prostate cancer, its prolonged
treatment develops MDR due to the over‑expression of P‑gp. Our hypothesis is that combination of
paclitaxel and lapatinib, which is a potent P‑gp inhibitor, can overcome MDR in prostate cancers.
Paclitaxel and lapatinib loaded lipopolymer micelle formulations were developed and evaluated in vitro
with cell‑based assay. The paclitaxel and lapatinib combination effectively inhibited in vitro MDR cancer
cell proliferation, induced cell cycle perturbation and cell apoptosis. In contrast, monotherapy with
paclitaxel or lapatinib alone showed minimal anticancer effect. The combination therapy was further
investigated in vivo with athymic nude mice xenograft MDR tumor model. Similar to in vitro study,
paclitaxel (5 mg/kg) and lapatinib (5 mg/Kg) combination therapy significantly inhibited tumor growth in
vivo when compared to high dose paclitaxel (10 mg/kg) monothearpy. These studies indicate that the
paclitaxel and lapatinib loaded PEG‑PCD lipopolymer micelle formulation could be used to treat MDR
prostate cancers.
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ABSTRACT
Ex vivo gene transfer has been used to improve the outcome of islet transplantation for
treating type I diabetes. RNA interference is an effective approach for reducing gene
expressions at the mRNA level. The application of RNA interference to improve the
outcome of islet transplantation was reviewed in Chapter 2, where I summarized
biological obstacles to islet transplantation, various types of RNAi techniques,
combinatorial RNAi in islet transplantation, and different delivery strategies.
Upregulation of inducible nitric oxide synthase (iNOS) and subsequent product of radical
nitric oxide (NO) impair islet β cell function. Therefore, we hypothesized that iNOS
gene silencing could prevent β cell death. In Chapter 3, we designed and used siRNA to
silence iNOS gene in a rat β cell line and human islets. We found that siRNA inhibited
rat iNOS gene expression and NO production in rat β cells in a dose and sequence
dependent manner. iNOS gene silencing also protected these β cells from inflammatory
cytokine-induced apoptosis and increased their capacity to secret insulin. Although there
was also dose and sequence dependent iNOS gene silencing and NO production in human
islets, the effect of iNOS gene on apoptosis of islets was only moderate, as evidenced by
25-30% reduction in caspase 3 activity and in the percentage of apoptotic cells. Since an
islet is a cluster of 20-1000 cells, the transfection efficiency of lipid/siRNA complexes
into human islets was only 21-28%, compared to effective transfection efficiency
(> 90%) in β cells.
Gene delivery vectors which can express a growth factor gene to promote
revascularization and silence of proapoptotic genes might be good for ex vivo genetic
modification of islet prior to transplantation. Thus, in Chapter 4, we constructed bipartite
plasmid vectors to co-express a vascular endothelial growth factor (VEGF) cDNA and
shRNA targeting iNOS gene. Firstly, shRNA sequences against human iNOS gene were
screened. Then, we determined the effect of different promoters and shRNA backbones
on gene silencing. The shRNA with H1, U6 and CMV promoters showed similar
efficiency in iNOS gene silencing. In addition, a conventional shRNA showed better
silencing of iNOS gene, compared to shRNA containing mir375 and mir30 backbones. A
bipartite plasmid was also constructed with mir30-shRNA and a VEGF cDNA controlled
by a single CMV promoter. This plasmid showed a better silencing effect compared with
plasmid without VEGF cDNA. In conclusion, we have successfully constructed bipartite
vectors co-expressing a VEGF cDNA and a shRNA against iNOS gene. These vectors
could be an attractive candidate to improve the survival of transplanted islets.
The second part of research was focused on the study of polymeric micelle formulations
for treating cancers. Two key elements were integrated in my research projects:
development of polymeric micelle delivery systems; discovery of new therapeutics for
better treatment of cancers.
The project described in Chapter 5 was carried out in collaboration with Dr. Miller’s
group at The University of Tennessee Health Science Center. In this study, we showed
iv

that SMART-100 effectively inhibited HepG2 cell proliferation and was able to
circumvent multiple drug resistance (MDR) in cancer cells. SMART-100 inhibited P-gp
activity, which may be responsible for its ability to overcome MDR. Since SMART-100
is poorly soluble in water, it was formulated in poly(ethylene glycol)-b-poly(D, L-lactide)
(PEG-PLA) micelles. The solubility of SMART-100 was increased by more than 1.1x105
folds. SMART-100 loaded PEG-PLA micelles could effectively inhibit HepG2 cell
growth and arrest cell cycle progression at G2/M phase, followed by cell apoptosis.
Increased caspase 3 activity was also observed when HepG2 cells were treated with
SMART-100. The anticancer activity of SMART-100 loaded PEG-PLA micelles was
also evaluated on luciferase expressing C4-2-Luc cell lines by IVIS imaging. Our results
suggest that SMART-100 has the potential to treat resistant cancers and PEG-PLA
micelles can be used to formulate SMART-100.
We are not only interested in using commercial polymers but also interested in designing
new polymers for micellar drug delivery. Therefore, the objective of study described in
Chapter 6 was to design lipopolymers for hydrophobic drug delivery. In this study,
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodeca
nol) (PEG-PCD) lipopolymers were synthesized and characterized by 1H NMR, FTIR,
GPC, and DSC. The critical micelle concentration (CMC) of PEG-PCD micelles was
around 10-8 M and decreased with increasing length of hydrophobic block. PEG-PCD
micelles could efficiently load a model drug embelin into its hydrophobic core and
significantly improve its solubility. The drug loading capacity was dependent on the
polymer core structure, but the length of hydrophobic core had little effect. PEG-PCD
formed both spherical and cylindrical micelles, which were dependent on the copolymer
structure and composition. Lipopolymers PEG-PCD with various hydrophobic core
lengths showed similar drug release profiles, which were slower than that of
poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate)
(PEG-PBC) micelles. Embelin loaded PEG-PCD micelles showed significant inhibition
of C4-2 prostate cancer cell proliferation, while no obvious cellular toxicity was observed
for blank micelles.
In Chapter 7, we studied the use of paclitaxel and lapatinib loaded lipopolymer micelles
for treating MDR prostate cancers. Although paclitaxel remains effective in treating
prostate cancer, its prolonged treatment develops MDR due to the over-expression of
P-gp. Our hypothesis is that combination of paclitaxel and lapatinib, which is a potent
P-gp inhibitor, can overcome MDR in prostate cancers. Paclitaxel and lapatinib loaded
lipopolymer micelle formulations were developed and evaluated in vitro with cell-based
assay. The paclitaxel and lapatinib combination effectively inhibited in vitro MDR cancer
cell proliferation, induced cell cycle perturbation and cell apoptosis. In contrast,
monotherapy with paclitaxel or lapatinib alone showed minimal anticancer effect. The
combination therapy was further investigated in vivo with athymic nude mice xenograft
MDR tumor model. Similar to in vitro study, paclitaxel (5 mg/kg) and lapatinib
(5 mg/Kg) combination therapy significantly inhibited tumor growth in vivo when
compared to high dose paclitaxel (10 mg/kg) monothearpy. These studies indicate that
the paclitaxel and lapatinib loaded PEG-PCD lipopolymer micelle formulation could be
used to treat MDR prostate cancers.
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CHAPTER 1. GENERAL INTRODUCTION
1.1.

RNA Interference and Islet Transplantation

Islet transplantation is a potential cure for type 1 diabetes mellitus. Despite recent
therapeutic success, it is still not common because a large number of transplanted islets
are damaged by multiple challenges: including instant blood mediated inflammatory
reaction, hypoxia/reperfusion injury, inflammatory cytokines, and immune rejections. As
a potent approach to selectively degrade target mRNA, RNA interference (RNAi) was
developed rapidly as a novel therapeutic strategy. The use of RNAi technologies to
down-regulate the expression of harmful genes has the potential to improve the outcome
of islet transplantation.
In the first part of this dissertation, I reviewed how to use RNAi technique to improve the
outcome of islet transplantation. And the following specific topics were discussed:





Develop potential RNAi targets based on biological obstacles for islet transplantation.
Design effective RNAi strategies: chemically synthesized small interfering RNA
(siRNA), vector-based short hairpin RNA (shRNA), and their critical design elements
(such as sequences, promoters, backbones).
Use combinatorial RNAi in islet transplantation.
Enhance gene silencing with various delivery strategies: chemical modification of
siRNA, complex formation, bioconjugation, and viral vectors.

Inducible nitric oxide synthase (iNOS) are up-regulated after islet transplantation, which
will increase the production of radical nitric oxide (NO), and impair islet β cell viability
and function. This is one of the major reasons lead to the failure of islet transplantation.
In the first project, we hypothesized that iNOS gene silencing will prevent β cell death
and improve the survival and function of islets. Following specific aims were studied in
this project:



Optimize the siRNA sequence, dose, and transfection conditions to effectively silence
iNOS gene expression in a rat β cell line and human islets.
Determine the effect of iNOS gene silencing on NO production, inflammatory
cytokine-induced cell apoptosis, and insulin production.

It is also known that multiple reasons are responsible for the damage of transplanted
islets, including inflammation and cell apoptosis, poor revascularization and hypoxia. In
the following project, we are interested in developing bipartite vectors for co-expression
of a growth factor cDNA, which can promote the revascularization of islets, and shRNA
against an apoptotic gene to improve the viability of islets. Therefore, we have the
following specific aims:



Screen shRNA sequences for silencing human iNOS.
Study the effect of different promoters (such as H1, U6 and CMV) and miRNA
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backbone (mir375 and mir30) on gene silencing.
Develop bipartite plasmid vectors co-expressing mir30-based shRNA and VEGF
cDNA with a single CMV promoter.
Develop bipartite plasmid vectors co-expressing shRNA and cDNA under separated
expression cassettes.



1.2.

Polymeric Micelle-based Nanomedicine for Prostate Cancer Therapy

Polymeric micelles can solubilize hydrophobic drugs and effectively deliver drugs into
tumors by the enhanced permeability and retention (EPR) effect. Several polymeric
micelle formulations are currently under clinical trials or approved for treating cancers [1,
2]. For an example, PEG-PLA micelles (Genexol-PM) have been successfully used as a
Cremophor EL-free formulation for paclitaxel. It was approved and marketed at Korean
in February 2007 and currently under clinical trial in USA (http://www.clinicaltrials.gov).
In this section, our research was focused on the development of polymeric micelle-based
nanomedicines for treating cancers.
The first project in polymeric micelles formulation development was carried out in
collaboration with Dr. Miller’s research group. They have discovered a potent anticancer
compound, substituted methoxybenzoyl-ary-thiazole-100 (SMART-100). SMART-100
showed excellent anticancer activity in many cancer cells and even in MDR prostate
cancers. However, the application of SMART-100 for chemotherapy was limited by its
low aqueous solubility (less than 2 ng/mL ). We are interested in developing a polymeric
micelle formulation for SMART-100, and have the following specific aims:





Determine in vitro anticancer effect of SMART-100 on HepG2 Cells and MDR
prostate cancer cells (DU145-TXR).
Prepare and characterize SMART-100 loaded PEG-PLA micelle formulations.
Determine drug solubility and loading efficiency of SMART-100 in polymeric
micelles.
Determine in vitro anticancer effect of SMART-100 loaded PEG-PLA micelles: cell
cycle perturbation and apoptosis, caspase 3 activity assay, IVIS imaging.

In the following study, we designed and synthesized a lipopolymer for micellular
delivery of embelin, which is an XIAP inhibitor and showed good anticancer activity on
prostate cells in combination with bicalutamide. We have following specific aims:





Design and optimize the synthesis procedure of lipopolymers poly(ethylene glycol)block-poly(2-methyl-2-carboxyl-propylene carbonate–graft-dodecanol).
Characterize lipopolymers with 1H NMR, FTIR, GPC, and DSC.
Determine the effect of hydrophobic core length and structure on the CMC value of
polymers.
Determine the effect of core structure and length on drug loading, micelle
morphology, and in vitro drug release.
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Evaluate the anticancer effect of embelin loaded lipopolymer micelle in vitro with
prostate cancer cells.

In the last project, we developed paclitaxel and lapatinib combination therapy to
overcome MDR in prostate cancers. Lipopolymer PEG-PCD was used to prepare
paclitaxel and lapatinib loaded micelles. Thus, the following specific aims were tested in
this project:






Synthesize and characterize PEG-PCD lipopolymers.
Develop a HPLC method to simultaneously determine paclitaxel and lapatinib in
lipopolymer micelles.
Optimized and characterize paclitaxel and lapatinib loaded lipopolymer PEG-PCD
micelle.
Determine the effect of paclitaxel and lapatinib combination on MDR prostate cancer
cells in vitro: MTT assay, TUNEL assay, cell cycle analysis.
Determine the effect of paclitaxel and lapatinib combination in vivo with athymic
nude mice xenograft MDR tumor model.
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CHAPTER 2. RNA INTERFERENCE FOR IMPROVING THE OUTCOME OF
ISLET TRANSPLANTATION*
2.1.

Introduction

The first attempt to transplant pancreatic tissue was performed 29 years before the
clinical introduction of insulin, when a young boy dying of diabetic ketoacidosis had
three small pieces of sheep’s pancreas implanted beneath his skin [3]. But the patient died
after 3 days. In 1966, the first pancreatic allotransplantation was performed at the
University of Minnesota [4]. Since then, more than 30,000 pancreas transplantations were
carried out worldwide. In 2008, approximately 1300 patients were transplanted with
pancreas in the United States with the majority of them being simultaneous pancreaskidney transplantations [5]. Although there are some beneficial effects, pancreas
transplantation remains an invasive procedure with significant mortality and morbidity
[6]. Pancreas transplantation is also limited by the death of organs, and the need for nonspecific immune suppression.
Insulin-producing β cells in the islets of Langerhans are the target of autoimmune
aggression in type I diabetes, and non-β cells and the exocrine pancreas is unaffected.
The islets constitute only a tiny fraction (1%) of the whole pancreas and it is functionally
unnecessary to transplant the whole pancreas when only its endocrine tissue is required.
Islet transplantation provides a less invasive alternative approach for the treatment of type
1 diabetes with reduced antigen load, relative simplicity, and low morbidity. However,
since the initiation of clinical islet transplantation from early 1970s, most of these trials
were failed, until the breakthrough at the University of Alberta in Edmonton, Canada.
The “Edmonton protocol” was published in 2000, reporting that seven patients with type
I diabetes became insulin independent after receiving islet transplantation with a
prednisone-free protocol [7].
The Edmonton protocol has been replicated and further modified worldwide with many
successes. In 2001, the National Center for Research Resources (NCRR) of the National
Institutes of Health (NIH) established ten islet resource centers with the mission of (1)
providing high quality human islets for both clinical and basic research use; (2)
optimizing processes for islet isolation, purification, and storage; and (3) developing the
methods for characterization of islets (http://icr.coh.org). In the same year, the Immune
Tolerance Network (ITN) with the joint help from the Juvenile Diabetes Research
Foundation (JDRF) and NIH began a trial at nine centers worldwide to perform
transplants in 40 subjects to determine if the Edmonton results could be reproduced on a
broad scale. The ITN aims at developing a core group of excellent clinical islet transplant
centers for future testing of tolerance-based trials (http://www.immunetolerance.org).
From 1999 to 2008, around 400 patients received allogeneic islet transplantation [8, 9].
* Adapted with permission. F. Li, R.I. Mahato, RNA interference for improving the
outcome of islet transplantation, Adv Drug Deliv Rev, 63 (2011) 47-68.
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Despite these successes, only less than 10% of the recipients remain insulin independent
for up to 5 years, and most recipients return to insulin because the islet function
decreased over time [10]. After transplantation, Islet grafts face multiple challenges
including innate and adaptive immune rejection, toxicity associated with immune
suppressive agents, and insufficient islet revascularization [11, 12]. Therefore, islets
isolated from two to four donors are needed for single patient islet transplantation [13].
At present, even with expansion in the currently available organ donor pool, islet
transplantation will only benefit about 0.5% of potential recipients [14].
Ex vivo genetic modification of islets before transplantation has the potential to
overcome several problems associated with islet transplantation [12, 13, 15-19]. Growth
factor gene expression has the potential to promote islet revascularization; while antiapoptotic gene expression can reduce inflammation and immune rejection; and prevent
islet cell apoptosis. This strategy can help to reduce the number of islets needed for each
recipient and prolong the time that a recipient can maintain insulin independence after
transplantation. The genetic modification of islets could be the over-expression of
protective genes or inhibition of harmful gene expression [20]. Antisense
oligonucleotides (ODNs), ribozymes, DNAzymes, and RNA interference (RNAi) are
major approaches which are currently being used to sequence specifically reduce or
inhibit gene expression. Among these approaches, RNA interference (RNAi) is relatively
new and evolutionally conserved biologic process that regulates gene expression using
small interfering RNA (siRNA) mediated sequence specific, post-transcriptional gene
silencing [21, 22]. Since the discovery of RNAi by Fire and Milo in 1998, it has been
widely used as a tool for basic research as well as a potential therapeutics [23-26]. The
application of RNAi and other approaches have been extensively reviewed [27]. siRNA
molecules can recycle between different copies of mRNA, while antisense ODN can only
block the translation of one mRNA before its degradation [28]. Therefore, siRNA is more
effective than antisense ODN in reducing target gene expression [29]. Miyagishi et al.
has demonstrated that the IC50 for siRNA was about 100-fold lower that of the antisense
[30]. Similarly, Bertrand et al. has reported that siRNAs are more efficient in silencing
target gene and its effect is lasting longer. In addition, RNAi could also be achieved
though the delivery of shRNA, which is expressed endogenously and has longer gene
silencing effect [29].
In this review, we will discuss the biological obstacles to islet transplantation and
potential RNAi targets; principles and design element for RNAi; and delivery
approaches.
2.2.

Obstacles to Islet Transplantation

Since the success of Edmonton protocol, significant progress has been made in human
islet transplantation. However, this protocol is still not widely used mainly due to the fact
that islets from several donors are needed for a single recipient, since majority of the
islets are damaged prior and post transplantation. The destruction of transplanted islets is
a complex problem with many facets including enzyme and mechanical damages induced
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by the isolation process, hypoxia, inflammatory reaction, and immune rejection. Since
many of these factors are inter-related, a thorough understanding of these molecular
processes will help us to develop more effective therapeutic interventions.
2.2.1.

Instant blood-mediated inflammatory reaction

Due to non-immunological and innate immunological factors, 50%-70% islets lose their
viability immediately after transplantation by instant blood-mediated inflammatory
reaction [31-33]. This phenomenon is also called “early graft loss” or “primary nonfunction.” The pathophysiology of blood-mediated inflammatory reaction involves
platelet binding and activation, coagulation, complement activation, and infiltration of
neutrophils, monocytes, and macrophages (Figure 2.1) [31]. Activation of coagulation
could be triggered through both the intrinsic pathway by islet surface collagen residues
and the extrinsic pathway by tissue factors or monocyte chemoattractive protein-1 (MCP1) [34, 35]. Complement is possibly activated through the alternative pathway [36, 37].
Infiltration of these immune cells could be observed within 1 h after coagulation and
complement activation [38]. There are multiple interactions between coagulation,
complement, and inflammatory cells, which are responsible for the infiltration of
inflammatory cells. Neutrophils and monocytes interact with activated platelets through
P-selectin over-expressed on platelets [39]. Macrophages could directly be activated by
tissue factor, fibrin, or fibrinogen [40]. Soluble C3a and C5a produced through
complement activation are potent chemoattractants for neutrophils and macrophages [36].
The effects of blood-mediated inflammatory reaction are multiple. Firstly, both
monocytes and macrophages are major phagocytes leading to the destruction of islet
cells. Secondly, proinflammatory cytokines lead to islet cell apoptosis and necrosis. Last
but not the least, the infiltrating neutrophils and macrophages will eventually induce
subsequent adaptive immune response [41].
2.2.2.

Inflammatory cytokine-induced islet cell death

Mechanical and enzymatic stresses during the islet isolation, purification and transfection
process result in the activation of resident islet macrophages, which release several
proinflammatory cytokines including interleukin-1ß (IL-1ß), tumor necrosis factor-α
(TNF-α), and interferon- (IFN-). In addition, infiltrating host immune cells (monocytes,
neutrophils) also produce inflammatory cytokines [42]. These proinflammatory cytokines
are responsible for the non-specific inflammation and the damage to transplanted islets
during the early stage of transplantation. The exact source and timing of proinflammatory
cytokine production still remains elusive and greatly depends on the islet isolation,
purification and transplantation protocols. For an example, Kupffer cells produce
inflammatory cytokines, NO, and reactive oxygen species (ROS), which are toxic to
intraportally transplanted Islets [43-45]. The release of cytokines by islet resident
macrophages is known to occur during in vitro culture prior to transplantation [46]. The
levels of IL-1β and TNF-α increase soon after transplantation, and maximum level was
reached at 3 h for IL-1β and at 6 h for TNF-α. Depletion of kupffer cells significantly
6
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reduced the levels of IL-1β and TNF-α, indicating the role of macrophage in producing
inflammatory cytokines [47]. Another study also showed that IL-1β mRNA was
detectable in islet immediately after isolation and was increased after transplantation. IL1β mRNA increased by 9 fold on day 1, by 7 fold on day 3 after transplantation, and
decreased to baseline level on day 7 [48]. It has also been reported that the expression of
proinflammatory cytokines (including IL-1β and TNF-α) were observed at 8 h after
transplantation and declined after 24 h. In the same study, however, IFN- was not
observed until 48 h post transplantation [49]. Ozasa et al. reported that IFN- mRNA was
observed in allogeneic transplantation at 1, 3, 5, and 7 days after transplantation with a
peak at day 5, however, it was almost absent in syngeneic transplantation [50]. Although
the exact source and level of proinflammatory cytokines production varies among
different transplantation protocols used, some common intracellular signal pathways are
activated. These cytokines activate JNK/p38, NF-β, STAT-1, up-regulate the expression
of several significant genes, and finally result in β cell death (Figure 2.2) [36-37].
The binding of IL-1β to its receptor IL-1R1 leads to the docking of the IL-1 receptor
accessory protein (IL-1AcP) and followed by the recruitment of IL-1R1 activated kinase
(IRAK) through an adaptor protein named myeloid differentiation factor 88 (MyD88).
Recruitment of IRAK leads to the activation of TNF-receptor-associated factor-6
(TRAF6), resulting in the phosphorylation and degradation of IκB. NF-κB is then
released from inhibitory IκB, translocates into the nucleus, and induces the expression of
multiple genes, including IL-1, IL-6, TNF-α, and iNOS [51, 52].
IFN- binds to IFN receptor 1 (IFNR1), which recruits IFN receptor 2 (IFNR2).
IFNR1and IFNR2 are associated with Janus tyrosine kinase 1 and 2 (JAK1/2) and
results in the activation of JAK1 and JAK2. Then signal transducers and activators of
transcription 1 (STAT1) is activated by JAK2 and then translocates to the nucleus, where
it binds to the regulatory regions of different genes [53]. In addition, the ischemiainduced STAT1 also regulates caspase gene expression through the activation of
transcription factor IRF-1 [54].
Upon binding of TNF-α, TNF receptors form trimers and undergo conformational
change, leading to the exposure of intracellular death domain. The death domain interacts
with TNF-α associated death domain (TRADD), which serves as an adaptor to initiate
three signal pathways, including the activation of NF-κB, activation of MAPK pathway,
and induction of apoptosis [55-57]. TNF receptor-associated factor 2 (TRAF2) and
receptor-interacting protein (RIP) are associated with TRADD to recruit and activate
kinase IKK, which in turn releases NF-κB by degradation of IκB [55]. TRAF2 also
activates MAPK pathways and leads to the protein kinases such as c-jun N-terminal
kinase (JNK) and p38 [58]. Apoptosis are activated through both MAPK pathway (direct
activation of caspase 3) or FADD mediated activation of caspase 8, which in turn leads to
the activation of effector caspase, such as caspase 3 [57].
Under in vitro conditions, IL-1β induces functional impairment in the mouse and rat β
cells, and prolonged exposure (6-9 days) to IL-1β in combination with IFN- and TNF-α
leads to human, mouse, and rat β cell death [52]. The fate of β cells after exposure to
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inflammatory cytokines depends on the type of cytokines, time course and severity of
perturbation to the key β cell gene networks [52, 59]. Inflammatory cytokines upregulate
or downregulate around 200 genes, which are either protective or deleterious to β cell
survival and function [59, 60]. These genes are related to metabolism, signal
transduction, and transcription factors, suggesting that β cells are making attempt to adapt
to the effect of cytokine exposure [59]. Several of these genes are putative targets of
transcription factor NF-B [61]. Transcriptional activity of NF-B is related to the
expression of proapoptotic genes in β cells [62]. The activation of NF-B is a necessary
step for inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO)
production [61]. The cytotoxic effect of cytokines is mediated through the production of
radical NO as well as other free radicals, such as peroxynitrite and superoxide [48, 63].
Increased iNOS gene expression leads to an early inflammatory process in islet
transplantation, suggesting iNOS is an important mediator of graft inflammation and islet
damage in the early stage of islet transplantation. Inflammatory cytokines initiate β cell
apoptosis mainly though the extrinsic pathway and function through several molecules in
the death receptor pathway, such as Fas (CD95), Fas-associated death domain (FADD),
and the death-inducing signaling complex (DISC), leading to the activation and release of
caspase 8, which in turn activate caspase 3 [64-66].
2.2.3.

Hypoxia and ischemic reperfusion injury

In an intact pancreas more than 15% of the total blood flow goes to islets, which accounts
for only 1% of the pancreatic tissue [67]. During isolation and purification process, the
capillary network for blood supply is destroyed; therefore, oxygen and nutrients are
solely supplied through diffusion. The oxygen tension in portal vein (where the islets are
transplanted) is 8-10 mmHg, which is much lower than that in the intact pancreas (PO2 =
40 mmHg) [68, 69]. Although the angiogenesis initiates soon after transplantation,
revascularization of islets may take up to 10-24 days [70]. Therefore, newly transplanted
islets are under persistent hypoxic conditions prior to and post transplantation, until
revascularization process is completed. The reperfusion following prolonged ischemia
causes injury, commonly known as ischemia/reperfusion (IR) injury. For an example, IR
injury in the liver activates Kupffer cells, which will produce inflammatory cytokines,
ROS and NO, resulting in islet cell apoptosis [71]. Hypoxia induces the intrinsic pathway
of apoptosis though the disruption of the mitochondrial integrity, induction of
cytochrome C release, and the activation of caspase 9 and 3 [64-66]. Nutrient deprivation
can also induce islet apoptosis through the intrinsic pathway [64].
2.2.4.

Autoimmune recurrence and allogeneic immune rejection

In addition to hyperacute rejection, acute rejection, and chronic rejection experienced
during the transplantation of other organs such as heart, lung, liver, and kidney,
transplanted islets are under additional attacks due to autoimmune rejection against β
cells in type I diabetic patients. In the following paragraph, we will briefly summarize the
immunology of islet transplantation (Figure 2.3).
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2.2.4.1. Autoimmune recurrence
Type I diabetes is caused by autoimmune mediated damage of islet β cells. It is
characterized by the presence of β cell reactive T cells, proinflammatory cytokines, and
other molecules. Transplanted islets are also attacked by the same stresses that destroy
host β cells. Among them, CD8+ T cells are one of the major players in destroying β
cells. The infiltration of CD8+ T cells is observed in the pancreas of type 1 diabetic
patients as well as transplanted pancreas [72, 73]. In addition, activated CD4+ T cells are
also involved in the killing of β cells. Reduced insulitis is observed in the absence of
CD4+ T cells [74]. The activation of CD8+ T cells is dependent on CD4+ T cells. CD8+
T cells kill target cells through direct contact and mediated by perforin and granzyme B.
Perforin can disturb target cell membrane integrity and facilitate the release of granzyme
B into the cytoplasm of target cells, whereas granzyme B cleaves proapoptotic molecule
Bid. Activated Bid sequesters anti-apoptotic Bcl-2 molecules and triggers β cell apoptosis
through the intrinsic apoptotic pathway [75-77]. Fas is also upregulated in pancreatic β
cells of type 1 diabetic patients and causes β cell apoptosis through FasL-Fas interaction
[78, 79].
2.2.4.2. Allogeneic immune rejection
Successful transplantation of allogeneic islets is difficult, because transplanted islets are
recognized not only by the host immune system, but the adaptive immune rejections are
also activated [80]. Failure of allogeneic islet transplantation is correlated with increased
T cell reactivity or alloantibody titers [81, 82]. Antigen presenting cells (APCs) process
and present peptide fragments of various surface, secreted and shed protein from the
donor. APCs from both donor and host (including dendritic cells, macrophages,
passenger leukocytes, and mononuclear cells) are involved in the antigen presentation.
After maturation, APCs provide three signals to fully activate T cells: signal 1,
recognition of major histocompatibility complex (MHC) and the bound peptide by the T
cell receptor on the host T cells; signal 2, interaction of co-stimulation signals (such as
CD40, CD80/86) with their corresponding receptors on host T cells; signal 3, soluble
cytokines (IL-12, IL-10, IL-2) further stimulate the proliferation and differentiation of T
cells [83, 84]. All of these three signals are required; otherwise, it will result in the
apoptosis, anergy, and differentiation of T cells. In addition, anti-donor antibodies are
also developed in most allograft recipients after immunosuppressive medication is
discontinued. The presence of alloantibodies usually lead to the graft failure of islets from
donors with the recognized human leukocyte antigen (HLA) allodeterminants [81].
2.3.

Potential Targets for Gene Silencing

As a potent approach for inhibiting aberrant protein expression, RNAi can theoretically
be used to silence any gene involved in the biological processes that lead to the damage
of islets. However, due to the complexity of pathophysiology of islet transplantation, only
some key mediators are potential targets for RNAi-based intervention. A wide variety of
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potential therapeutic targets are investigated in the past, which are discussed in the
following paragraphs.
2.3.1.

Modulation of immune rejection

Immunosuppressive agents mediated non-specific immunosuppression is commonly used
to reduce the immune rejection in islet transplantation, however, even the most isletfriendly immunosuppressive regimen are toxic to islets. For example, the treatment of
islets with sirolimus (also known as rapamycin) or tacrolimus (also known as FK-506 or
Fujimycin) causes islet apoptosis [85]. Immune modulation with other biological
approaches could also provide alternative ways to reduce immune rejection [12].
2.3.1.1. Genetic modification of dendritic cells
Dendritic cells are one of the most important APCs, which play a critical role in the
regulation of immune responses. The activation and maturation of T cells relies on the
signals from APCs. T cells will undergo apoptosis, if any one of these signals is blocked.
DCs are genetically modified to act as a suppressor of immune responses. These DCs are
called tolerogenic DC (Tol-DC). Clinically, we could isolate DCs from the host and then
administer them back to the host after making them tolerogenic. Inhibition of the genes
associated with DC maturation is one of the promising approaches to generate Tol-DC.
NF-B is an essential transcription factor for DC differentiation and maturation. It
includes a group of proteins with similar structures. Inhibition of NF-B pathway has
been shown to produce tolerogenic DC [86, 87]. Silencing of RelB, which is a primary
NF-B protein, reduces the expression of MHC-II, CD80, CD86, and finally prevents DC
maturation. RelB silenced DCs were able to inhibit antigen-specific alloreactive immune
rejection, and decrease antigen specific T cell proliferation [88]. Significantly reduced
allograft rejection was achieved after administration of RelB silenced donor DC [88].
Inhibition of the expression of p35, which is a subunit of IL-12, was an effective
approach for antigen-specific immune modulation [89, 90]. DCs treated with siRNA
against p35 were able to induce potent Th2 deviation of antigen-specific response; reduce
alloreactivity by effective inhibition of T cell proliferation; shift allogeneic T cell
polarization from Th1 to Th2. In another study, Tol-DC was generated through the
treatment of antisense ODN to inhibit the expression of CD80 or CD86. Allograft
survival was prolonged by administration of modified DCs, which could induce T cell
hyporesponsiveness and apoptosis of T cells [91]. In addition, silencing of CD80 or
CD86 with siRNA inhibited T cell responses in mixed lymphocyte reaction (MLR),
generated T regulatory cells [92], and improved cardiac allograft survival [93]. Tol-DC
could also be generated through the silencing of CD40, which is another critical costimulatory molecules [94]. Silencing of CD40 gene expression in DCs resulted in
increased IL-4 production, and decreased IL-12 production and allostimulation activity.
The Th2 cytokine production from allogenic T cells was stimulated [95]. MyD88 is a key
adaptor of toll-like receptor signaling [83]. It is critical for DC function and
proinflammatory cytokine production. The silencing of MyD88 significantly improved
the allograft survival [96]. Suppressor of cytokine signaling (SOCS) molecule is an
13

intracellular inhibitor of Janus kinase. Silencing of SOCS gene in DC resulted in reduced
allogeneic mixed leukocyte reactions. In addition, systemic administration of SOCS
silenced DCs improved the survival of allograft in rat [97].
2.3.1.2. Reducing immunogenicity of donor islets
HLA is one of the primary causes of Th1/HLA class II antigen rejections in solid organ
transplantation. Human islet also has an immunogenic potential, which depends on their
HLA incompatibility with the recipient. The alloreactivity is correlated with acute
rejection and graft failure. In HLA matching human islet transplantation, the
alloreactivity is significantly reduced [98]. However, because of the limited sources of
islet donor and extensive HLA polymorphisms, the availability of HLA-match donors is
extremely limited. In addition, the fact that multiple donors being required to obtain a
sufficient number of islets for transplantation makes the donor selection based on HLA
more difficult. Therefore, HLA-unmatched islets are used to meet the clinical needs.
These transplanted islets undergo aggressive immune rejections. Silencing of HLA
expression provides a promising method to reduce the immunogenicity of HLAunmatched donor islets [99]. Enhanced resistance to allo-reactive T cell toxicity was
observed in human cells treated with lentivirus expressing shRNA against pan class I and
allele-specific HLA [100]. Silencing of HLA in solid organ transplantation was also
reported [101, 102].
2.3.2.

Preventing ischemic reperfusion injury and apoptosis

There are multiple challenges including ischemia/reperfusion, mechanical and enzymatic
stresses during islet isolation and preservation processes. These factors can activate
inflammation and intracellular stress signal pathways, and lead to the over-expression of
proinflammatory mediators, such as proinflammatory cytokines, ROS, caspases, and
transcription factors. The consequence is the loss of islet function and viability. In
addition, further adaptive immune response against transplanted islets will also be
triggered [103].
2.3.2.1. Block the apoptosis
During the isolation and preservation processes, islets are challenged with various
stresses. After transplantation, there are multiple factors that could induce the islet cell
death. The survival of transplanted islets could be improved by preventing islet β cells
apoptosis [64]. Caspases are the most important mediators of apoptosis, which include
initiator caspases (caspase 8 and 9), and effector caspases (caspase 3, 7). Inhibition of
caspase activity with caspase inhibitors, or anti-apoptotic genes, has been reported to
prevent apoptosis of islets and improve their function [64]. The silencing of caspase 3
and/or caspase 8 was able to reduce renal and liver ischemia/reperfusion injury, which is
a significant problem in organ transplantation [104-106]. Silencing of caspase 8, which is
a mediator of extrinsic apoptosis pathway, could minimize Fas or proinflammatory
cytokines-induced cell apoptosis. Silencing of caspase 3 (which is the converging point
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for both extrinsic and intrinsic apoptotic pathways) prevented β cell apoptosis triggered
by both extrinsic and intrinsic stimulations. We have demonstrated that the silencing of
caspase 3 protects islets from inflammatory cytokine-induced apoptosis [107]. Delivery
of caspase 3 siRNA to rat insulinoma (INS-1E) cells significantly reduced the number of
apoptotic cells. Ex vivo transduction of human islets with adenoviral shRNA prior to
transplantationreduced caspase 3 activity in islets and significantly improved islet
function. All of the mice transplanted with adv-caspase 3 shRNA transduced islets
achieved normoglycemia one day posttransplantation and maintained up to 17 days. In
contrast, for mice transplanted with untreated islets, where normoglycemia was achieved
in only 60% at day 1, and 80% at day 4 post transplantation. Fas: Fas/FasL interaction is
another important mechanism for triggering β cell apoptosis [78]. Treating β cells with
siRNA-Fas significantly reduced caspase 3 activity and inhibited Fas-mediated β cell
apoptosis [108]. In other studies, Fas siRNA has been successfully used to reduce
apoptosis in the liver [109, 110] and heart transplantation [111]. Burkhardt et al. used
siRNA to silence Fas expression in murine insulinoma cells. Their results showed that
siRNA against Fas inhibited cytokine-induced Fas mRNA expression and reduced cell
surface Fas protein. However, due to the slow turn-over of Fas protein, a complete
inhibition was not observed until prolonged incubation with siRNA. In addition, Fas
siRNA effectively reduced cytokine-induced β cell apoptosis as determined by caspase 3
activity and TUNEL assay [108].
2.3.2.2. Prevent complement activation
Downregulation of complement 3 or complement C5a receptor with siRNA has the
potential to prevent renal ischemia-reperfusion injury [104, 112]. In another study, UW
solution containing siRNA against complement 3 also showed the ability to protect donor
organs in heart transplantation [111]. For islet transplantation, the complement pathway
is activated during the ischemia-reperfusion injury and blood-mediated inflammatory
reaction. siRNA targeting C3 and C5a receptors might be a potential target for improving
the viability of transplanted islets.
2.3.2.3. Inhibit inflammatory pathway
As discussed in the previous section, proinflammatory cytokines activate several
inflammatory signal pathways, upregulate multiple key genes, and finally results in islet
cell death. The major mediators in this process are potential targets for preventing islet
cell death. iNOS gene: iNOS gene expression on islets increased significantly after
transplantation. The maximal iNOS gene expression was observed one day after islet
transplantation and then declined progressively [48]. Increased iNOS gene expression led
to an early inflammatory process in transplanted islets. Nearly, 50% of the cytokineinduced genes are NO dependent, emphasizing the role of this radical in the late effects of
cytokines on insulin producing β cells [59]. Therefore, silencing of iNOS gene might
reduce iNOS mediated inflammatory response and prevent islet cell death. McCabe et al.
used lentiviral vector expressing shRNA to suppress IL-1β-mediated induction of iNOS
expression, resulting in significant protection against the cytotoxic effects of IL-1β
exposure [113, 114]. We designed siRNA to inhibit rat and human iNOS gene expression
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[115, 116]. Due to the difference between human and rat iNOS mRNA sequences,
different iNOS siRNA were designed for efficient gene silencing. A dose and sequence
dependent inhibition of iNOS gene expression and NO production was observed in rat β
cell line (INS-1E cell) and human islets. iNOS gene silencing protected β cells from
inflammatory cytokine-induced apoptosis and preserved their insulin secretion ability.
However, the effect of iNOS gene silencing on the apoptosis of islet was only moderate,
as evidenced by 25–30% reduction in caspase 3 activity and in the percentage of
apoptotic cells. Since an islet is a cluster of 200–1000 cells, the transfection efficiency of
lipid/siRNA complexes on human islets was only 21–28%, in contrast to the high
transfection efficiency ( > 90%) in β cell lines. Therefore, to achieve satisfactory
protective effects on human islets, we need to improve the transfection efficiency, which
could be achieved by the rationale design of vectors [107, 117] or modifying the delivery
approaches. This will be discussed in the later sections.
Transcription factor NF-B plays an important role in the inflammation and ischemiareperfusion injury. For example, several genes are putative targets of NF-B and their
expression levels are changed after cytokine exposure [61]. Transcriptional activity of
NF-B is related to the expression of proapoptotic genes in cytokine stimulated β cells
[62]. Recombinant adeno-associated virus (AAV) encoding shRNA against NF-B RelA
(p65) subunit was evaluated to reduce NF-B mediated inflammation [118]. The
expressed shRNA against RelA significantly reduced p65 protein expression and
suppressed IL-8 secretion in a cellular TNF-α-induced inflammation model. In another
study, siRNA against NF-B RelB significantly attenuated ischemia-reperfusion injuryinduced renal dysfunction and protected mice against lethal kidney ischemia [119].
2.4.

Method of Gene Silencing

2.4.1.

Types of RNAi methods

The applications of RNAi generally utilize two types of molecules: chemically
synthesized short interfering RNA (siRNA) or vector-based short hairpin RNA (shRNA).
Although siRNA and shRNA can be applied to achieve similar functional outcomes, they
are intrinsically different molecules as discussed below.
2.4.1.1. Chemically synthesized siRNA
siRNA of 19-23 bp can be synthesized chemically in vitro. Advances in solid phase
synthesis technique make it possible to produce siRNA with high purity and precisecontrolled sequence. Both sense and antisense strands are synthesized separately and
annealed to form double stranded siRNA duplex. After being delivered into cytoplasm,
siRNA is directly incorporated into RNA-induced Silencing Complex (RISC) to have its
function. Several rate-limiting steps for vector-based shRNA are avoided in siRNA
mediated gene silencing. Therefore, the gene silencing effect of siRNA is potent and can
appear in a short time after transfection. This feature also makes the design of siRNA
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relatively simple, since the factors regarding short hairpin expression and process are not
involved. However, the 2’-OH group in siRNA molecules makes them extremely
unstable and susceptible to enzymatic degradation. Only transient gene silencing can be
achieved with siRNA and it disappears within several days post transfection.
2.4.1.2. Vector-based shRNA
shRNA is an RNA sequence that makes a tight hairpin turn that can be used to silence
gene expression via RNAi. Vector-based shRNA utilizes endogenous cellular machinery
to function. After entering the cell nucleus, vector-based shRNA with stem loop structure
is expressed to produce pri-shRNA in the nuclei, which is then processed into pre-shRNA
by an enzyme named Drosha. Pre-shRNA is exported to the cytoplasm by exportin-5,
where it is further processed by Dicer (an RNAse III enzyme) to produce functional
siRNA [120]. siRNA is then incorporated into RISC. Activated RISC with antisense
strand is formed by cleavage of sense strand. Activated RISC recognizes target mRNA
with a complementary sequence, and result in the cleavage of target mRNA (perfect
complementarities) or translation inhibition (not prefect complementarities) [24].
2.4.2.

Design elements of siRNA and shRNA

2.4.2.1. siRNA and shRNA sequences
siRNA sequence is the most important factor that determines the level and duration of
gene silencing. Because of high sequence specificity, gene silencing efficiency changes
dramatically with minor alteration in siRNA sequence. Mutation in the antisense strand
usually makes the activated RISC unable to recognize target mRNA. There are several
web-based tools available for predicting effective siRNA sequences and empirical rules
are incorporated in the siRNA design software to optimize siRNA sequence [121-124].
These rules includes: thermodynamic property [125], length of siRNA sequence [126],
GC contents, RNA secondary structure, sequence region, single nucleotide polymorphism
sites, avoiding repeats and low complex sequence, avoiding off-target effects on other
genes or sequences [127, 128]. siRNA sequences predicted by software, however, are not
always very effective in silencing a target gene, and sometime the most potent siRNA
sequence is missed. Practically, a potent siRNA can be selected through testing of several
candidate siRNA sequences designed with bioinformatics tools.
Since shRNA works through the production of siRNA within the cells, there are plenty of
common rules applicable to both siRNA and shRNA sequence design. Actually, people
have used the siRNA designing software to predict shRNA sequence with success. Due to
the similarity between siRNAs algorithm and that of shRNAs, it is not surprising to keep
the gene silencing efficiency after converting siRNAs into shRNAs. However, some
features are not required for siRNA but are essential for shRNA expression. For an
example, strong GC preference at position 11 and the preference for AU but not GC at
position 9 might be the different properties for shRNA sequences [125]. The
incompatibility of siRNA design algorithm for shRNA design has also been reported
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[129]. It would be a good idea to design shRNA sequences using shRNA design
algorithm. Similar to siRNA design, several shRNA sequences should be experimentally
screened to find potent shRNA sequences. An obvious disadvantage of this approach is
that the cloning of shRNA into plasmid is a time consuming process. Fortunately, predesigned shRNA plasmids for most genes are now commercially available. In most cases,
potent shRNA sequences for a particular gene could be found by screening several predesigned shRNAs.
2.4.2.2. Expression cassette for shRNA
Although shRNA sequence design is critical for efficient gene silencing, it is equally
important to have a proper shRNA expression cassette, which determines the magnitude,
duration and specificity of shRNA expression. In addition, the structure of shRNA
backbone also plays an important role in shRNA transcription, processing, and nuclear
export. The effect of different promoters and shRNA structures has been extensively
investigated to improve the level and duration of gene silencing.
Promoters refer to DNA sequences that provide a binding site for RNA polymerase and
transcription factors. DNA transcription starts after transcription factor binding to
promoter sequences and recruitment of polymerase. The level and duration of shRNA
expression depends on the properties of promoters used. Three types of promoters, such
as constitutive promoter, inducible promoters, and islet specific promoter will be
discussed here.
The first type of promoters is constitutive promoters. There are three types of constitutive
promoters used for shRNA expression, including polymerase III, polymerase II, and
polymerase I promoters. U6 and H1 are the two most commonly used polymerase III (Pol
III) promoters for shRNA expression. This is because Pol III promoters transcribe small,
highly structured RNAs without poly (A) and 5’-cap in mammalian cells [130]. However,
Pol II promoters such as CMV [131, 132], U1 promoter [133], and E1b promoter [134]
are also used for shRNA expression. Particularly, CMV promoter can be used for coexpression of a cDNA and a shRNA with a single promoter or to drive the expression of
a shRNA embedded in a miRNA structure [132]. Usually, a poly (A) signal is needed for
the termination of CMV promoter expression. A modified CMV promoter can also be
terminated by poly(T) termination signal [131]. To increase the activity of U6 or H1
promoter, hybrid promoters composed of CMV enhancer and U6 or H1 promoter were
constructed for shRNA expression [135-137]. Polymerase I promoter has also been
reported for shRNA expression [138], however, the use of pol I promoter is still not well
investigated.
The second type of promoters is inducible promoter. High level constitutive expression of
shRNA may saturate cellular machinery and cause cell toxicity. In addition, it is
undesirable to constitutively silence genes that are essential for cell viability. Therefore,
inducible promoters that can silence genes in a tunable pattern were developed. Different
conditional RNAi strategies have been reviewed elsewhere [139]. Here, we list some
examples to discuss the concept of using inducible promoters for gene silencing.
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Czauderna and coworkers [140] constructed tetracycline-inducible U6 or 7SK promoters
by introducing a tetracycline operator (tet O) sequence between TATA box and
transcription start site. shRNA expression was induced by adding tetracycline which
could dissociate the repressors from the tet O. Similarly, tetracycline inducible H1
promoter was also constructed to silence β-catenin [141]. An IPTG-H1 promoter has
been developed by placing a lac operator between TATA box and transcription start site
[142]. Reversible gene silencing was achieved with above expression systems and the
gene silencing effect will disappear within 3-4 day after removing the inducers. An
alternative way for inducible gene silencing is Cre-LoxP recombination system, which
usually results in an irreversible gene silencing. In this system, a Lox-flanked stuffer
sequence with termination sequence (five thymidines) is inserted between H1 promoter
and transcription start site. After expression of Cre protein, the stuffer sequence is
removed due to the recombination of two loxP sites and thus activate the promoter [143].
Hypoxia inducible promoter may have additional advantages for its application in islets,
which are usually under the hypoxic condition after isolation. The use of hypoxia
inducible promoter could restrict the gene or shRNA expression within hypoxic islets.
Therefore, it could avoid unwanted gene expression and silencing on normoxic tissue or
organs and prevent potential toxic side effects. Lee et al. constructed pRTP801-Luc or
pRTP801-VEGF plasmids bearing a hypoxia inducible promoter. After transfection into
rat islets, transgene expression was higher in hypoxic islets than those in normoxic
condition [144, 145]. Although there is still little report about the use of hypoxia
inducible expression cassette for gene silencing in islets, we believe that its application in
islet gene silencing will increase in the future.
The third type of promoters is islet-specific promoter. Several islet-specific promoters
have been tested to drive the specific transgene expression in islets. Among them, rat
insulin promoters are being extensively investigated [108, 146, 147]. To improve the
performance of rat insulin 2 gene promoter in isolated pancreatic islets, an expression
cassette including 1.5 kb of the porcine INS 5’ UTR and the 3’ UTR of the bovine growth
hormone gene was constructed, which showed robust and specific gene expression on
islet β cells [148]. Chai et al. have compared a series of rat insulin promoter sequences
with various lengths. The highest promoter activities was observed in a modified RIP3.1
promoter including the non-coding regions in exon1, intron1, and part of exon2 of the rat
insulin gene 1 as well as the insulin gene promoter region. This promoter showed 5-fold
higher activity in INS-1E cells than a full-length RIP promoter or a CMV promoter. In
addition, RIP3.1 promoter demonstrated β cell specific gene expression and glucose
responsive gene expression [146]. Recently, the promoter for pri-mir375 has been
indentified, which could selectively express pri-mir375 in pancreatic islets [149]. Since
miRNA-based shRNAs have been successfully used for shRNA expression, the finding
of this promoter provided an option for islet specific shRNA expression.
shRNA backbone structure is also critical for effective gene silencing. High level of
shRNA expression does not necessarily lead to efficient gene silencing, because nuclear
export, dicer enzyme processing and other rate limiting steps are also critical for efficient
gene silencing. These processes are greatly influenced by the shRNA structure, which
includes the stem length, loop sequence, the sequence of flanking regions. A typical
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shRNA is composed of a 19-21bp sense sequence and a 19-21bp antisense sequence
linked with 6-9bp loop sequence. A termination sequence of 5-6 thymidines is usually
included at the end of stem-loop structure, except for shRNA driven by a pol II promoter.
Various shRNA structures have been studied to improve gene silencing efficiency. Siolas
et al. found that synthetic 29-mer shRNAs were more potent than 19-mer shRNAs, while
the loops sequence did not have any effect [150]. In contrast, Jeanson-Leh et al. reported
that increase in the stem length from 19-mer to 29-mer did not show any improvement in
gene silencing [151]. It was also reported [125] that gene silencing of shRNAs with 19mer stem was better than those of shRNA with 29-mer stem in the context of a 9-bp
loop.
An emerging trend in shRNA design is to incorporate siRNA into a miRNA precursor
backbone so that it can be processed efficiently by intracellular miRNA machinery.
mir30-based shRNA has been reported to be more efficient than conventional shRNA
[152-154]. Boden et al. designed a shRNA against HIV-1 transactivator protein TAT with
a mir30 backbone, which showed 80% more potency in silencing target gene than a
conventional shRNA [152]. In another study, Li et al. compared 14 pairs of conventional
shRNA and mir30-based shRNA against luciferase gene, and 10 pairs of conventional
shRNA and mir30-based shRNA against the mouse tyrosine gene. Results indicated that
in 11 out of 14 pairs of shRNA against luciferase and all of those for mouse tyrosine
gene, a better gene silencing was observed in conventional shRNA rather than in mir30based shRNA [125]. Boudreau et al. have also demonstrated that optimized shRNA are
more efficient than mir30-based shRNA in silencing of several genes, including green
fluorescent protein (GFP), spinocerebellar ataxias, and Huntington disease [155]. In our
own studies, we also found that mir30-based shRNA against human iNOS genes was less
potent compared with conventional shRNA [117]. These discrepancies indicate that
current understanding of shRNA design is still limited and further exploration is
necessary to develop a satisfactory rule for shRNA design. The use of miRNA backbone
for shRNA expression also has the potential to reduce toxicity [156] and to have tissue or
cell type specific gene silencing [157].In addition, we could also construct pri-miRNA
cluster, in which multiple miRNA-based shRNA is driven by a single promoter to form a
single transcript [158, 159].
Recently, several other shRNA structures have been investigated for different
applications. In one study, a tRNA-shRNAs chimeric expression cassette was
constructed, in which a tRNA promoter was used to drive the expression of shRNA
linked to the 3’ acceptor stem of tRNA [160]. This system could achieve similar or even
high gene silencing than shRNAs expressed from U6 or H1 promoters [160-162]. Since
exportin-t, but not exportin-5, was used for the nuclear export of tRNA-shRNAs, it could
reduce toxicity related to exprortin-5 saturation [161, 163]. Tandem siRNAs: Zheng et al.
designed a dual promoter system (pDual) by inserting siRNA sequence between two
promoters (including mouse U6 and human H1 promoters) with opposing directions
[164].
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2.4.2.3. Off-target effects
Since the first report by Jackson et al. in 2003 [165], many studies have shown that both
siRNA and shRNA could cause off-target effects. From a therapeutic standpoint, the offtarget effects should be avoided to prevent unintended effects. Therefore, understanding
the mechanisms of off-target effects and developing strategies to enhance RNAi
specificity is critical for the application of RNAi. There are two types of off-target
effects: specific off-target effects, which are caused by the partial sequence
complementarity between mRNA and siRNA, and non-specific off-target effects, which
are the outcome of overall translation inhibition due to the activation of immune system
and cellular toxicity. The mechanism of off-target effects was reviewed extensively
elsewhere [166, 167].
One type of off-target effecs is specific off-target effects. Silencing of non-target genes is
possible if there is as little as 8-nt homology at the seed region sequence [168]. The offtarget effects may also be observed when mRNA shared 7-nt homology with the guide
siRNA sequence [169]. However, not all the mRNA with this level of homology will be
silenced and it depends on the location of complementary region within siRNA and the
mRNA. Seed region is the nucleotides 2–7 at the 5′ end of siRNA. Complementarity
between the siRNA seed region and the 3’ UTR of mRNA is an important predictor for
off-target effects [168]. Several approaches have been developed to avoid the specific
off-target effects. It could be prevented by designing siRNA sequences to minimize the
complementarity between seed region of siRNA and the 3’ UTR of mRNA [170]. One or
two base mismatch between siRNA and target mRNA are usually tolerated without losing
gene silencing efficiency [171]. This allows us to modify the siRNA sequence to
minimize the complementarity with 3′UTRs of the untargeted mRNAs. However, the
modification of siRNA sequence is associated with the risk of losing gene silencing
efficiency. Since the passenger strand is not involved in the recognition with target
mRNA, modifications of passenger stand is preferred and more tolerant. For example,
breaking a passenger strand into two segments significantly reduced off-target effects
[172]. RNA-DNA chimeras [173] have also been developed to avoid off-target effects.
Another type of off-target effects is nonspecific. The innate immune systems could be
activated by several elements including dsRNA, plasmid or viral vectors, cationic
delivery carriers. The activation of immune system causes the inhibition of global gene
expression and false positive gene silencing effect. There are multiple receptors involved
in the activation of immune system. They are cytoplasmic receptors, including dsRNAdependent protein kinase R (PKR), retinoic acid-inducible gene-1 (RIG-1), and
melanoma differentiation-associated gene-5 (MDA-5) [174-176] and endosomal toll-like
receptors (TLRs) [177, 178]. For an example, introduction of long dsRNA into cells leads
to the activation of PKR , and results in the activation of innate immune system and typeI IFN production [176]. Although the use of shorter siRNAs could minimize the
activation of immune response, sequence dependent activation of TLR7 and 8 could not
be eliminated [179]. For vector-based shRNA, siRNA expressed inside the nucleus and
exported into the cytoplasm. The use of vectors-based shRNA could thus avoid the
activation of TLR3, which recognize dsRNA. However, the plasmid vectors will activate
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TLR9, unless the unmethylated CpG motifs were removed from the vectors [180, 181].
High levels of siRNA and shRNA could also compete for intracellular miRNA/shRNA
process machinery. The saturation of epxortin-5 and RISC component, Argonaute-2 will
cause cell toxicity [182]. This can be minimized by designing of proper expression
cassettes to carefully control shRNA expression levels and avoid the saturation of
miRNA machinery.
2.5.

Combinatorial RNAi

Due to the complexity of molecular mechanism of islet cell death, it is almost impossible
to effectively prevent islet cell apoptosis by silencing the expression of a single gene or
over-expression of a single protective gene. Therefore, combinatorial RNAi strategies
which could synergistically work on multiple targets are required to achieve satisfactory
outcomes. This could be realized by simultaneous knockdown of different genes involved
in multiple biological processes or signal pathways. Alternatively, we could also
simultaneously silence certain harmful genes and at the same time over-express
protective genes. Different strategies for combinatorial RNAi will be discussed (Figure
2.4).
2.5.1.

siRNA pool

The use of several siRNAs target different regions of a single gene is more efficient than
the use of a single siRNA sequence in reducing gene silencing. Cheng et al. tested a pool
of two siRNA sequences against TGF-β1 gene in HSC-T6 cells [183]. In that study, the
siRNA pool showed better inhibition of TGF- β1 protein expression as determined by
western blot analysis. In addition, an enhanced inhibition of the expression of
downstream genes including type α1 (I) collagen and α-smooth muscle actin (α-SMA)
were also observed. In another study, Chen et al. used siRNA pool targeting different
regions of human hepatitis B surface antigen. The treatment of this siRNA pool showed
efficient inhibition of hepatitis B surface antigens production at HBV-producing
HepG2.2.15 cells [184]. Alternatively, co-silencing of multiple genes with siRNAs has
also been used to achieve synergistic effect. For an example, siRNA against three
different genes including TNF-α, complement 3 (C3) and Fas were tested to reduce
ischemia/reperfusion injury to donor organs. The siRNAs used in this study, were
supposed to silence several different genes involved in apoptosis, complement activation,
and inflammations [111]. In other studies, combination of siRNAs targeting complement
3 and caspase 3 [104] or siRNAs targeting caspase 3 and caspase 8 [105] have been used
to prevent renal ischemic injury. siRNA pool targeting mRNAs of multiple genes will be
suitable for improving the islet viability because of the involvement of multiple
processes in islet damage.
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Figure 2.4

Combinatorial RNAi strategies for islet genetic modification.

(A) siRNA pool targeting different sites of a single gene or targeting multiple genes. (B)
Co-expression of multiple shRNAs, (I) multiple shRNAs under separate promoters, (II)
miRNA cluster mimics, (III) long hairpin RNA. (C) Co-expression of shRNAs and
cDNAs, (I) from a single miRNA backbone, (II) from separate promoters.
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2.5.2.

Co-expression of multiple shRNAs

There are several scenarios for co-expression of multiple shRNAs from a single vector:
(1) multiple shRNAs with the same sequence, (2) multiple shRNAs against different
regions of the same gene, or (3) multiple shRNAs against different genes. For the first
one, the purpose is to increase the intracellular shRNA levels. However, it is rarely used
because the shRNAs levels could be controlled more conveniently by selecting proper
promoters. The use of multiple shRNAs against different regions of a single gene is
believed to be more efficient in reducing target gene expression levels, possibly due to
the synergistic effect. The advantage of using multiple shRNAs against different genes is
the possibility to block multiple mediators in the signal pathways. Co-expression of
multiple shRNAs were widely studied as an antiviral treatment modality [185]. Although
the disease targets are different, the shRNAs expression strategies could be applied to
genetic modification of islets. Here, some strategies for co-expression shRNAs will be
reviewed.
Gonzalez et al. constructed a vector where multiple shRNAs against HLA class genes
were under the control of a common U6 promoter. A dose dependent increase in RNAi
efficiency was achieved though raising shRNA copy numbers up to six [186]. Several
other studies demonstrated the feasibility of co-expressing multiple shRNAs by utilizing
miRNA backbone. In these studies, strong promoters (such as a CMV promoter or a
unbiquitin C promoter) were used to control the expression concatemerized multiple
miRNA (miR30 or miR155)-based shRNAs [158, 187-189]. However, the increase in
shRNA copy number does not necessary improve gene silencing efficiency. Further
investigation will help us to understand the optimal hairpin numbers, positions, backbone
sequences required for efficient RNAi.
Long hairpin RNA (lhRNA) [190, 191] or extended hairpin RNAs (e-shRNAs) [192,
193], also showed the potential to co-express several siRNAs. For an example, Liu et al.
constructed a vector with e-shRNAs containing two siRNAs and found that a stem length
of 43 bp is the minimal requirement. The 66 bp was the minimal length needed to
produce three siRNAs [193]. Instead of expressing multiple shRNAs, a single hairpin
with multiple siRNAs was expressed in this type of construct. Different levels of gene
silencing were observed among these siRNAs and were dependent on their position to the
stem loop. The siRNA most close to the loop showed comparable gene silencing to single
shRNA, however, other siRNAs usually showed less gene silencing efficiency [191,
193]. In addition, three siRNA units is the upper limit for one construct and the gene
silencing efficiency was significantly reduced when four siRNA units were included
within one construct [193].
Alternatively, it is also possible to express shRNAs from two or more independent
promoters. For example, two shRNAs against different isoforms of glycogen synthase
kinase 3 gene were under the control of separate U6 promoters and achieved efficient
inhibition of target gene with additive effect [194]. A similar study showed the use of
separate U6 promoters to control the expression of shRNAs targeting different Smads
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[195]. Co-expression of multiple miRNA-based shRNAs against different gene has also
been reported [196].
2.5.3.

Co-expression of shRNAs and cDNAs

We have recently demonstrated the beneficial effects of co-expressing multiple genes
from a single vector for improving the outcome of islet transplantation. The combination
of growth factor and anti-apoptotic genes showed synergistic effect in protecting
transplanted islets [18, 19]. A vector could co-express both siRNA and cDNA will be
particularly interesting [197]. Not only is the inhibition of harmful genes but also overexpression of protective genes is needed to protect islets. We constructed vectors for coexpression of shRNAs against iNOS genes and a VEGF cDNA. In this vector, VEGF was
designed to promote the revascularization of transplanted islets. The shRNA against
iNOS were designed to reduce the expression of iNOS genes and minimize iNOS
mediated islet cell death. In this study, we also investigated the use different expression
cassettes for co-expression of shRNA and cDNA from a single vector. The plasmid
vector contained two expression cassettes, where VEGF was under the control of a strong
CMV promoter and shRNA was driven by U6, H1, or CMV promoters. Alternatively, it
was also possible to express cDNA and shRNA from a single expression cassette. In this
case, we used CMV promoter to drive the expression of miRNA-based shRNA and
VEGF cDNA was inserted between the CMV promoter and shRNA. This strategy was
reported previously by Qiu et al. , where a miRNA-based shRNA was placed in the 3’UTR of a red fluorescent protein (RFP) for co-expression of both shRNA and RFP [198].
Similar study was also reported by Shin et al., where a GFP gene was inserted between
the Tet response element promoter and miR30-based shRNA. This construct allows the
co-expression of both GFP and shRNA [196]. In our study, both monocistronic and
bicistronic systems showed high VEGF expression and efficient reduction of iNOS gene
expression. These vectors could be further modified by replacing VEGF cDNA with
another cDNA such as hepatocyte growth factor (HGF), which will enhance angiogenesis
and promote β cell proliferation. The shRNA against iNOS genes could be replaced
various other shRNA targeting proapoptotic and inflammatory genes.
2.6.

Delivery Strategies for Enhanced Gene Silencing

Although good progress has been made since the discovery of RNAi technique, the
application of RNAi for therapeutic purposes is still limited, because of several
biological barriers for siRNA delivery [199]. Systemic delivery of siRNA is required to
block host against islet graft immune rejection. However, siRNA face several biological
barriers after systemic administration [199], which usually result in the degradation of
siRNA. Another potential issue for systemic siRNA delivery is the lack of its targeting
ability, which requires the use of targeted delivery system to avoid gene silencing on
other tissues or organs. In addition, the systemic administration will possibly induce the
immune reaction not only by the siRNA but also by the delivery system, especially, when
a viral vector is used. Alternatively, ex vivo delivery is an ideal approach for genetic
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modification of islets prior to transplantation. Since after isolation, islets are usually
preserved in storage solutions before transplantation, we can transfer siRNA into islets
prior to transplantation. This ex vivo siRNA delivery approach can also be used to
generate immune tolerant dendritic cell (Tol-DC).
The design of proper delivery systems is critical for the clinical application of RNAi
technology. Both non-viral and viral vectors have been widely used. The main advantage
of viral vectors is their high transduction efficiency. However, the use of viral vectors is
undermined due to safety issues and also the construction of individual viral vector is a
time consuming process. Alternatively, non-viral approaches, which could avoid the
problems for viral vectors, have become a promising approach for gene silencing. In this
section, we will discuss siRNA delivery systems applicable to islet transplantation
(Figure 2.5). Firstly, we will discuss the possibility of using free siRNA and chemically
modified siRNA. Secondly, we will visit the cationic lipids or polymers for siRNA
delivery. Thirdly, the use of bioconjugation will be discussed, which could enhance
siRNA delivery into the cells and increase siRNA stability. Finally, we will summarize
some viral vectors used for gene silencing including adenovirus and lentivirus.
2.6.1.

Free siRNA

Free siRNAs are difficult to be transfected into the cells mainly because of their poor cell
membrane permeability and sensitive to nuclease mediated degradation. However, it is
still possible to deliver free siRNAs to islets with some physical approaches, such as
hydrodynamic injection [200], in situ perfusion [201], and microporation [202]. Zheng et
al. protected donor organs for heart transplantation with siRNA-containing solution
[111]. In that study, heart graft from BALB/C mice were preserved in solution containing
siRNAs against several genes involved in ischemia/reperfusion injury. This treatment
resulted in efficient silencing of target genes in the grafts and lead to improved graft
function. Due to the similarity among different organ transplantations, this approach
should be equally applicable for islet transplantation.
However, native siRNA is degraded rapidly due to nuclease attack, therefore, chemical
modification of siRNA has been extensively studied to (1) minimize nuclease
degradation; (2) avoid innate immune system activation; and (3) reduce off-target effects
[203, 204]. Since most siRNAs were produced through chemical synthesis, it is
technically possible to incorporate various modifications into siRNA backbones (Figure
2.6). These modifications could be applied to phosphodiester or ribose. Non-bridging
oxygen in the phosphodiester could be replaced with sulfur (phosphorothioate), boron
(boranophosphate), or methyl (methylphosphonate) groups. The 2’-position of the ribose
could also be modified to improve the stability of siRNA. The modification of ribose
includes 2’-O-methyl (2’OMe), 2’-fluoro(2’-F), 2’-O-fluoro-β-D-arabinonucleotide
(FANA), 2’-O-(2-methoxyethyl) (MOE), and locked nucleic acid (LNA), which contains
a methylene bridge connecting the 2’-O with the 4’-C of the ribose ring. Single or
combination of various types of modifications could be used depending on the aim of
modification, which will be briefly discussed below.
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Figure 2.5

Delivery strategies for gene silencing.

Cationic liposomes and polymers are commonly used as transfection reagents for siRNA
and shRNA. To avoid the use of cationic carriers, siRNA can also be conjugated to
polymers such as poly(ethylene glycol) carrying targeting ligand(s). For enhanced and/or
prolonged gene silencing, shRNA is often cloned into a viral (adenovirus, lentivirus, or
adeno associate virus) vector. After administration, these delivery systems enter the cells
mainly through endocytosis. Vector-based shRNA is further translocated into cell
nucleus, where shRNA is expressed to produce pri-shRNA, which is further processed
into pre-shRNA by an enzyme named Drosha. Pre-shRNA is exported to the cytoplasm
by exportin-5, where it is processed by Dicer (an RNAse III enzyme) to produce
functional siRNA. For siRNA bioconjugation or siRNA complex, the escape and release
of free siRNA from endosome into cytoplasm is an essential step. Finally, siRNAs will be
incorporated into RNA-induced silencing complex (RISC) and guide the recognition and
degradation of target mRNA.
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2.6.1.1. Enhancing serum stability
Unmodified naked siRNAs are extremely unstable with a serum half-life of less than 5
min [205, 206], which restricts their clinical application. Thus, chemical modification of
siRNAs has been extensively studied to improve the resistance of siRNAs to nuclease
degradation. Theoretically, all above mentioned modifications can be applied to increase
the serum stability of siRNA. The modification strategies should be carefully designed,
since extensive modification of siRNAs usually leads to decreased potency [207-209].
Alternatively, selective modification of siRNAs at minimal position has been
demonstrated to significantly improve the serum stability, while keeping the gene
silencing potency. The 2’-O-Me or 2’F-RNA modification have been applied to the
termini of the strands or a pyrimidine nucleotide which are vulnerable position for
nuclease cleavage [24, 207, 210].
2.6.1.2. Reducing innate immune system activation
As we discussed previously, siRNAs will activate the innate immune system and result in
non-specific off-target effects. Chemical modifications can also be used to avoid or
minimize siRNA-mediated activation of immune system. For an example, 2’-O -Me
modification of siRNA was able to minimize the immune system activation [211]. Since
the 2’-O-Me group is a competitive inhibitor of TLR7, minimal number of 2’modification is sufficient to inhibit the TLR-7 mediated immune stimulation [212].
2.6.1.3. Reducing off-target effects
Chemical modification could be applied to reduce specific off-target effects through
minimizing the unwanted participation of siRNA in miRNA pathways. For an example,
modification of the +2 position with 2’-O-Me on the antisense strand effectively reduced
seed region mediated off-target effects [168]. The seed region could also be replaced
entirely with DNA residues to reduce off-target effects while preserving the gene
silencing potency [173].
2.6.2.

Complex formation

Both cationic liposomes and polymers are widely used to form complexes with siRNA or
plasmid shRNA through electrostatic interaction between positive charged carriers and
negatively charged nucleic acids. Complex formation helps to condense siRNA or
plasmid DNA and thus facilitate their cellular uptake.
Cationic lipids: Since the introduction of lipofectin at late 1980s [213], many cationic
liposomes have been tested for delivery of plasmids, and recently for the delivery of
siRNA. There are several commercial cationic lipid formulations for siRNA delivery,
including lipofectamine 2000, oligofectamine, lipofectamine, RNAifect, and Fugene HD.
We have tested lipofectamine to transfect a plasmid encoding an enhanced green
fluorescent protein gene, pCMS-eGFP into intact human islets. However, only low
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transfection efficiency was observed, this is due to the fact that human islets are a cluster
of around 1000 non-dividing cells [16]. In our further studies, a novel lipid with
methylsulfonic acid in the cationic head group region to enhance lipid/DNA interaction
was synthesized, which showed higher transfection efficiency than those of lipofectamine
in intact human islets [214]. In contrast to plasmids, siRNA is efficiently transfected into
human islets as well as INS-1E rat β cell line. In this study, we used lipofectamine 2000
to transfect fluorescein-labeled siRNA. The transfection efficiency was determined by
flow cytometry analysis. There was increase in transfection efficiency with increase in
siRNA concentration, with maximum transfection efficiency of 95.9% and 28.3% on rat
β cell line and intact human islets, respectively [115]. This demonstrated the feasibility of
in vitro genetically modifying human islets with siRNA/lipid complex.
Cationic polymers: In addition to cationic lipids, cationic polymers are also being used
for plasmid or siRNA delivery. Although we could achieve decent in vitro transfection
efficiency by optimizing transfection conditions, the cellular toxicity of cationic carrier is
a major concern for its therapeutic applications. Furthermore, the poor intracellular
dissociation of siRNA/polycation complex may reduce the intracellular bioavailability of
siRNA. Recently, several biodegradable carriers have been developed to reduce toxicity
and improve transfection efficiency. Here, we focus on the some recent progresses, rather
than a comprehensive review of the use of cationic polymer for siRNA delivery which
was extensively discussed elsewhere [215].
Reducible biodegradable carriers are designed based on the different redox potential
between intra and extra cellular environment. The disulfide bonds in these carriers are
usually stable enough to keep the integrity of the carrier and protect siRNA before
cellular uptake. After cellular uptake, the disulfide bonds are cleaved, in response to the
reducing intracellular environment. This will result in the degradation of carriers and
release of siRNA. Reducible polymers with disulfide bonds have been investigated for
delivery of both plasmid and siRNA [216-222]. The advantage of using reducible
polymers is obvious, which not only reduced carriers associated toxicity, but also
enhanced dissociation of siRNA from polycation/siRNA complex and thus improved
gene silencing efficiency. The performance of these carriers could be further improved by
incorporation of endosomal escaping moieties, such as histidine [220], and protonatable
pendants [221]. Since the endosomal release of siRNA is a significant barrier for siRNA
and gene delivery, those components which could facilitate “endosomal escape” will
greatly enhance the gene silencing efficiency.
Poly (amino ester) (PAE) is another type of biodegradable polymers which has been
extensively studied for gene delivery. Green et al. generated a library of PAE and
determined parameters such as polymer type, polymer weight, DNA loading, and other
biophysical properties. The leading PAE carrier found in their studies were better than
jetPEI and lipofectamine2000 [223]. PAE has also been successfully used for siRNA
delivery into lung cancer cells [224], hepatoma cells and primary hepatocytes [225], and
fibroblasts [226]. Besides, several other biodegradable polymers can also be used for
siRNA delivery, including polyphosphoesters [227-229], poly(2-aminoethyl ethylene
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phosphate) [230], poly(ethylene glycol)-peptide copolymers [231] and ketalized
polyethylenimine [232].
2.6.3.

siRNA bioconjugation

Bioconjugation of siRNA with lipids, polymers or other molecules will help to enhance
its cellular uptake, systemic stability, and targeted delivery to specific cells. Technically,
siRNA could be modified at the 5’ or 3’ terminus of sense strand or antisense strand.
Because of the pivotal role of antisense strand in gene silencing, the modification of
sense strand is preferred. Both cleavable and non-cleavable bonds can be used for siRNA
conjugation. Acid-sensitive or reducible disulfide bonds are the most commonly used,
because of the enhanced release of siRNA from conjugation inside the cell. It could avoid
potential negative effects of bioconjugation and provide more amount of free siRNA
available for gene silencing.
The molecules used for conjugation with siRNA determine the properties of siRNA
conjugate. Attachment of lipids usually increases the hydrophobicity of siRNA, which
are highly hydrophilic macromolecules. Lipophilic molecules such as cholesterol [233],
bile acid and long chain fatty acid [234, 235], and vitamin E [236] could be conjugated to
siRNA. After systemic injection, siRNA-lipid conjugate binds with lipoproteins
depending on the degree of hydrophobicity. The interaction between siRNA-lipid
conjugate and lipoproteins, lipoprotein receptors and transmembrane proteins has a great
influence on the biodistribution and cellular uptake of siRNA after intravenous injection
[234]. For an example, siRNA bound to low density lipoprotein (LDL) is mainly
delivered to the liver, while a broader distribution was observed for siRNA binding to
high density lipoprotein (HDL).
Conjugation of siRNA with cell-penetrating peptides (CPPs) such as TAT [237, 238],
penetratin [238] and Transportan [239], has also been studied for siRNA delivery.
siRNA-peptide conjugates show a cellular uptake as efficient as that achieved by cationic
lipids and resulted in efficient silencing of target genes. However, conjugation of siRNA
with peptides does not improve the in vivo stability of siRNA [238]. In addition, innate
immune response could be activated after intratracheal administration of pentratin-siRNA
conjugate [238], may be due to the immunogenicity of peptide.
To increase the systemic stability of siRNA, poly(ethylene glycol) (PEG) has been
conjugated to siRNA by several research groups. In this type of conjugation, siRNA can
be linked with PEG through disulfide bond or ß-thio-propionate linkage. Polyelectrolyte
complex micelles (PEC micelles) were formed between PEG-siRNA and cationic peptide
(KALA) [240] or cationic polymers, such as polyethylenimine (PEI) and poly(L-lysine)
(PLL) during the application of siRNA-PEG conjugate. A core was formed between
negatively charged siRNA and polycation through condensation, while PEGs are
surrounding the core to form a hydrophilic shell. This special core-shell structure can
effectively protect siRNA against enzymatic degradation; prevent self-aggregation
between PEC micelles, and increase the circulation time after systemic administration.
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This delivery system can efficiently silence VEGF gene expression in PC-3 cells in vitro
[240, 241]. After intravenous injection, enhanced distribution of PEC micelles in tumor
was observed, which resulted in significant reduction in VEGF expression in tumor and
suppressed tumor growth [242]. siRNA-PEG PEC can be further improved by
conjugation of lactose moiety at the distal end of PEG (siRNA-PEG-Lac). This will
confer targeting ability to this carrier. The cellular uptake of siRNA in hepatoma cells
was enhanced via receptor mediated endocytosis [243, 244]. Delivery of siRNA against
RecQL1 gene with lac-PECs inhibited muticellular HuH-7 spheroids growth for up to 21
days, while almost no effect was observed with oligofectAMINE/siRNA lipoplexes. It is
probably due to the facilitated cellular uptake of Lac-PECs into the spheroids cells [244].
In addition to the enhanced delivery, siRNA are also conjugated with probes or dyes for
bioimaging [245]. Multiple component siRNA conjugate was prepared which includs
iron oxide core coated with crosslinked dextran coat, cy5.5 dye, as well as siRNA. After
in vitro incubation, this conjugate was efficiently taken up by murine islets. The celluar
uptake of siRNA was observed by magnetic imaging of iron core and near-infrared
imaging. This study showed the posibility to integrate gene silencing and imaging
components into a single conjugate to create a multiple function siRNA conjugtes.
2.6.4.

Viral vectors

As naturally evolved vehicles, viral vectors utilize the virus infection mechanism for
efficient gene transfer into host cells. Although safety concerns retarded the clinical use
of viral vectors, their application in genetic modification of islets has the potential to
improve the outcome of islet transplantation. This is mainly because of their high
transduction efficiency compared with non-viral vectors. Here, we will discuss the
properties of some commonly used viral vectors and their application in islet
transplantation.
2.6.4.1. Adenovirus
Adenovirus is non-enveloped DNA virus, which could infect both dividing and nondividing cells. Recombinant adenovirus derived from adenovirus serotype 5 is commonly
used for gene delivery. E1 region, which is essential for virus replication, is usually
deleted to make replication-deficient adenovirus. In addition, adenoviral genome will not
integrate to the targeting cells; therefore, a transient gene expression is achieved by
adenoviral vector. The advantages of adenovirus include capacities to carry large DNA
insert, easy to produce high titer virus, and its ability to infect non-dividing cells with
high efficiency and high gene expression level.
We and others have used replication deficient adenoviral (Adv) vectors for ex vivo
transduction of genes to islets to reduce the immune attack, prevent apoptosis, and
promote the revascularization of transplanted islets [15, 18, 19, 64, 107, 117, 246]. Bain
et al. first reported the feasibility of using Adv vector for gene silencing in islets and β
cell lines [247]. Adv vectors expressing siRNA against GLUT2 gene was used in their
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study to transduce rat islets. Maximum reduction in GLUT2 gene expression was
achieved 3 days post transduction with > 90% at both mRNA and protein levels. After
then, Adv vectors have been used to silencing different genes in islets to study the
function of genes, such as synaptotagmin 9 [248], pyruvate carboxylase [249], tissue
factor [250], and proislet amyloid polypeptide [251]. The maximum silencing efficiency
was varied from 35% to 75% and achieved 3-4 days post-transduction. Gene silencing
efficiency is determined by several factors: (1) the properties (turnover time, abundance)
of target gene mRNA and protein; (2) the design of siRNA targeting sequence as well as
expression cassette.
Since caspase 3 played an important role in islet β cell apoptosis induced by different
factors, the inhibition of caspase activities was a potential approach to improve the graft
survival [64]. Recently, we determined the level and duration of caspase 3 gene silencing
after transfection of caspase 3 siRNA into INS-1E cells and demonstrated transient gene
silencing which did not last beyond 3 days. In an attempt to enhance the level and
duration of caspase 3 gene silencing, we then constructed Adv vectors expressing shRNA
against caspase 3 (Adv-caspase-3-shRNA) and determined their gene silencing efficiency
in human islets. This adenoviral vector showed efficient caspase 3 gene silencing, which
became more significant on day 5. Further, Adv-caspase 3-shRNA mediated caspase 3
gene silencing was able to counteract inflammatory cytokine-induced islet cell apoptosis
in vitro. Taking care of these encouraging in vitro results, we then transduced human
islets with this advenoviral vector prior to transplantation under the kidney capsules of
diabetic NOD-SCID mice. There was some improvement in islet survival and function
after transplantation [107].
Adv vectors have several particular advantages for gene silencing in human islets. (1)
Thorough understanding of the structure of Adv DNA may provide much flexibility in
genetically engineer Adv vectors to make them more proper for shRNA delivery and
expression. For example, it is convenient to construct shRNA expression vectors with
different promoters and backbones with commercially available Adv shuttle vectors for
optimal gene silencing; (2) high expression levels achieved by Adv vectors will help to
increase gene silencing efficiency and help to get more beneficial effect. (3) Adv vectors
has the capacity to carry a large insert, which will make it possible to express multiple
shRNAs; or to co-express an shRNA to silence harmful genes and a cDNA to protect
islets [117]. The disadvantage of Adv vector is the transient expression profile, which is
not suitable for long-term gene silencing. Since the majority of islet cell death occurs
within several days after transplantation, the use of Adv to silence genes involved in this
process is appropriate.
2.6.4.2. Lentivirus
Lentivirus is a type of retroviral vector, which reverse transcribes into DNA, be actively
transported into the nucleus, and integrate into the genome of target cells. Therefore,
stable gene expression or silencing could be achieved by using lentiviral vector [252].
Unlike other retrovirus such as moloney murine leukemia virus, which could only
transduce dividing cells, lentivirus can transduce both dividing and non-dividing cells.
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Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vectors is the
most commonly used vector, which could transduce a broad range of cell types [253].
Lymphocytic choriomeningitis virus (LCMV)-pseudotyped is more efficient in
transducing human islet insulin-secreting ß cells and shows less toxicity compared with
VSV-G pseudotyped lentivirus [254]. Lentivirus were successfully used for genetic
modification of islets with various genes, including reporter genes (GFP, Luciferase)
[255, 256], antioxidative genes [257], antiapoptotic genes (cFLIP) [255], antiinflammatory and immunoregulatory genes (CTLA4, TGF-β, interleukin-1 receptor
antagonist, and IL-4) [258-260]. Unlike Adv vectors which give high level transient gene
expression, a prolonged gene expression is usually achieved after transduction islets of
lentiviral vectors. For example, after transduction of islets with lentiviral vectors
encoding a luciferase gene, bioluminescence is persistent for above 140 days post
transplantation. However, the bioluminescence of islets transduced with Adv vector
encoding a luciferase gene decrease from thousand fold at the beginning to ten fold over
background at 60 days posttransplantation [256]. An optimized ex vivo transduction
procedure should neither induce significant toxicity nor affect the insulin release function
of islets [257]. In addition, lentiviral vectors-induced immune system activation was also
minimal [260]. Under optimized conditions, lentivirus could transduce around 10% to
30% of islet cells in an intact islet, which are mainly the cells at the periphery [255, 261,
262]. This is still enough to have significant effect on the viability, probably due to the
“barrier” effect, that is shield the core of islets by protecting the periphery of islets [255].
Several other approaches have also been investigated to improve the transduction
efficiency. Callewaert et al. demonstrated increased transduction efficiency from around
11.2% to 80.0% by dissociation of islets to single cells prior to transduction and reaggregation of islets before transplantation [262]. However, improvement in the
transfection efficiency did not translate into the improved function of islets. More cells
are needed to achieve normoglycemia compared with intact islets. Barbu et al. tested the
possibility to transduce islets by whole pancreas perfusion. This transduction procedure
could transduce 30% of the cells, while keeping the structural integrity of islets.
However, the cells within the core of islets still cannot be effectively transduced [263].
Lentiviral vector has also been used for shRNA delivery for gene silencing [264].
Because of the long term expression achieved by lentiviral vectors, it has been used to
stably silence harmful genes to prevent the death of islet β cells. For example,
transduction of lentiviral vectors carrying shRNA against iNOS gene, significantly
reduced IL-1β-induced iNOS expression in islet β cells and protect β cells from IL-1βinduced cell death [113]. Since the silencing effect achieved by lentiviral vector is long
term, it is suitable for delivery of shRNA against genes that need to be continuously
silenced. Otherwise, an inducible or switchable expression cassette should be used to
control the timing of gene silencing and thus avoid potential side effects.
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2.7.

Concluding Remarks

Theoretically, any gene of interest could be silenced or effectively inhibited, which is
unachievable by conventional small molecule chemicals. In the past few years, RNAi
technology has moved rapidly from bench to bedside at unprecedented speed. Currently,
there are more than ten ongoing and completed clinical trials using siRNA as therapeutics
(http://clinicaltrials.gov). It is interesting to note that one of these trials sponsored by
Quark Pharmaceuticals was related to kidney transplantation, where a siRNA named
I5NP was tested for the prophylaxis of delayed graft function in kidney transplantation
patients. Although recent progresses have already demonstrated its great potential, the
application of RNAi technology for improving the outcome of islet transplantation is still
a fledgling area. Further understanding of the biological perspective of the islets
transplantation is essential, as it may help to discover effective RNAi target genes. A
combination of multiple gene silencing or simultaneously gene silencing and gene overexpression is likely to have improved beneficial effects through synergistic effects.
Meanwhile, the advances in RNAi technology will enable us to design more potent
siRNA or shRNAs, while minimizing the side effects caused by off-target effects and
immune simulation. Last but not the least, the development of safe and efficient delivery
systems is the key for successful gene silencing.
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CHAPTER 3. INOS GENE SILENCING PREVENTS INFLAMMATORY
CYTOKINE-INDUCED β CELL APOPTOSIS*
3.1.

Introduction

Human islet transplantation is a promising therapeutic strategy for treating type I diabetes
mellitus. Despite recent success, islet transplantation still lags behind primarily because a
large number of transplanted islets do not function. This results in the need for multiple
islet infusions for each patient. Most islet grafts are destroyed due to immune and
inflammatory reaction mediated by proinflammatory cytokines, such as interleukin-1ß
(IL-1β), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). These
proinflammatory cytokines induce a series of intracellular inflammatory signal cascades,
leading to β-cell death, probably due to apoptosis, necrosis, and other processes [52]. The
stimulation of inducible nitric oxide synthase (iNOS) expression and consequent
production of radical nitric oxide (NO) as well as of the other radicals, such as
peroxynitrite (OONO-) and superoxide (O2-) represent a pivotal step in these processes
[48, 63, 265, 266]. The inhibition of iNOS has shown significant protection of β cells
from proinflammatory cytokine-induced damage [113, 267, 268]. Therefore, it is
reasonable to suggest that iNOS might be a potential target for improving the outcome of
human islet transplantation.
RNA interference (RNAi) is a promising therapeutic strategy which utilizes an
evolutionary conserved biologic process to induce sequence-specific, post-transcriptional
gene silencing by small interference RNA (siRNA) [269]. siRNA-mediated gene
silencing in rodent β-cells and pancreatic islets has been shown to inhibit a target gene
[270, 271]. In mouse insulinoma cells, Burkhardt et al. [108] demonstrated that siRNA
targeting Fas, another important mediator of β-cell death, was able to silence Fas gene
expression and inhibit Fas-mediated β-cell damage in response to inflammatory
cytokines. Keeping these promising findings in mind, we recently tested the effect of
chemically synthesized siRNAs against iNOS and NF-κB on gene expression, NO
production, and apoptosis in insulin producing β-cell line (INS-1E) and demonstrated
that silencing of iNOS gene to be more effective than that of NF-κB [116]. There are also
conflicting reports on the role of NF-κB on pancreatic β-cell death [62, 272, 273].
McCabe and O’Brien used lentiviral vector-based shRNA delivery to suppress IL-1mediated induction of iNOS expression, resulting in significant protection against the
cytotoxic effects of IL-1 exposure [113, 114]. However, these authors used rat
insulinoma (RIN-r) cell lines and not human islets. Moreover, they did not determine the
functional viability of RIN-r cells by measuring glucose-stimulated insulin release.
Taking care of the usefulness of iNOS gene silencing in islet transplantation, in this
study, we compared transfection efficiency and effect of iNOS gene silencing on
* Adapted with permission. F. Li, R.I. Mahato, iNOS gene silencing prevents
inflammatory cytokine-induced ß cell apoptosis, Mol Pharm, 5 (2008) 407-417.
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apoptosis in INS-1E cells and intact human islet, which is a cluster of 200-1000 cells and
hard to transfect.
This report implicated the pivotal role of iNOS in cytokine-induced β cell death. We
demonstrate the possibility of using iNOS gene silencing as a strategy to improve the
outcome of human islet transplantation.
3.2.

Materials and Methods

3.2.1.

Materials

Fetal bovine serum (FBS), sodium pyruvate, and CMRL 1066 medium were purchased
from Mediatech, Inc (Herndon, VA). Penicillin/streptomycin, phosphate-buffered saline
(PBS), 0.25% (w/v) trypsin-EDTA and RPMI-1640 medium and OptiMEM-I reduced
serum medium were purchased from GIBCO-BRL (Gaithersburg, MD). 2Mercaptoethanol was obtained from Sigma Aldrich (St. Louis, MO). Recombinant IL-1β,
TNF-α and IFN- were purchased from R&D Systems (Minneapolis, MN). siRNA
against rat iNOS (Gene Bank # NM_012611, Table 3.1) and human iNOS (Gene Bank #
NM_000625, Table 3.2), control siRNA, fluorescein-labeled siRNA, and Lipofectamine
2000 were purchased from Invitrogen (Carlsbad, CA). All primers used for real time RTPCR were obtained from Integrated DNA Technology (Coralville, IA). TUNEL assay kit
was from BD Pharmingen (Franklin Lakes, NJ). Caspase 3 cellular activity assay kit was
purchased from EMD Biosciences, Inc. (San Diego, CA). RNeasy Mini kit and RNaseFree DNase Set were purchased from Qiagen (Valencia, CA). Multiscribe reverse
transcription kit was from Applied Biosystems (Foster City, CA). SYBR Green-I dye
universal PCR master mix and other reagents for real time RT PCR were from Roche
(Indianapolis, IN). Griess assay kit was from Promega (Madison, WI). BCA protein assay
kit was from Pierce Chemical Company (Rockford, IL).
3.2.2.

Cell culture and transfection

Rat insulin producing β-cells (INS-1E cells), a kind gift from Professor Claes B.
Wolheim (University Medical Center, Geneva, Switzerland), were cultured at 37ºC in a
humidified atmosphere containing 5% CO2 in complete medium composed of RPMI
1640 supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 50 M
2-mercaptoethanol, 100 U/mL penicillin, and 100 g/mL streptomycin.
INS-1E cells were seeded 24 h before transfection in a 24-well plate (5 x 105 cells/well)
for all the experiments except for TUNEL assay, for which we used 12-well plates (106
cells/well). siRNAs were transfected into INS-1E cells after complex formation with
Lipofectamine 2000 according to the manufacturer’s instructions. Briefly, siRNA
molecules and Lipofectamine 2000 were mixed together in OPTMEM I reduced serum
medium at a ratio of 30 nmol/1 mg (siRNA/ Lipofectamine 2000), and complex
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Table 3.1

Small interfering RNA (siRNA) sequences of rat iNOS (NM_012611).

Start site
224
675
898
2225

siRNA sequence
S†: 5’-CUACCAAGGUGACCUGAAAGA[dT][dT]-3’
AS‡: 5’-UCUUUCAGGUCACCUUGGUAG[dT][dT]-3’
S: 5’-GAAGCCGUAACAAAGGAAAUA[dT][dT]-3’
AS: 5’-UAUUUCCUUUGUUACGGCUUC[dT][dT]-3’
S: 5’-CCUCGGAUAUCUCUUGCAA[dT][dT] -3’
AS: 5’-UUGCAAGAGAUAUCCGAGG[dT][dT] -3’
S:5’-GUUCGAUGUUCGAAGCAAACA[dT][dT] -3’
AS: 5’-UGUUUGCUUCGAACAUCGAAC[dT][dT] -3’

*ORF region; † S, sense; ‡ AS, antisense.
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Coding region*
224-244
675-695
898-916
2225-2245

Table 3.2

Small interfering RNA (siRNA) sequences of human iNOS (NM_000625).

Start site
511
539
691

siRNA sequence
S†: 5’-CGGCAUGUGAGGAUCAAAA[dT][dT] -3’
AS‡: 5’-UUUUGAUCCUCACAUGCCG[dT][dG] -3’
S: 5’-GCGGGAUGACUUUCCAAGA [dT][dT] -3’
AS: 5’-UCUUGGAAAGUCAUCCCGC[dT][dG] -3’
S:5’-GCUAUCGAAUUUGUCAACC[dT][dT] -3’
AS: 5’-GGUUGACAAAUUCGAUAG [dT][dT] -3’

*ORF region; † S, sense; ‡ AS, antisense.
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Coding region*
511-529
539-557
691-709

formation was allowed to proceed for 30 min at room temperature before adding into
INS-1E cells. At 12 h post transfection, medium containing lipid/siRNA complexes were
replaced with fresh medium.
To determine the transfection efficiency and effect of iNOS gene silencing on protection
of human islets from proinflammatory cytokines, we re-designed three siRNA sequences
targeting different regions of human iNOS mRNA (Table 3.2), and used for transfection
into human islets. These islets were received from one of the several Islet Cell Resource
(ICR) Centers through ICR Services for Basic Science Applications. On arrival at our
facility, islets were cultured at 37 ºC in CMRL 1066 medium supplemented with 10%
FBS. Human islets were seeded at 24-well plate (2000 IE/well) 2 hours before
transfection and were transfected with siRNA after complex formation with
Lipofectamine 2000 as described above.
3.2.3.

Fluorescence microscopy and flow cytometry

To determine the transfection efficiency, INS-1E cells and human islets were transfected
with fluorescein-labeled siRNA after complex formation with Lipofectamine 2000. At 12
h post transfection, cells were visualized under fluorescence microscopy. To determine
the percentage of transfected cells, INS-1E cells were washed with 1 x PBS, trypsinized,
and suspended in 1 x PBS. Since human islets are a cluster of cells, they were treated
with trypsin-EDTA for 10 min at 37 °C followed by vigorous pipeting to create a singlecell suspension. Then the cell suspension were directly introduced to a FACSCaliburTM
Flow Cytometer (Becton Dickinson, NJ) equipped with a 488 nm argon ion laser. The
FL-1 emission channel was used to monitor the fluorescein and results from 10,000
fluorescent events were obtained for analysis. Cells without transfection were served as
negative controls.
3.2.4.

Real time RT-PCR

Expression of rat iNOS gene in INS-1E cells and that of human iNOS in human islets
was determined at mRNA level by real time RT-PCR. Following treatment, total RNA
was extracted with RNeasy Mini KIT and treated with DNase by on-column digestion
(RNase-Free DNase Set). RNA concentration was determined by spectrophotometer
(NanoDrop). One hundred and seventy nanograms total RNA was converted into cDNA
using multiscribe reverse transcriptase reagents and random hexamers at a 10 µl reaction
system. Two microliters of cDNA were used as a template and analyzed by SYBR
Green-I dye universal PCR master mix on LightCycler 480 Instrument. The primers used
for real-time PCR were as follows: rat iNOS [116] Forward: 5’ACCAGAGGACCCAGAGACAAGC-3’; Reverse: 5’TCCAGGCCATCTTGGTGGCAAA-3’ (amplicon size 208 bp); rat 18S rRNA
[274]:Forward: 5’-CGG CTA CCA CAT CCA AGG AA-3’ ; Reverse : 5’-GCT GGA
ATT ACC GCG GCT-3’(amplicon size 186 bp); human iNOS [275]: Forward 5’ACGTGCGTTACTCCACCAACA-3’; Reverse 5’-CATAGCGGATGAGCTGAGCA40

3’(amplicon size 102 bp); human ribosomal protein S19 (human S19); Forward 5’
GCTTGCTCCCTACCGATGAGA-3; Reverse 5’-ACCCCGGAGGTACAGGTG3’(amplicon size 73 bp). To assess the specificity of the amplified PCR product, the
Melting Curve Analysis was performed on the LightCycler 480 Instrument. The results
iNOS mRNA level were compared by calculating the CP value and normalized by the
reference genes (rat 18S or human S19). Four independent experiments were performed
and the results were expressed as a percentage of control.
3.2.5.

Griess assay

Nitric oxide (NO) is rapidly oxidized in culture medium into nitrite, which accumulate in
the sample and can be easily correlated with NO production. Therefore, nitrite
concentration was determined using the Griess assay (Promega, Madison, MI). Fifty
microliters of cell culture supernatant was added to a 96 well-plate and mixed with 50 µL
of 1% sulfanilamide in 5% phosphoric acid solution and incubated for 5 min at room
temperature in dark. Then, 50 µL of 0.1% N-1-napthylethylenediamine dihydrochloride
(NED) aqueous solution was added to each well. The plate was incubated for additional
10 min, and absorbance was measured at 560 nm using a microplate reader. To determine
the nitrite concentration in each sample, a standard curve was prepared using nitrite
standard solution and culture medium as matrix.
3.2.6.

Effect of iNOS gene silencing on apoptotic cell death

3.2.6.1. Microscopy
To determine whether iNOS gene silencing inhibits apoptosis of  cells due to
inflammatory cytokines, INS-1E cells (106 cells/well in a 12 well plate) were transfected
with siRNA against iNOS as well as with control siRNA. The cells were incubated with a
cocktail of TNF- (50 pg/mL), IL-1 (5 ng/mL) and IFN- (50 ng/mL) for 48h, then
visualized under microscopy.
3.2.6.2. Caspase 3 activity assay
The cellular caspase 3 activity of INS-1E cells or human islets was measured with
Caspase 3 Cellular Activity Assay Kit. INS-1E cells were seeded at a density of 5 x 105
cells/well in 24-well plate; human islets were seeded at a density of 2000 IE/well in 24well plate. After treatment, cells were collected and lysed with lysis buffer. Ten
microliters of the cell lysate solution was added in 40 µL assay buffer and mixed with 50
µL caspase 3 substrate (Ac-DEVD-pNA) at a half volume 96-well plate. The mixture
was kept at 37°C and absorbance at 405 nm was read continuously using a
spectrophotometer every 5 min for one hour. The absorbance versus time for each sample
was plotted and the activity was calculated from the slope of the linear curve. To
normalize the activity, total protein concentration of each sample was also measured with
BCA protein assay kit.
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3.2.6.3. TUNEL assay
To gain insights on the mechanism of  cell death, a terminal
deoxynucleotidyltransferase dUTP nick end labeling (TUNEL) assay with the APODIRECTTM kit was used to detect apoptotic cells. Following transfection and incubation
with a cytokine cocktail, INS-1E cells and human islets were made to single cell
suspension as described above. The cells were fixed in 1% paraformaldehyde in PBS (pH
7.4) and then treated with ice-cold 70% ethanol, stained with FITC-dUTP, and then with
propidium iodide. The intensity of fluorescence was measured by a flow cytometer and
analyzed using CELLQUEST software (BD Bioscience). Non-transfected cells without
cytokine treatment were served as a negative control. Three sets of independent
transduction experiments were carried out for each assay.
3.2.7.

Assessment of human islet function post-transfection

The ability of human islets to respond to glucose stimuli was used to determine the effect
of transfection of Lipofectamine 2000/siRNA complexes on human islet function.
Following transfection, islets were incubated with a cocktail of inflammatory cytokines
including TNF- (50 pg/mL), IL-1 (5 ng/mL) and IFN- (50 ng/mL) for 48 h. Then,
islets were challenged with two different concentration of glucose (60 mg/dL and 300
mg/dL) for 1 h at 37 C. Supernatants were then collected for measuring insulin secretion
by human insulin ELISA Kit (Alpco Diagnostics, Windham, NH). Results were
normalized by measuring the total protein using a BCA assay kit. Stimulation index was
calculated by measuring insulin release by islets 1h after incubation with media
containing basal (60 mg/dL) and stimulated (360 mg/dL) levels of glucose.
3.2.8.

Statistical analysis

The difference between groups was determined by unpaired t-test and a P < 0.05 was
considered statistically significant. Results are expressed as the means ± standard
deviation (SD).
3.3.

Results

3.3.1.

Transfection efficiency of lipid/siRNA complexes in rat β cells

We used fluorescein labeled siRNA at a concentration of 50,100, and 150 nM to
quantitatively asses the incorporation of siRNA into rat β cells. After 12 h of incubation
with Lipofectamine 2000/fluorescein-labelled siRNA complexes, cells were observed
under fluorescence microscopy. Figure 3.1A demonstrates that these cells were
effectively transfected with fluorescein-labeled siRNA. The photographs show green
cells with distinct spots speckled their surface and in the nucleus, suggesting enhanced
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Transfection efficiency of siRNA into rat insulin producing β cells.

INS-1E cells were transfected with fluorescein-labeled siRNA, after complex formation
with Lipofectamine 2000 at siRNA concentration of 50,100,150 nM. At 12 h after
transfection, cells were visualized under fluorescence microcopy and analyzed with flow
cytometry. (A) Fluorescent images showing fluorescein-labeled siRNA incorporation into
INS-1E cells. Left panels show cells under visible light, and right panel under visible
light. Upper panel is low magnification (100 X) and lower panel is high magnification
(400 X). (B) Percentage of green fluorescence positive cells. Results are the mean ± SD,
n = 3. The p value of < 0.05 was considered statistically significant.
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cellular uptake and nuclear translocation. To quantitatively determine the transfection
efficiency, cells were analyzed by flow cytometry. As shown in Figure 3.1B, the
transfection efficiency increased from 75.9% to 95.9% with increase in siRNA
concentration from 50 nM to 150 nM. The average fluorescence intensity also increased
accordingly from 2.48 x 104 to 6.72 x 104 (Data not shown).
3.3.2.
cells

Effect of siRNA sequence on iNOS gene silencing and NO production on rat β

Figure 3.2A demonstrates the effect of siRNA sequences on iNOS gene silencing. All
four siRNA sequences were able to silence iNOS expression and siRNA-iNOS-898
showed silencing around 50% of iNOS expression. Figure 3.2B shows the effect of
siRNA sequence on the NO production by rat β cells. Compared with control siRNA, all
four siRNAs targeting different regions of rat iNOS mRNA showed inhibition of NO
production by rat β cells. Among them siRNA-iNOS-898 was the most potent one, which
reduced the NO production by 60%. Therefore, siRNA 898 was used for further studies
on rat β cells. We also noticed that there was almost no change in the NO production in
the control siRNA treated group (Figure 3.2B), which indicates the inhibition of NO
production was due to the specific silencing of iNOS mRNA, and not due to the nonspecific effects.
3.3.3.

Effect of iNOS gene silencing on rat β-cell death

To determine whether iNOS gene silencing inhibit apoptosis of rat β-cells induced by
inflammatory cytokines, INS-1E cells (106/well in a 12 well plate) were transfected with
siRNA against rat iNOS as well as the control siRNA. Then the cells were incubated with
cytokine cocktail (IL-1β 50 pg/mL, TNF-α 5 ng/mL, and IFN-γ 50ng/mL) for 48 h. As
visualized under microscopy, almost all the cells transfected with the control siRNA were
aggregated and round up, indicating cell death, probably due to apoptosis (Figure 3.3A).
In contrast, only a small part of the cell treated with siRNA-iNOS were aggregated,
indicating only a small fraction of the cells were undergoing apoptosis.
One of the later steps in apoptosis is DNA fragmentation, which results from the
activation of endonucleases during the apoptotic process. Therefore, the analysis of DNA
fragmentation with TUNEL assay is a useful approach to get information regarding cell
apoptosis. As shown in Figure 3.3B, cells with no cytokine treatment showed 0.8%
apoptotic cells, cells transfected with control siRNA treated with cytokines showed
42.3% apoptotic cells. The cells transfected with siRNA against iNOS and treated with
cytokines showed 12.3% apoptotic cells; clearly demonstrating that iNOS gene silencing
can help protect  cell from proinflammatory cytokines.

44

A
iNOS mRNA level
(% of control)

120
P<0.05

*

p<0.001

80

p<0.001

***

p<0.01

***

**

40

0

Control

224

675

siRNA

898

2225

siRNA-iNOS

B
Nitrite concentration
(% of control)

120

p<0.001

80

***

p<0.001

p<0.001

***

p<0.001

***

***

40

0
control
siRNA

224

675

898

2225

siRNA-iNOS

Figure 3.2
Effect of siRNA sequences on iNOS gene expression and NO
production in rat β cells.
Effect of siRNA sequences on iNOS gene expression, (A) and NO production (B) in rat β
cells. Following transfection of INS-1E cells with 150 nM siRNA-iNOS complexed with
5 μg/mL Lipofectamine 2000, cells were treated for additional 12 h with the cytokine
cocktail of IL-1β (50 pg/mL), TNF-α (5 ng/mL), and IFN-γ (50 ng/mL). Cells not treated
with the cytokines were used as negative control. iNOS expression is expressed as the
amount of iNOS mRNA measured by real time RT-PCR. Nitrite concentration is
expressed as percentage of positive control. Results are the mean ± SD (n = 3) and were
normalized with live cells. The p value of < 0.05 was considered statistically significant.
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Effect of iNOS gene silencing on rat β cell death.

Following transfection of INS-1E cells with siRNA-iNOS-898 as well as the control
siRNA, the cells were incubated with a cytokine cocktail of IL-β (50 pg/mL),TNF-α (5
ng/mL), and IFN-γ (50 ng/mL) for 48 h, then visualized under microscopy (A) and
analyzed by TUNEL assay (B). A), left panel, most cells treated with the control siRNA
were aggregated and round up, indicating cell death; right panel, only a part of the cell
treated with siRNA-iNOS were aggregated and indicating only a small fraction of the
cells were undergoing apoptosis. B), TUNEL assay of INS-1E cells treated with siRNAiNOS-898 as well as control siRNA. Negative control, cells with no cytokine treatment;
siRNA-iNOS, cells treated with siRNA-iNOS-898 and cytokine; control siRNA, cells
treated with control siRNA and cytokine. The values show the percentage of positive
cells.
46

3.3.4.

Transfection efficiency of lipid/siRNA complexes into human islets

After confirming the beneficial effect of iNOS gene silencing on rat β-cells from
proinflammatory cytokines, we used fluorescein-labeled siRNA at doses of 100 and 400
nM to determine the transfection efficiency in human islets under fluorescence
microscopy. Figure 3.4A demonstrates that human islets were transfected with
fluorescein-labeled siRNA. While the untreated control human islets showed only weak
background fluorescence, human islets transfected with fluorescein-labeled siRNA
showed distinct spots speckled throughout their surface with some concentrations noted
at the edges and over their interior surface. These images clearly demonstrated that
siRNA was introduced into human islets in culture, but we could not determine whether
siRNA has penetrated into the interiors of human islets. Thus, transfected human islets
were analyzed by flow cytometry upon dispersion into single cells after treating with
trypsin-EDTA for 10 min at 37 C followed vigorous pipeting. Both the fluorescent
images for siRNA dose titration and the more quantitative FACS date help document
how much siRNA was incorporated into islet cells. Almost 21.5% and 28.3% islet cells
incorporated fluorescein-labeled siRNA when transfected with siRNA at a concentration
of 100 nM and 400 nM, respectively (Figure 3.4B).
3.3.5.

Effect of siRNA sequences on iNOS gene silencing in human islets

Following screening of the siRNA sequences using INS-1E cells and demonstrating the
beneficial effect of iNOS gene silencing on the protection of -cells from inflammatory
cytokines, we determined the effect of iNOS gene silencing in human islets. Since there
is not 100% homogeneity in rat iNOS mRNA (Gene Bank Accession# NM_012611) and
human iNOS mRNA (Gene Bank Accession# NM_000625), we re-designed three siRNA
sequences targeting different regions of human iNOS and used for transfection into
human islets. Quantitative real-time RT-PCR was used to measure the human iNOS gene
expression level using SYBR green chemistry with human iNOS specific primer and
human S19 as a reference gene. Figure 3.5A shows that all three siRNAs tested were able
to reduce iNOS gene expression levels in human islets. Among all the siRNAs tested,
siRNA-iNOS-691 was the most potent one, which reduced iNOS expression level by
50%. Therefore, siRNA-iNOS-691 was used for further evaluation. Compared to the
control siRNA group, there was significant decrease in NO production when human islets
were transfected with lipid/siRNA-iNOS-691 complexes (Figure 3.5B). This result
indicates that the inhibition of NO production was due to the specific silencing of iNOS
mRNA and not due to the off-target effects.
3.3.6.

Effect of iNOS gene silencing on human islet cell death

We have shown that siRNA against iNOS mRNA could reduce the apoptosis of rat βcells. In addition, siRNA can be delivered into human islets and reduce iNOS mRNA
level. Therefore, we continued to test whether iNOS gene silencing can also prevent the
cytokine-induced apoptosis of human islets. TUNEL assay was used to detect DNA
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Transfection efficiency of siRNA into intact human islets.

Fluorescein-labeled siRNA were transfected into human islets and visualized under
fluorescence microscope at 12 h post transfection. (A) Fluorescent images showing
fluorescein-labeled siRNA incorporation into intact human islets, Left panels show
human islets under visible light, and right panel under fluorescence. (B) flow cytometry
analysis showing percentage of green fluorescence positive cells.
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Effect of siRNA sequence on iNOS expression on human islets.

Human islets (2000 IE) were transfected for 12 h with 400 nM iNOS-siRNA complexed
with 13.3 μg/mL Lipofectamine 2000. Then human islets were treated for additional 12 h
with a cytokine cocktail of IL-1β (50 pg/mL), TNF-α (5 ng/mL), and IFN-γ (50 ng/mL).
The iNOS mRNA were measured by real time RT-PCR and expressed as the percentage
of control. B) Nitrite concentration of the culture supernatants was determined by Griess
assay. Human islets treated with control siRNA were used as control. Results are
represented as the mean ± SD , n = 3. Significance established at P < 0.05 (), P < 0.01
(), and P < 0.001 ().
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fragmentation. As shown in Figure 3.6A, siRNA against human iNOS reduced the
percentage of apoptotic cells to 28.5% compared to the control siRNA group (36.2%).
Although the prevention of apoptosis in human islets was not as high as shown in rat β
cells (Figure 3.3B and Figure 3.6A), this is not a surprise to get different results from
INS-1E cell and human islets, which is a cluster of 200-1000 cells. Increased caspase 3
activity is often used as a marker for apoptotic signaling cascade [276]. Therefore, we
tested the effects of iNOS gene silencing on caspase 3 activities of human islets (Figure
3.6B). Compared with the control siRNA treated group, siRNA-iNOS reduced human
islets caspase 3 activity by around 25%.
3.3.7.

Human islet function after iNOS gene silencing

The effect of transfection process on in vitro islet function was determined by static
incubation of islets with different concentration of glucose. There was increase in insulin
secretion as a function of glucose concentration for islets transfected with lipid/siRNAiNOS complexes, with stimulation index of 1.40. In contrast, there was little increase in
insulin secretion with increase in glucose concentration for islets transfected with
lipid/siRNA-control (Figure 3.7). The results suggest that iNOS gene silencing partly
protected human islet from inflammatory cytokine mediated destruction.
3.4.

Discussion

Human islet transplantation has great potential for treating insulin dependent diabetes,
allowing stable glucose homeostasis without exogenous insulin regimens and thus
avoiding several diabetic glucose complications. Despite some recent improvements in
transplantation technology, a large number of transplanted islets do not function properly,
which results in the need for multiple islet infusions for each patient. Moreover, the
success of islet transplantation is currently dependent on chronic treatment of the patient
with strong immunosuppressant drugs, which are often associated with serious side
effects. Due to the limited supply of cadaver donor, it is essential to improve the survival
of transplanted islets. Therefore, we and others have been working on genetic
modification of islets to improve the outcome of islet transplantation [12, 17, 64, 246,
247, 277].The over-expression of therapeutics genes has been demonstrated to improve
the survival and function of islets post-transplantation [246, 278]. Our previous work
showed improved islet transplantation by genetic modification of human islets with
human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor
antagonist (hIL-1Ra) [246]. The expression of hVEGF and hIL-1Ra synergistically
suppress islet dysfunction and NO production in human islets. After transplantation of
these transfected human islets into diabetic mice, reduced blood glucose levels and
increased blood insulin and c-peptide level was observed [246].
In contrast to the over-expression of therapeutic genes, ex vivo silencing of harmful
genes, offers an alternative approach to induce human islets to modify their internal
signal transduction pathways to prevent the damage inflicted upon them by
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Effect of iNOS gene silencing on human islets cell death.

Following transfection with 400nM siRNA-iNOS-691 as well as the control siRNA,
human islets (2000 IE) were incubated with the cytokine cocktail of IL-1β (50 pg/mL),
TNF-α (5 ng/mL), and IFN-γ (50 ng/mL) for 48 h. (A) The TUNEL assay was used to
analyze cell apoptosis. (B) Human islets were collected and lysed with 50 μL lysis buffer.
Ten microliters of cell lysate from each group sample were used for caspase 3 activity
assay using Ac-DEVD-pNA substrate. Results are expressed as the percentage of control
and represented as the mean ± SD, n = 3. Significance established at P < 0.05 () and P <
0.01 ().
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Human islet function after iNOS gene silencing.

At 12 h post- transfection with Lipofectamine 2000/ siRNA-iNOS or Lipofectamine
2000/siRNA-control complexes, islets were incubated with inflammatory cytokines
cocktail of IL-1β (50 pg/mL), TNF-α (5 ng/mL), and IFN-γ (50 ng/mL) for 48 h. Then,
islets were challenged with two different concentration of glucose(60 and 360 mg/dL).
Insulin stimulation index (SI) was determined. Results are the average of three replicates.
(A) insulin secretion as a function of glucose concentration, (B) stimulation index. P <
0.05 was considered statistically significant.
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proinflammatory responses. Therefore, we recently determined the effect of chemically
synthesized siRNAs against iNOS and NF-κB on iNOS gene expression, NO production
and apoptosis in insulin producing β-cell line, INS-1E, and demonstrated that silencing of
iNOS is more effective than that of NF-κB [116]. Since human islets are clusters of 1002000 cells, it is difficult to achieve high transfection efficiency. Therefore, in present
study, we compared the transfection efficiency of lipid/siRNA complexed in rat β cells
and intact human islets. We first determined the transfection efficiency on INS-1E cells,
which showed 95.9% cells were incorporated with fluorescein-labeled siRNA (Figure
3.1B). This result is consistent with a previously report by Hagerkvist et al [271], who
demonstrated a transfection efficiency of 96.2% in another murine β cells line, ß-TC-6
cells.
For human islets, as shown in Figure 3.4B, the transfection efficiency was 21.5% and
28.3% at siRNA concentrations of 100 nM and 400 nM in human islets, which are lower
than that reported by Bradly et al,[270] (46.3% at siRNA concentration of 400 nM), but
higher than that reported by Hagerkvist et al [271], (10.9% at siRNA concentration of
100 nM). This discrepancy may be due to the fact that these authors used mouse islets,
while we used human islets. In addition, the difference in transfection protocol may also
contribute to the varied transfection efficiency achieved. Nevertheless, this is an
interesting finding suggesting that siRNA may penetrate beyond the periphery into a
larger percentage of an intact islet cell mass than previously thought. Unlike intact islets,
transfection efficiency was > 90% in dispersed islets, which is close to that observed in
cultured -cells. However, we prefer to use intact islets, which are a cluster of 200-1000
cells and represent the real situation [271]. Nevertheless, these results shed light on the
reasons that cause the different transfection efficiency between intact human islets and βcell lines.
It is widely believed that the treatment of proinflammatory cytokine results in β-cell
death possibly due to apoptosis and necrosis [52, 279]. This cytotoxic effect of cytokines
may be mediated by inducing iNOS and subsequently producing radical NO as well as of
other free radicals, such as peroxynitrite (OONO-) and superoxide (O2-)[59, 280, 281].
As reported previously [59], nearly 50% of the gene related to cytokine-induced β cell
death are NO-dependent, which shows the essential role of iNOS pathway in cytokinemediated cell toxicity. Necrosis and apoptosis are found shortly after rat islet
transplantation. Non-specific inflammation at the graft site may contribute to the initial
islet damage which results in massive loss of transplanted tissues, and primary non-graft
function [282]. iNOS gene expression on islets increased significantly after
transplantation. The maximal iNOS gene expression was observed day 1 after
transplantation and then declined progressively [48]. Increased iNOS gene expression led
to an early inflammatory process in islet transplantation, suggesting iNOS is an important
mediator of graft inflammation and islet damage in early islet transplantation [48].
Therefore, we hypothesized that the silencing of iNOS gene might reduce iNOS mediated
inflammatory response, and prevent islet cell death.
To determine iNOS gene silencing in human islets, we redesigned three siRNA
sequences targeting different regions of human iNOS and used for transfection in human
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islets. As shown in Figure 3.5A, there was around 50% iNOS gene expression has been
silenced by siRNA complexed with Lipofectamine 2000, which is similar to that reported
by Bradley et al., [270] who demonstrated 55% reduction of Ins-2 gene expression by
isolated rodent islets. This finding is attractive which demonstrates the possibility to
specifically reduce the target mRNA in human islets with siRNA. Various extent of iNOS
gene silencing was achieved in present study with different siRNA duplexes targeting
different regions of iNOS mRNA, with the highest gene silencing for the siRNA-iNOS691 group compared to the control siRNA group (Figure 3.5A). There was also
significant decrease in NO production when islets were transfected with lipid/siRNAiNOS-691 complexes (Figure 3.5B). As reported previously, the gene silencing effect of
siRNA varied considerably depends on target sequences [283], and the secondary
structure of target region that is essential for siRNA binding [284]. Therefore, a more
potent siRNA could be found by designing and screening more siRNA sequences target
different regions of mRNA.
Caspases play a key role in apoptosis. In mammals, there are 14 caspases, among them
caspase3 is the major effector caspase involved in apoptosis. It is activated by upstream
proteases including caspase 6, caspase 8, and cytotoxic T cell-derived granzyme B [65].
The critical role of caspase 3 in cytokine-induced β cell apoptosis has been reported [285287]. Both caspase 3 inhibitor (Z-DEVD-FMK) [288] and X-linked inhibitor of apoptosis
protein (XIAP) [64] have been shown to prevent apoptosis of transplanted human islets.
We observed that siRNA targeting iNOS decreased proinflammatory cytokine-induced
caspase 3 activity in human islets (Figure 3.6B). The reduced caspase 3 activity probably
contributes to the prevention of human islets from apoptosis.
One of the later steps in apoptosis is DNA fragmentation, which results from the
activation of endonucleases during the apoptotic process. The free 3′-OH strand breaks
resulting from DNA degradation can be measured by a TUNEL assay using the APODIRECTTM, which is a single-step staining method for labeling DNA breaks to detect
apoptotic cells by flow cytometry analysis. Consistent with the results of caspase 3
activity, TUNEL assay demonstrated the prevention of β cell apoptosis on human islet as
well as INS-1E cells. As shown in Figure 3.3B, siRNA-iNOS treatment significantly
reduced cytokine-induced INS-1E cell apoptosis to 12.3%, compared to the control
siRNA treated cells with 42.3% apoptotic cells. In human islets the protective effect is
less than that observed in INS-1E cells. The treatment of siRNA-iNOS decreased the
percentage of cell apoptosis from 36.2% to 28.5% (Figure 3.6B). The difference in the
protective effects can be explained by much lower transfection efficiency achieved in
intact human islets compared to that achieved in INS-1E cells (21-28% VS 95%; Figure
3.1B and 3.4B). Besides, due to the heterogeneous feature of human islets, we cannot
exclude the existence of other mechanisms involved in the apoptosis of human islets [52].
To determine the effect of transfection process on the in vitro islet function, islets were
transfected with lipid/siRNA-iNOS and lipid/siRNA-control complexes and then
incubated with a cocktail of inflammatory cytokines. The islet function was determined
by static incubation of islets with different concentration of glucose. There was increase
in insulin release as a function of glucose concentration for the islets transfected with
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lipid/siRNA-iNOS complexes. In contrast, there was little increase in insulin secretion
with increase in glucose concentration for the islets transfected with lipid/siRNA-control
(Figure 3.7). The results suggest that iNOS gene silencing partly protected human islets
from proinflammatory cytokine-mediated destruction. The stimulation index is somewhat
lower than what we usually achieve, possibly due to the poor quality of human islets.
Our results demonstrate that silencing of iNOS gene expression results in reduction of
NO production and reduced cell death in rodent β cell line as well as in human islets. Due
to the pivotal role of iNOS in cytokine signal cascade, it is not unexpected that we could
prevent proinflammatory cytokine-induced β cell death by silencing iNOS gene
expression. iNOS gene silencing also partly protected human islets from inflammatory
cytokine mediated destruction of glucose stimulated insulin secretion. The present study
is the first to demonstrate the prevention of proinflammatory cytokine-induced cell death
in human islets with siRNA target iNOS gene.
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CHAPTER 4. BIPARTITE VECTORS FOR CO-EXPRESSION OF A GROWTH
FACTOR CDNA AND SHRNA AGAINST AN APOPTOTIC GENE*
4.1.

Introduction

RNA interference (RNAi) is an evolutionarily conserved biologic process that regulates
gene expression by small interfering double stranded RNA (siRNA) mediated sequencespecific, post-transcriptional gene silencing [21, 22, 269]. Several steps are involved in
RNAi: 1) long double-stranded RNA (dsRNA) is processed by DICER into 19-23 base
pair siRNA duplex; 2) siRNA duplex is incorporated into a complex named RNAinduced silencing complex (RISC); 3) RISC is activated by eliminating passenger strand
of siRNA duplex, and results in mRNA degradation or translational repression [120].
RNAi has been extensively used as a tool for gene knockout in cell lines and animal
models [289, 290]. In addition, it is also a promising therapeutic approach for disease
therapy [26, 291]. Recently, we have tested the effects of siRNAs against inducible nitric
oxide synthase (iNOS) genes on insulin producing β-cell line (INS-1E) and on human
islets [25, 115]. iNOS gene silencing with chemically synthesized siRNA decreased NO
production in INS-1E rat β-cells and human islets, reduced proinflammatory cytokineinduced β-cell death, and partially protected the human islet function [115]. We also
observed in another study that adenovirus-based shRNA against caspase 3 gene (Advcaspase 3-shRNA) efficiently silenced caspase 3 gene and its gene silencing effect lasted
beyond five days, which resulted in the protection of islets from cytokine-induced
apoptosis[107].
As an alternative cure for type I diabetes, human islet transplantation has made a great
progress, especially after the success of Edmonton protocol [7, 292]. However, a large
number of the patient returned to insulin dependent within a year after islet
transplantation [293]. The main reason for the failure of islet transplantation is that less
than 30% of the transplanted islets are survived in the early days post-transplantation due
to several reasons, including (1) poor revascularization, which results in insufficient
supply of oxygen and nutrition; and (2) proinflammatory cytokines-induced islet β-cell
death including apoptosis and necrosis [12]. In our previous study, we investigated the
use of bipartite plasmid or Adenoviral vectors which co-express one gene for reducing
inflammatory response (e.g. hIL-1Ra) and another for facilitating revascularization (e.g.
HGF, VEGF) [18, 294]. This combinatorial approach showed synergistic effect by
working on two independent therapeutic targets. Therefore, it is possible to observe
improved therapeutic efficacy with bipartite vectors that co-express a vascular endothelial
growth factor (VEGF) cDNA and shRNA targeting an apoptotic gene such as iNOS or
caspase 3.
* Adapted with permission. F. Li, R.I. Mahato, Bipartite vectors for co-expression of a
growth factor cDNA and short hairpin RNA against an apoptotic gene, J Gene Med, 11
(2009) 764-771.
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In order to co-express two genes in a single vector, we can use two separate expression
cassettes driven by two promoters or using internal ribosome entry site (IRES) sequence
[295, 296]. The use of IRES is usually not preferred, since the gene after IRES usually
showed lower expression level [297]. Co-expression of a shRNA and a gene with two
separate promoters is similar to that of two different genes, but it might be different for
co-expression of a shRNA and a gene with a single promoter. Unlike gene expression
plasmid which utilizes a Pol-II promoter, shRNA expression can utilize both Pol-II
promoters (such as CMV promoter) and Pol-III promoters (such as H1, U6 promoters).
IRES sequence is not necessary for co-expressing multiple shRNA or combination of a
shRNA and a cDNA within a single promoter [158, 298, 299]. It is has also been reported
that co-expression of shRNA and cDNA can be realized by inserting a promoterless
shRNA within the intron of a gene [197].
A bipartite vector, which can effectively silence a target gene and expresses a therapeutic
gene properly, is in great need for treating various diseases including diabetes, cancer and
viral infection. siRNA targeting sequence and promoters used will greatly influence gene
silencing efficiency. A shRNA and cDNA could be expressed by two different promoters
or by a single promoter. It was also reported that the miRNA-based shRNA showed
improved gene silencing than conventional shRNA [152, 153]. In this study, we have
systemically investigated these factors to find a most optimal bipartite vector and
indentify parameters defining a potent shRNA and gene co-expression vector.
4.2.

Materials and Methods

4.2.1.

Materials

Fetal bovine serum (FBS) was purchased from Mediatech, Inc (Herndon, VA).
Penicillin/streptomycin, phosphate-buffered saline (PBS), 0.25% (w/v) trypsin-EDTA
and DMEM medium were purchased from GIBCO-BRL (Gaithersburg, MD). All
oliginucleotides used for shRNA cloning were obtained from Integrated DNA
Technology (Coralville, IA). All the enzymes used in cloning were purchased from New
England Biolabs (Ipswich, MA).
4.2.2.

Plasmids

Negative control shRNA plasmid and Human iNOS cDNA plasmid (p-iNOS) were
purchased from OriGene (Rockville, MD). Plasmids encoding shRNA targeting five
different regions of iNOS gene were purchased from Open Bioystems (Huntsville, AL).
To generate p-H1-shiNOS-CMV-GFP, p-U6-shiNOS, and p-CMV-shiNOS, two shRNA
oligos ( synthesized by IDT DNA) were annealed and cloned into pRNAT-H1.1/shuttle
(BamHI, HindIII), pSIREN-Shuttle (BamHI, EcoRI) and p-shuttle2 (XbaI+AflII),
respectively. p-H1-shiNOS-CMV-VEGF was generated by replacing GFP gene with
VEGF PCR fragment from p-CMV-VEGF165. Briefly, p-H1-shiNOS-CMV-GFP was
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digested with PflmI, followed by treating with Klenow enzyme. After purification, it was
digested with NheI and then purified. VEGF gene was amplified with PCR using
following primer: Forward (Nhe I) –
GCCTAGCTAGCTAGATGAACTTTCTGCTGTCTTG; Reverse (DraI)
CGCTATTTAAATCACCGCCTCGGCTTGTCACATC. To make p-U6-shiNOS-CMVVEGF, pSIREN-shuttle was digested with I-ceu and Bam HI, and the fragment with U6
promoter was sub-cloned into I-Ceu and Bam HI site in p-H1-shiNOS-CMV-VEGF.PU6-mir375-shiNOS was generated by cloning annealed mir375 oligos into pSIRENshuttle (BamHI,EcoRI). To make p-U6-mir30-shiNOS, mir30-shiNOS sequence was
synthesized and sub-cloned into pSIREN-Shuttle (BamHI, EcoRI). mir30-shiNOS
sequence:GGATCCGTGCTCGCTTCGGCAGCACATATACTAGTCGACTAGGGATA
ACAGGGTAATTGTTTGAATAGGCTTCAGTACTTTACAGAATCGTTGCCTGCAC
ATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACCCAACAGAAGGG
CGGCCGCAAGGTATATTGCTGTTGACAGTGAGCGCGTGTATTTAACTGCCTTG
TGTAGTGAAGCCACAGATGTACACAAGGCAGTTAAATACACATGCCTACTGC
CTCGTCTAGAAAGGGGCTACTTTAGGAGCAATTATCTTGTTTACTAAAACTGA
ATACCTTGCTATCTCTTTGATACATTTTTTGaattc. To make p-CMV-mir30shiNOS, mir30-shiNOS sequence was amplified with PCR using following primer:
forward (Dra I) GTATTTAAAGGATCCGTGCTCGCTTCGGC; reverse (Afl II)
CGCCTTAAGAATGTATCAAAGAGATAGCA and PCR product was cloned into pshuttle2 (DraI, AflII) after restriction enzyme digestion. p-CMV-VEGF-mir30-shiNOS
was made by inserting VEGF PCR fragment between CMV promoter and mir30 shiNOS
sequence in p-CMV-mir30-shiNOS using NheI and DraI sites. shRNA sequences are
listed in supplementary information. All the plasmids were purified by Promega miniprep kit and confirmed by DNA sequencing.
4.2.3.

Cell culture and transfection

AD-293 cells were cultured in DMEM supplemented with 10% FBS, 100 U/mL
penicillin, and 100 mg/ml streptomycin. In transfection experiments, cells were seeded in
a 48-well plate at a density of 20,000 cells per well 24 h before transfection. Then, 0.05
µg iNOS cDNA plasmid and 0.3 µg shRNA plasmid were co-transfected into cells with
Fugene HD transfection reagent (Roche applied science, Indianapolis, IN).
4.2.4.

Real time RT-PCR

Human iNOS and VEGF expression were determined at mRNA level by real time RTPCR. Following treatment, total RNA was extracted with RNeasy Mini KIT and treated
with DNase by on-column digestion (RNase-Free DNase Set). RNA concentration was
determined by spectrophotometer (NanoDrop). One hundred and seventy nanograms total
RNA was converted into cDNA using multiscribe reverse transcriptase reagents and
random hexamers at a 10 µl reaction system. Two microliters of cDNA were used as a
template and analyzed by SYBR Green-I dye universal PCR master mix on LightCycler
480 Instrument. The primers used for real-time PCR were as follows: human iNOS:
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Forward 5’-ACGTGCGTTACTCCACCAACA-3’; Reverse 5’CATAGCGGATGAGCTGAGCA-3’(amplicon size 102 bp); human ribosomal protein
S19 (human S19); Forward 5’ GCTTGCTCCCTACCGATGAGA-3; Reverse 5’ACCCCGGAGGTACAGGTG-3’(amplicon size 73 bp) [115]. The primer for VEGF
gene was the same as previously described [18].To assess the specificity of the amplified
PCR product, the Melting Curve Analysis was performed on the LightCycler 480
Instrument. The results iNOS mRNA level were compared by calculating the CP value
and normalized by the reference genes (rat 18S or human S19).
4.2.5.

Determination of nitric oxide production

Nitric oxide (NO) is rapidly oxidized in culture medium into nitrite, which accumulates
in the sample and can be easily correlated with NO production. Therefore, nitrite
concentration was determined using the Griess assay (Promega, Madison, MI). Fifty
microliters of cell culture supernatant was added to a 96 well-plate and mixed with 50 μL
of 1% sulfanilamide in 5% phosphoric acid solution and incubated for 5 min at room
temperature in the dark. Then, 50 μL of 0.1% N-1-naphthylethylenediamine
dihydrochloride (NED) aqueous solution was added to each well. The plate was
incubated for an additional 10 min, and absorbance was measured at 560 nm using a
microplate reader. To determine the nitrite concentration in each sample, a standard curve
was prepared using nitrite standard solution and culture medium as matrix.
4.2.6.

Determination of VEGF expression from bipartite plasmids with ELISA

At 36 h after transfection of AD-293 cells with 0.3µg per well plasmids, culture medium
of AD-293 cells were collected. The VEGF concentration in the culture medium was
measured by ELISA according to the manufacture’s protocol (R& D systems,
Minneapolis, MN).
4.3.

Results

4.3.1.

Effect of targeting sequence on iNOS gene silencing

Targeting sequence is one of the most important elements for effective gene silencing.
Therefore, we first screened five plasmids encoding shRNA targeting different regions of
human iNOS gene. The targeting sequences of different plasmids are listed in Figure
4.1A. To find the most potent targeting sequence, plasmids expressing shRNA against
five different iNOS mRNA regions were co-transfected with p-iNOS into AD-293 cells.
Plasmid with scrambled sequence was used as a control. At 24 hours after transfection,
NO production from iNOS gene expression was measured as nitrite by Griess Assay. As
demonstrated in Figure 4.1B, all five shRNA expression plasmids were able to silence
iNOS expression and among them the 4060 showed 66% reduction of NO production.
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Effect of targeting sequence on iNOS gene silencing.

(A) Sequences of shRNA against different regions of human iNOS gene (NM_000625).
(B) Plasmids with different shRNA sequences as well as control plasmid were cotransfected with piNOS into AD293 cells. At 24 h after transfection, NO production was
measured by Griess Assay. Nitrite concentration is expressed as the percentage of
control. Results are the mean ± SE (n = 4). ** indicates P < 0.01 compared with control
plasmid group.
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Therefore, the targeting sequence 4060 was used in the following experiments for
shRNA-based or miRNA-based shRNA construction.
4.3.2.

Effect of promoters on iNOS gene silencing

Promoter is an important regulatory element in gene expression. Among several
promoters, H1, U6 and CMV promoters are most widely used for shRNA mediated gene
silencing. Since some discrepancies have been reported for the efficiency of these
promoters [125, 153], we compared the efficiency of these three promoters for shRNA
mediated iNOS gene silencing by constructing iNOS shRNA expression plasmids with
H1, U6 and CMV promoters (Figure 4.2A). After co-transfection with p-iNOS plasmid
into AD-293 cells, we found that iNOS shRNA expression plasmids could effectively (p
< 0.01) reduce the NO production by 69, 62, and 60% for H1, U6 and CMV, respectively
(Figure 4.2B). This suggests that there is no significant difference among these three
promoters in iNOS gene silencing.
4.3.3.

Effect of VEGF co-expression on iNOS gene silencing

Co-expression of shRNA and therapeutic proteins is a promising combinatorial RNAi
strategy [185], which will have synergistic effect by acting on different targets. However,
it is not sure whether the over-expression of VEGF gene under a strong CMV promoter
will interfere with the expression and processing of shRNA. As illustrated in Figure 4.3A,
a plasmid has been constructed to co-express VEGF cDNA and iNOS-shRNA. VEGF
cDNA was under the control of CMV promoter, while iNOS-shRNA was driven by U6
promoter. As shown in Figure 4.3B, p-U6-shiNOS-CMV-VEGF and p-U6-shiNOS
reduced the NO production by 59% and 62%, respectively (p < 0.01). In contrast, the
plasmid expressing VEGF did not shown significant reduction of NO production. It was
also noticed that there was no significant difference between p-U6-shiNOS and p-U6shiNOS-CMV-VEGF. Therefore, the co-expression of VEGF cDNA and iNOS-shRNA
will not have much interference with the shRNA-mediated gene silencing.
4.3.4.

Effect of mir375 and mir30 backbones on iNOS gene silencing

Efficient gene silencing has been reported when shRNA was embedded in miRNA
backbone [153, 154]. To find out the possibility of increasing iNOS gene silencing effect
by shRNA with miRNA backbone, two shRNA were designed based on mir375 and
mir30 structures (Figure 4.4A). As shown in Figure 4.4C, significant reduction of NO
production were observed in all of three vectors tested, p-U6-shiNOS (reduced by 62%, p
< 0.01), p-U6-mir375-shiNOS (reduced by 39%, p < 0.01) and p-U6-miR30-shiNOS
(reduced by 30%, p < 0.01). In addition, p-U6-shiNOS is significantly more efficiently
than p-U6-mir375-shiNOS or p-U6-mir30-shiNOS (p < 0.01). Gene silencing efficiency
of these three shRNA vectors was further investigated at mRNA levels by real-time PCR
(Figure 4.4B). All of these three vectors reduced NO mRNA expression significantly
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Effect of different promoters on iNOS gene silencing.

(A) Structure of pH1-shiNOS-CMV-GFP, pU6-shiNOS and pCMV-shiNOS. (B)
Plasmids with different promoters (H1, U6 and CMV) as well as control plasmid were
co-transfected with piNOS into AD293 cells. At 24 hours after transfection, NO
production was measured by Griess Assay. NO concentration is expressed as the
percentage of control. Results are the mean ± SE (n = 4). ** indicates P < 0.01 compared
with control plasmid group.
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Effect of VEGF gene co-expression on iNOS gene silencing.

(A) Structure of pU6-shiNOS, and pU6-shiNOS-CMV-VEGF. (B) Plasmids coexpressing shRNA and VEGF, plasmid expressing VEGF alone, as well as control
plasmid were co-transfected with piNOS into AD293 cells. At 24 h after transfection, NO
production was measured by Griess Assay. Nitrite concentration is expressed as the
percentage of control. Results are the mean ± SE (n = 4). ** indicates p < 0.01 compared
with control plasmid group.
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Effect of mir375 and mir30 backbone on iNOS gene silencing.

(A) Structure of pU6-shiNOS, pU6-mir375-shiNOS and pU6-mir30-shiNOS. Plasmids
with different backbones as well as control plasmid were co-transfected with piNOS into
AD-293 cells. At 24 hours after transfection, (B) iNOS mRNA levels was measured by
Real-time PCR, (C) NO production was measured by Griess Assay. NO concentration is
expressed as the % of control. Results are the mean ± SE (n = 4). **, p < 0.01 compared
with control plasmid group; ++ , p < 0.01, +, p < 0.05, respectively, compared with pU6shiNOS group.
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(p < 0.01, compared with control). In addition, p-U6-shiNOS（reduced by 56%） is
significantly more efficiently than p-U6-miR375-shiNOS (reduced by 30%) or p-U6miR30-shiNOS (reduced by 28%) (p < 0.05, compared with p-U6-shiNOS).
4.3.5. Inserting VEGF gene between CMV promoter and mir30-shRNA enhanced
iNOS gene silencing
We have shown the successful co-expression of iNOS shRNA and VEGF cDNA under
two expression cassettes. To further investigate the possibility of co-expressing VEGF
cDNA and iNOS shRNA under a single promoter, a plasmid with mir30-shiNOS under
the control of CMV promoter was constructed and a VEGF cDNA was inserted between
CMV promoter and mir30-shiNOS (Figure 4.5A). As shown in Figure 4.5B, a 39%
reduction in NO production was achieved with p-CMV-mir30-shiNOS (p < 0.01,
compared with control plasmid), which is close to that of p-U6-mir30-shiNOS (30%).
However, the gene silencing effect was significantly enhanced by inserting a VEGF
cDNA between CMV promoter and mir30-shRNA. In contrast, 61% reduction in NO
production was achieved with p-CMV-VEGF-mir30-shiNOS (p < 0.01, with p-mir30shiNOS).
4.3.6.

Expression of VEGF from bipartite plasmids

Not only potent silencing of proapoptotic gene, but also sufficient expression of VEGF is
essential. Therefore, we measured VEGF gene expression from two bipartite plasmids, pU6-shiNOS-CMV-VEGF and p-CMV-VEGF-mir30-shiNOS. We measured VEGF gene
expression by ELISA of the cell culture medium. VEGF concentration was around 65
ng/mL for all above plasmids and there is no significant difference among these two
plasmids (Figure 4.6B). The VEGF gene expression from these two bipartite plasmids
was also measured at mRNA levels with real-time PCR by using VEGF gene specific
primers (Figure 4.6A). The results indicated VEGF mRNA levels in these two plasmids
treated groups were 914 ± 18 and 922 ± 35 folds high than that in control group,
respectively.
4.4.

Discussion

Co-transfection approach for evaluating gene silencing effect has been extensively
reported [125, 152, 155, 300], which allowed researchers to measure the gene silencing
effect with good convenience and reliability. Therefore, a co-transfection of p-iNOS
plasmid was used in this study to investigate gene silencing effect of shRNA iNOS
vectors with different gene target sequence, promoters, backbones we have constructed.
The use of a stably transfected cell line has also been reported [136]. A C6 cell stably
expressing firefly luciferase gene was used to study the gene silencing effect shRNAs
vectors against firefly luciferase gene. However, this is not appropriate for iNOS gene
silencing. iNOS is up-regulated only after stimulation with cytokines or other reagents.
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Figure 4.5
Insertion of VEGF gene between CMV promoter and mir30-shRNA
enhanced iNOS gene silencing.
(A) Structure of pCMV-mir30-shiNOS and pCMV-VEGF-mir30-shiNOS. (B) pCMVmir30-shiNOS, pCMV-VEGF-mir30-shiNOS as well as control plasmid were cotransfected with piNOS into AD-293 cells. At 24 h after transfection, NO production was
measured by Griess Assay. Nitrite concentration is expressed as the % of control. Results
are the mean ± SE (n = 4).** indicates p < 0.01 compared with control plasmid group; ++
indicates p < 0.01 compared with pCMV-VEGF-mir30 group.
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Figure 4.6
Expression of VEGF from pU6-shiNOS-CMV-VEGF and pCMVVEGF-mir30-shiNOS.
pU6-shiNOS-CMV-VEGF and pCMV-VEGF-mir30-shiNOS was transfected into AD293 cells. (A) At 24 hours after transfection, VEGF gene expression levels were
measured by Real-time PCR, (B) At 36 h after transfection, VEGF expression was
measured with ELISA. Results are the mean ± SE (n = 4).
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By using co-transfection approach, the iNOS mRNA was expressed from p-iNOS
plasmid after transfection. This could mimic the scenario of cytokine-induced iNOS gene
much better than iNOS stable expressing cell lines, in which iNOS gene was constantly
over-expressed. In addition, there are several limitations for the using of stable cell lines:
1) the establishment of a stable cell line usually takes a long time (at least several weeks);
2) a cDNA expressing vector with an antibiotics resistance gene (eg. Neomycin,
puromycin); 3) Only a gene that is not toxic or will not interfere with the vital cellular
process could be used to make a stable cell line. Because of above mentioned reasons, a
co-transfection method would be a good approach for evaluation gene silencing effect
during the development of gene silencing vectors.
The selection of potent targeting sequence that leads to effective gene silencing still
remains the key issue for practical application of RNAi technique for disease therapy.
Web-based computer programs with different algorithms for designing siRNA and
shRNA are available. To increase the chance of finding a potent sequence, empirical
rules usually incorporated in these algorithms. These empirical rules includes:
thermodynamic property; length of siRNA target; GC content; and RNA secondary
structure [121, 126, 301-303]. However, the selection of targeting sequence is still an
empiric process and depends on experimental screening of potential targets. This is
because our understanding of RNAi mechanism is still insufficient. In addition, most of
the algorithms for shRNA sequence design are actually that of siRNA design and convert
the siRNA into shRNA sequence. In our study, we have converted potent siRNA
targeting sequence into shRNA sequence with success [184, 304]. However, we also
observed loss of silencing effect after converting potent siRNA sequence into shRNA
(data not show). A better understanding of RNAi mechanism is required for improved
design of shRNA. In this study, five shRNA expression plasmids were purchased and
screened to find the potent shRNA targeting sequence. In practical, this might be an
efficient way to find a potent shRNA for certain application.
Promoter is another important element that determines the duration, intensity and
specificity of gene expression [305-307]. The activity of several promoters including
tRNA, H1, U6, CMV, LTR, CMV enhancer/H1 has been investigated [136, 153, 299]. In
this study, we did not observe significant difference in the levels of iNOS gene silencing
when CMV, U6, and H1 promoters were used for driving shRNA-iNOS. Similar results
have been reported by other research groups, where they found that when a less efficient
luciferase shRNA sequence was used, there were some differences in luciferase gene
silencing among different promoters; with H1 promoter being less efficient than CMV
and U6 promoters. However, when a potent luciferase shRNA sequence was used, the
difference in gene silencing effect among different promoters became minimal [153].
The use of miRNA-shRNA in siRNA expression vector is an attractive strategy, which
mimics the structure of natural occurring miRNA and thus can be processed by cellular
miRNA machinery more efficiently compared with conventional shRNA [153]. Almost
80% more effective in reducing HIV p24 antigen production was achieved with TAT
shRNA using mir-30 backbone compared with conventional shRNA [152]. shRNA is
expressed in high level and yields an abundance of precursor, while miRNA-based
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shRNA is expressed at low levels but processed more efficiently [300]. In order to further
improve the silencing effect, we designed two shRNAs-based the mir375 and mir30
sequences. The gene silencing potency of mir375-shRNA and mir30-shRNA was
compared with that of conventional shRNA. However, the shRNA showed best gene
silencing effect (62% reduction of NO production), while mir375 or mir30 shRNA are
less potent with 39% and 30% reduction of NO production, respectively. Similar findings
have been reported by other groups [125, 155]. Li et al., have compared conventional
shRNA and mir30-based shRNAs against luciferase gene or mouse tyrosinase. Among 14
different targeting sequences against luciferase tested, in 11 sequences the conventional
shRNA showed better silencing effect than mir30-based shRNA. All the conventional
shRNA with 10 different targeting sequences against mouse tyrosinase showed
significantly better silencing effect than mir30-based shRNA counterpart. They explained
that the shRNA structure used previously for comparison [153] which has a 29-nt stem
and a 4-nt loop is not a optimal design for shRNA. When a 4-nt loop sequence was used
in shRNA, an insufficient processing of shRNA by Dicer was observed which resulted in
poor gene silencing [125]. However, when a 9-nt loop (UUCAAGAGA) and 19-nt stem
structure was used in shRNA design, a better gene silencing was observed in
conventional shRNA compared with mir30-based shRNA. Therefore, it is reasonable
observe better gene silencing effect in shRNA used in our study which has a 21-nt stem
and 6-nt loop (CTCGAG). Boudreau et al. also demonstrated in their work that optimized
shRNAs are more potent than mir30-based shRNAs for silecing of three genes including
GFP,SCA 1 and HD, when the variables were minimized in the comparision [155]. For
our study, the ultimate goal is to develop a vector for therapeutic purpose, thus the
conventional shRNA which showed better iNOS gene silencing effect will be used in our
future study.
Another important feature of miRNA-based shRNA is that they are more amendable to
pol II transcription and polycistronic strategies, allowing delivery of multiple siRNA
sequences (or a siRNA sequences and a cDNA) with a single promoter [158, 198, 298].
We first designed a miRNA30-based shRNA plasmid p-CMV-mir30-shiNOS, but it was
not as potent as we expected. However, when we inserted a VEGF cDNA between CMV
promoter and mir30-shiNOS sequence (p-CMV-VEGF-mir30-shiNOS), the gene
silencing effect was significantly increased. This result is consistent with the work of
Stegmeier et al.,[154] who reported that the insert of GFP, dsRED and Neo genes
between CMV promoter and mir30-shRNA cassette increased the knock down of Rb
gene. The exact reason for this is still unknown. Probably certain space between CMV
promoter and mir30-shRNA is necessary for efficient gene silencing. The p-CMVVEGF-mir30-shiNOS could be another bipartite vector for therapeutic application, which
co-expresses shRNA and a cDNA with a single promoter.
The purpose of this study was to construct bipartite plasmids that could co-express VEGF
gene for promoting revascularization and shRNA against iNOS gene to reduce human
islet β-cell death. This combinatorial strategy will help to improve the survival and
function of islet graft by promoting revascularization and inhibiting apoptosis [12]. The
reason for using bipartite plasmids is that it will reduce the use of total plasmid backbone,
thus minimizing the immunogenic effect caused by bacterial plasmids [294]. In addition,
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the bipartite plasmids were specially designed as a shuttle plasmid for construction of
adenoviral vectors. Moreover, two restriction enzyme sites have been preserved flanking
shRNA sequence in our bipartite vector. This feature will allow us to replace the shRNA
sequence with a new one through directional cloning. We could conveniently construct pU6-shCas3-CMV-VEGF by replacing shRNA sequence in p-U6-shiNOS-CMV-VEGF
and caspase 3 gene silencing was observed (data not shown.).
In conclusion, we have constructed bipartite plasmids which co-express VEGF cDNA
and shRNA against proapoptotic genes, e.g. iNOS gene. VEGF cDNA and shRNA were
driven by two different promoters or by one single promoter. These plasmids are properly
designed, which allows us to conveniently change shRNA sequence. In addition, all of
these plasmids could be used as a shuttle plasmid for producing adenoviral vectors.
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CHAPTER 5. SYNTHESIS, FORMULATION AND IN VITRO EVALUATION OF
A NOVEL MICROTUBULE DESTABILIZER, SMART-100*
5.1.

Introduction

Several microtubule-targeting drugs, including paclitaxel and docetaxel, have been
developed for treating breast, prostate and non-small-cell lung cancers with great success
[308-312]. However, their anticancer effects are diminished because of their intrinsic or
acquired drug resistance, which involves the over-expression of P-glycoprotein (P-gp),
multidrug resistance protein 7 (MRP 7) and the βIII-tubulin isotype [313-316]. Therefore,
the development of novel anticancer drugs that can circumvent MDR will contribute
significantly to the progress of cancer chemotherapy. Ixabepilone (IXEMPRA), an
epothiline analog, has recently been approved the FDA to be used as a monotherapy or in
combination with capecitabine for treating patients with metastatic or locally advanced
breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is
taxane resistant and for whom further anthracycline therapy is contraindicated [317].
Recently, we have also we have synthesized a series of substituted methoxybenzoyl-arythiazole (SMART) with good anticancer activity on different cancer cell types, including
leukemia, non-small cell lung cancer, colon cancer, CNS cancer, renal cancer, melanoma,
ovarian cancer, prostate cancer, and breast cancer [318]. The SMART compounds work
as microtubule destabilizers by inhibiting tubulin polymerization. Compared with other
microtubule–targeting drugs [316], SMART drugs are much easier to synthesize, which
will reduce the manufacturing cost and thus make them more affordable to patients.
Although SMART compounds demonstrated excellent anticancer bioactivities, their use
was limited due to their poor intrinsic aqueous solubility. Two possible approaches could
be used to address this problem. One is chemical modification, which may involve an
extensive structure activity relationship (SAR) study. Another way is to improve the
solubility of SMART drugs through formulation approaches. Conventionally, dimethyl
sulfoxide (DMSO), Cremophor EL, polysorbate 80 (Tween 80) or other surfactants are
commonly used to solubilize hydrophobic drugs such as taxane. However, the use of
these solubilizing agents is usually associated with liver and kidney toxicity, hemolysis,
acute hypersensitivity reaction and peripheral neuropathies [319].
Biodegradable polymeric micelles have recently been developed as vehicles for
hydrophobic drugs, since these micelles significantly increase the aqueous solubility of
hydrophobic drugs and reduce their toxicity by avoiding the use of toxic co-solvents or
solubilizing agents [320]. The improved safety profile makes it possible to administer
drugs at a higher dose which may enhance their therapeutic efficacy while minimizing
* Adapted with permission. F. Li, Y. Lu, W. Li, D.D. Miller, R.I. Mahato, Synthesis,
formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100, J
Control Release, 143 (2010) 151-158.
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their side effects. Previously, we used a poly(ethylene)-b-poly(D,L-lactide) (PEG-PLA)
polymeric micelles to solubilize two hydrophobic drugs such as bicalutamide and
embelin, and at least 60-fold increase in drug aqueous solubility was observed [321].
Micelles prepared using PEG-PLA copolymer has PLA as a hydrophobic core, which is
responsible for drug loading, and PEG as a hydrophilic shell to confer stealth properties
and thus prevents recognition by the reticuloendothelial system (RES) [322]. Due to its
small size of 20-60 nm and stealth properties, a passive tumor targeting using these
micelles through enhanced permeability and retention (EPR) could be achieved [323].
In this study, the anticancer effect of SMART-100 on cancer cells and its ability to
circumvent P-gp mediated drug resistance were determined. PEG-PLA micelles were
used to improve the aqueous solubility of SMART-100. In addition, the in vitro
anticancer activity of SMART-100 loaded micelles and its mechanism of action were
determined.
5.2.

Materials and Methods

5.2.1.

Materials

Materials Formyl terminated PEG-PLA of 4500-5100 Da was purchased from Polymer
Source (Montreal, Canada). HepG2 and C4-2 cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA). Parent DU145 and paclitaxel resistant
DU145-TXR cells were provided by Professor Evan T. Keller of the University of
Michigan. Caspase-Glo™ 3 assay kit was purchased from Promega (Madison, WI). All
other reagents were obtained from Sigma–Aldrich (St. Louis, MO).
5.2.2.

Synthesis of SMART-100

SMART-100, (2-Phenyl-thiazol-4-yl)-(3,4,5-trimethoxy-phenyl)-methanone, was
synthesized as described [318]. Briefly, benzonitrile (40 mmol) was mixed with Lcysteine (45 mmol) in 100 mL of 1:1 MeOH/pH 6.4 phosphate buffer solution (PBS).
The reaction was stirred at 40 C for 3 days. The precipitate was removed by filtration,
and methanol was removed using a rotary evaporator. 1 M hydrochloric acid was added
to the remaining solution to adjust pH to 2 at 0 C. The resulting precipitate was filtered
to yield a white solid 2-phenyl-4, 5-dihydrothiazole-4-carboxylic acid, which was used
directly for the next step.
A mixture of 2-phenyl-4, 5-dihydrothiazole-4-carboxylic acid (5 mmol), 1-ethyl-3-(3'dimethylaminopropyl) carbodiimide (EDCI, 6 mmol) and hydroxybenzotriazole (HOBt, 5
mmol) in CH2Cl2 (50 mL) was stirred for 10 min. To this solution, N-methylmorpholine
(NMM, 11 mmol) and HNCH3OCH3 HCl salt (5 mmol) were added and stirring
continued at room temperature for 6-8 h. The reaction mixture was diluted with CH2Cl2
(100 mL) and sequentially washed with water, satd. NaHCO3, brine and dried over
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MgSO4. The solvent was removed under reduced pressure to yield a crude product, which
was purified by column chromatography to get 2-phenyl-4, 5-dihydrothiazole-4carboxylic acid methoxymethylamide (Yield 92.0%). A solution of 2-phenyl-4, 5dihydrothiazole-4-carboxylic acid methoxymethylamide (1 equiv) in CH2Cl2 was cooled
to 0 C and distilled DBU (2 equiv) was added. Bromotrichloromethane (1.7 equiv) was
then introduced dropwise via syringe over 10 min. The reaction mixtures were allowed to
warm to room temperature and stirred overnight. Upon washing with satd. aqueous
NH4Cl (2 × 50 mL), the aqueous phase was extracted with ethyl acetate (3 × 50 mL). The
combined organic layers were dried on MgSO4, filtered and concentrated in vacuo. The
residue was purified by flash chromatography as needed providing 2-phenyl-thiazole-4carboxylic acid methoxymethylamide (87.1%).
To a solution of 3, 4, 5-trimethoxyphenylmagnesium bromide (0.5 M, 3 mL) in 2 mL
tetrahydrofuran (THF) was charged a solution of 2-phenyl-thiazole-4-carboxylic acid
methoxymethylamide (1 mmol) in 3 ml THF at 0 C. The mixtures were stirred for 30
min until amides disappeared on TLC plates. The reaction mixture was quenched with
satd. NH4Cl, extracted with ethyl ether, dried with MgSO4. The solvent was removed
under reduced pressure to yield a crude product, which was purified by column
chromatography to obtain pure compound SMART-100.
5.2.3.

Preparation and characterization micelles

5.2.3.1. Preparation of micelles
Drug loaded micelles were prepared by a film-dispersion method. Briefly, various
amounts of SMART-100 and PEG-PLA were dissolved in acetonitrile and a thin film was
formed after removing solvent under reduced pressure. The resulting film was hydrated
and sonicated. The resultant formulation was then centrifuged to remove residual free
drug. The supernatant was then filtered using a 0.22 µm filter and used within 48 h.
5.2.3.2. Determination of drug solubility and loading efficiency
To determine water solubility of free drug, 1 mg of SMART-100 was suspended in 1 mL
water and shake for 48 h at room temperature. The suspension was centrifuged at 10,000
rpm for 10 min and filtered on 0.22 µm filter. To determine the solubility of SMART-100
in micelles, 50 µL of SMART-100 loaded micelles solution was diluted with acetonitrile,
and the drug concentration was measured by UV-spectrometer or reverse phase high
performance liquid chromatography (RP-HPLC, Waters, Milford, MA) with UV detector
at 292 nm using a reverse phase C18 column (250 mm x 4.6 mm, Alltech, Deerfield, IL).
The mobile phase was composed of 40:60 V/V water and acetonitrile. SMART-100
concentration was calculated by peak area according to the following calibration equation:
C = 188.24A-593.64 (R2 = 1, detection limit: 2 ng/mL). The drug encapsulation
efficiency of SMART-100 in polymeric micelles was calculated with the following
equation: drug encapsulation efficiency % = ((weight of drug in micelles) / (weight of
drug origally fed)) × 100%.
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Fold of drug solubility increase were calculated with following equation: fold of drug
solubility increse = drug solubility in micelles / drug solubility in water.
5.2.3.3. Measurement of particle size
The particle size distribution of micelles was determined by dynamic light scattering with
Malvern Nano ZS. The intensity of scattered light was detected at 90°.
5.2.4.

Propidium iodide staining and cell cycle analysis

Cells were cultured in a 24-well plate to 90% confluence and treated with SMART-100
(2.8 µM) for 24 h. Cells were trypsinized and fixed in 70% ice-cold ethanol. After
washing with PBS, cell pellet was re-suspended in 5 µg/mL propidium iodide staining
solution for 15 min at room temperature. Cell cycle distribution was measured by flow
cytometry (Becton, Dickinson, NJ). Results from 10,000 fluorescent events were
obtained for analysis.
5.2.5.

MTT assay

Cells were seeded in 96-well plates at a density of 5,000 cells per well. At the end of
treatment, cell culture media was replaced by 100 μl medium with 0.5 mg/mL MTT (3(4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide and incubated for 1 h at
37°C. After removing the media, 200 μL of DMSO was added into each well to dissolve
the formazan crystals. The absorbance was measured in a microplate reader at a
wavelength of 560 nm. Cell viability was expressed as the percentage of control group.
5.2.6.

Calcein acetoxymethylester (calcein AM) assay

Cells were seeded into a black wall clear bottom 96-well plate at a density of 20,000 cells
per well one day before the experiment. After treating cells with various concentration of
SMART-100 in 50 μL DPBS for 20 min at 37 Ԩ, 50 μL Calceim AM (10 μM) in DPBS
were added to each well and the plate was incubated at 37 C for additional 20 min.
Fluorescence intensity in each well were determined using a SpectraMax M2/M2e
spectrofluorometer (Sunnyvale, CA) at the excitation wavelength of 494 nm and emission
wavelength of 517 nm.
5.2.7.

Determination of caspase 3 activity

Cells were seeded in a 48-well plate to reach 80% confluence before experiment. After
treating the cells for 16 h, culture media was removed and 100 µL Caspase Glo 3 reagent
was added to each well. After gently mixing the content in each well, the plate was
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incubated at room temperature for 60 min protected from light. Finally, 70 µL of the
reaction solution was measured using a luminometer.
5.2.8.

Establishing a luciferase expression cell line for IVIS imaging

For stable luciferase expression, C4-2 cells were seeded in a 6-well plate 24h before
being transfected with pRc/CMV2-Luc plasmid (from Dr. Shu Wang, National
University of Singapore) for 18 h. Two days after transfection, cells were transferred into
a T-25 cell culture flask and selected with 600 µg/mL G418. The resulting
bioluminescent cells were maintained in media containing 300 µg/mL G418. These cells
were then seeded from 120,000 to 100 cells into a black wall clear bottom 96-well plates.
D-luciferin (150 µg/mL) in DPBS was added to each well at 2 min prior to imaging using
an IVIS imaging system (Xenogen, Alameda, CA).
5.3.

Results

5.3.1.

Synthesis and characterization of SMART-100

SMART-100 was synthesized as described by Lu et al.[318], and illustrated in Figure
5.1A. SMART-100 was characterized by 1H NMR (Figure 5.1B), 13C NMR and ESI-MS.
1
H NMR (300 MHz, CDCl3): δ 8.29 (s, 1 H), 8.03 (q, 2 H), 7.80 (s, 2 H), 7.49-7.47 (m, 3
H), 3.96 (s, 6 H), 3.97 (s, 3 H). 13C NMR (75 MHz, CDCl3): 185.1, 168.1, 167.0, 155.4,
152.7, 133.1, 131.9, 130.6, 129.1, 127.7, 126.6, 108.6, 60.9, 56.2. MS (ESI) m/z 378.1
[M + Na]+.
5.3.2.

Anti-cancer activity of SMART-100 on HepG2 cells

The anticancer activity of SMART-100 was determined in HepG2 cells with MTT assay.
SMART-100 effectively inhibited HepG2 cell growth (Figure 5.2), with an IC50 of
around 0.56 µM. The effect was observed as early as 24 h post treatment and became
more significant after 48 h post treatment. There is no significant difference between “0”
group, which is the cells treated with 0.5% DMSO and “DMEM” group, which is the
cells treated with DMEM cell culture medium. Dose response curve was of typical
sigmoid shape, with steep linear response at the mid-range dose groups. While there was
no measurable effect at low doses ( 0.06 nM), the dose response curve became less
steep and finally reaches plateau at high dose groups.
5.3.3.

Anti-cancer activity of SMART-100 in resistant prostate cancer cells

We also tested the anticancer effect of SMART-100 on DU145-TXR cell, a paclitaxel
resistant prostate cancer cell line with high P-gp activity and the parent DU145 cell, a
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Figure 5.1

Synthesis and characterization of SMART-100.

(A) Synthesis scheme of SMART-100. (B) 1H NMR spectrum of SMART-100.
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Anti-cancer effect of SMART-100 on HepG2 cells.

HepG2 cells were treated with increasing concentration of SMART-100 for 24, 48 and 72
h. Cell viability was determined by MTT Assay and expressed as % of control.
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paclitaxel sensitive cell with low P-gp activity. Even though paclitaxel showed good
activity on DU145 cells (IC50 < 50 nM), its efficacy was greatly reduced on DU145-TXR
cells and killing only 20% of cells at a concentration of 1 µM (Figure 5.3A). In contrast,
SMART-100 showed equally good anticancer activity on both DU145 and DU145-TXR
cells with IC50 around 70 nM (Figure 5.3B). From Figure 5.3B, we could see that
SMART-100 at 1 µM inhibited 63.7% and 67.6% cancer cell growth for DU145 and
DU145-TXR, respectively. 74.2% (DU145) and 74.9% (DU145-TXR) cancer cell growth
inhibition was achieved by SMART-100 at concentration of 5.63 µM. 82.1% (DU145)
and 83.8 % (DU145-TXR) cancer cell growth inhibition was achieved by SMART-100 at
concentration of 11.26 µM.
Intracellular calcein levels in DU145 cells were much higher than those in DU145-TXR
cells (Figure 5.4A), indicating higher P-gp activities in DU145-TXR cells but not in
DU145 cells. The treatment of verapamil, a P-gp inhibitor, significantly increased
intracellular calcein levels in DU145-TXR cells in a dose dependent manner, while no
changes in intracellular calcein levels were observed in DU145 cells. Treatment of
DU145-TXR cells with SMART-100 also increased intracellular calcein levels, while
treatment of paclitaxel showed no effect (Figure 5.4B). This indicated that SMART-100
might also act as a P-gp inhibitor in addition to its anti-mitotic activity and thus overcome
the drug resistance in DU145-TXR cells due to P-gp over-expression.
5.3.4.

Micellar solubility of SMART-100

Although SMART-100 showed good anticancer activity, its application was limited due
to its poor water solubility, which is less than 2 ng/mL. Therefore, PEG-PLA micelles
were used to improve its solubility. A film dispersion method was used to prepare
micelles [321]. The mean particle size of micelles was around 50 nm and no significant
difference in particle size was observed in micelles with and without drug. These micelles
were stable for at least 12 days without significant change in particle size.
When we increased the theoretical loading from 0.5% to 5% w/w, the drug solubility
increased from 26.8 ± 0.1 µg/ml to 48.0 ± 0.3 µg/ml until theoretical loading reached 1%
(Figure 5.5A). The drug loading efficiency decreased significantly after the theoretical
loading became larger than 1% (Figure 5.5B).To further increase the drug solubility, the
effect of polymer concentration on drug solubility was determined. The solubility of
SMART-100 increased linearly from 48.0 ± 0.3 to 213.9 ± 8.1 µg/mL (2.4 x 104 to 1.1 x
105 folds as that of free SMART-100 in water), when the polymer concentration was
increased from 5 mg/mL to 20 mg/mL (Figure 5.5C).The drug loading efficiency was
around 100% for all tested polymer concentration (Figure 5.5D).
5.3.5.

Anticancer effect of SMART-100 loaded PEG-PLA micelles

No obvious cytotoxicity was observed in blank PEG-PLA micelles group with a polymer
concentration of as high as 1 mg/mL (Figure 5.6). Significant anticancer effect was
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Anti-cancer effect of SMART-100 on MDR cancer cells.

Inhibition of DU145 and DU145-TXR cells growth by SMART-100 (A) and paclitaxel
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Effect of SMART-100 on P-gp activity.

(A) Intracellular calcein accumulation in DU145 and DU145-TXR cells. (B) Effect of
SMART-100 on intracellular calcein accumulation in DU145-TXR cells. Results are
expressed as the mean ± SE (n = 3).
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Anti-cancer effect of PEG-PLA micelles formulated SMART-100.

HepG2 cells were treated with different SMART-100 formulations for 48 h. Cell viability
was determined by MTT Assay and expressed as the percentage of control. *, p < 0.001,
compared with blank PEG-PLA control.
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observed in both SMART-100 loaded PEG-PLA micelles and SMART-100 dissolved in
DMSO and the anticancer activity increased with the dose. Even though the final DMSO
concentration used was 0.5%, which did not show any obvious toxicity on our
experiment, no direct comparison can be made with the results of SMART-100 dissolved
in DMSO, as DMSO is known to kill tumor and may not be suitable for in vivo
applications.
5.3.6.

Cell cycle perturbation

The treatment of SMART-100 formulated in both DMSO and PEG-PLA micelles caused
cell cycle arrest in HepG2 cells, while no effect was observed after treating cells with
blank PEG-PLA micelles or DMSO (Figure 5.7). The treatment of SMART-100
formulations caused the cells in G0/G1 phase decreased from 49.18 ± 1.59% in the
control group to 21.03 ± 0.54% in DMSO dissolved SMART-100 group and 19.24 ±
0.89% in PEG-PLA micelles formulated SMART-100 group, respectively. While the
cells in G2/M phase were increased from 29.59 ± 1.55% in control group to 73.06 ±
1.68% in DMSO dissolved SMART-100 group and 74.91 ± 1.10% in PEG-PLA micelles
formulated SMART-100 group, respectively. In addition, we also determined the effect
of treatment time on cell cycle distribution (Figure 5.7B). Cells were treated with
SMART-100 loaded PEG-PLA micelles for 24, 48, and 72 h. There was no change in the
percentage of cells in G0/G1 phase after treating the cells for prolonged time at 48 or 72
h. The percentage of the cells in G2/M phase was decreased from 74.91 ± 1.1% at 24 h to
68.71 ± 1.95% at 48 h and to 65.5 ± 1.65% at 72 h. In addition, the cells in sub G1 phase
were also increased from 0.29 ± 0.21% at 24 h to 2.96 ± 1.34% at 48 h and to 8.94 ±
1.15% at 72 h. The increase of cell population in subG1 phase indicated that apoptotic
cells were increased after SMART-100 treatment for prolonged time.
5.3.7.

Caspase 3 activity

In the cell cycle analysis, we found that the treatment of SMART-100 resulted in
increased cell population in subG1 phase, which is an indication of apoptosis. To confirm
whether cell death induced by SMART-100 was associated with apoptosis, caspase 3
activity was measured after treating HepG2 cells with SMART-100. As shown in Figure
5.8, no significant difference was observed between untreated cell and cells treated with
DMSO or empty PEG-PLA micelles. The treatment of SMART-100 with both DMSO
and PEG-PLA micelles at a concentration of 2.8 µM resulted in increased caspase 3
activity (p < 0.05), which is comparable to those caused by paclitaxel with the same
molar concentration (p > 0.05). This result indicated that SMART-100 may cause cell
apoptosis by the activation of caspase 3 activity. However, increase of caspase 3 activity
in SMART-100 treated groups was relatively low compared with cells treated with
staurosporine, a well-known caspase 3 activator (p < 0.01).
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Effect of SMART-100 on cell cycle and apoptosis.

(A) HepG2 cells were treated with different SMART-100 formulations (drug
concentration 1µg/ml) for 24 h and cell cycles were analyzed by flow cytometry. Upper
panel, Cell cycle distribution; Lower panel, quantitative analysis. (B) Time course of cell
cycle perturbation in HepG2 cells treated with SMART-100 loaded PEG-PLA micelles.
Upper left panel, cell cycle distribution; Upper right panel, graphical representation of
apoptotic index (percent sub-G1 cells) over time; and Lower panel, quantitative analysis.
Results are expressed as the mean ± SE (n = 3). * P < 0.001, ** P < 0.01, compared with
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Effect of SMART-100 on caspase 3 activity.

After treatment with 1µg/ml SMART-100 or same molar concentration of paclitaxel or
saturosporeine for 16 h, caspase 3 activity was determined. Caspase 3 activities were
expressed as relative light unit (RLU) and normalized by cell viability. Drugs were
dissolved in DMSO, unless otherwise stated. Results are the mean ± SE (n = 3). *, p <
0.001, **, p < 0.01, ***, p < 0.05 compared with DMSO control. ++, p < 0.01 compared
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5.3.8.

IVIS imaging for assessing antitumor activity

We established a luciferase expressing C4-2 prostate cancer cell line for IVIS imaging
(Figure 5.9A). There was a good correlation between the cells number and
bioluminescence signals captured by IVIS imaging (R2 = 0.9769, Figure 5.9B), thus live
cell number could be quantitatively determined by IVIS imaging. Treatment with
SMART-100 resulted in significant reduction in the bioluminescence signal (Figure
5.9C). However, the treatment with empty PEG-PLA micelles did not cause any change
in bioluminescence signal. The viable cell number was also been quantitatively
determined by measuring bioluminescence signal (Figure 5.9D).
5.4.

Discussion

The discovery of paclitaxel has resulted in significant progress for the treatment of
several cancers including breast, ovarian, and non-small cell lung cancers. Paclitaxel
works through stabilizing microtubules, and thus causing mitotic arrest and apoptosis.
Despite the potent anticancer activity of paclitaxel, its clinical application is often
undermined due to the occurrence of MDR. Cancer cells become resistant to anticancer
drugs due to the change in cell membrane ATP-binding cassette (ABC) super family
transporters such as P-gp, multiple drug resistance protein (MRP) and breast cancer
resistance protein (ABCG2). Particularly, the over-expression of P-gp encoded by MDR1
gene is widely investigated and known to be responsible for the resistance to several
anticancer agents such as paclitaxel and docetaxel.
Several strategies have been studied to overcome MDR mechanism including the use of
novel drug delivery systems, co-administration of P-gp inhibitors, and the search of new
compounds that could overcome MDR. Drug delivery systems such as HPMA copolymer
drug conjugates [324], polymeric micelles [325], liposomes [326], and nanoparticles [327]
have been successfully used to reduce the drug resistance by enhanced intracellular drug
delivery and/or inhibition of P-gp activities. In addition to formulation approaches,
scientists have also successfully discovered several new compounds to overcome MDR.
Ixabepilone, for example, has been approved by the FDA as a drug for MDR breast
cancer [328].
To test whether SMART-100 could overcome MDR, a paclitaxel-resistant cell line,
DU145-TXR, was used in this study. DU145-TXR is resistant to paclitaxel as well as
several other anticancer agents including estramustine phosphate, docetaxel, doxorubicin
and vinblastine [329]. SMART-100 showed potent anticancer activities in both
paclitaxel-sensitive (DU145) and paclitaxel-resistant (DU145-TXR) cancer cells (Figure
5.3B). These results suggest that SMART-100 has the potential to be used for treating
MDR cancers.
To further understand why SMART-100 could keep its anticancer activity in paclitaxelresistant cells capable of overexpressing P-gp, Calcein acetoxymethylester (Calcein AM)
assay was carried out to determine the effect of SMART-100 on P-gp functions. Calcein
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Determination of anti-cancer activity by IVIS imaging.

(A) In vitro bioluminescence of C4-2 human prostate tumor cell lines expressing
luciferase. C4-2-luc cells were seeded from 120,000 to 100 cells per well and imaged
after the addition of luciferin. Wells containing cells but no luciferin were served as
negative controls. (B) Correlation between cell number and mean bioluminescence
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compared with blank PEG-PLA control.
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AM is a substrate for efflux activity of P-gp. In cells with high P-gp activity, Calcein AM
is constantly pumped out, preventing intracellular accumulation of fluorescent calcein.
The inhibition of P-gp function by inhibitors such as verapamil results in reduced efflux
of fluorescent calcein and thus increases intracellular fluorescence intensity. The change
of fluorescence intensity could be quantitatively determined by fluorometer and used as
an indicator for P-gp activities. The treatment of SMART-100 significantly increased the
intracellular accumulation of calcein, which indicated that it might be an inhibitor of P-gp
and prevented the efflux of drug out of P-gp over-expressing cells (Figure 5.4). Therefore,
inhibition of P-gp activity might be a mechanism of SMART-100 to overcome multiple
drug resistance.
Our previous study showed that SMART-100 works by targeting and destabilizing
microtubules. As a microtubule destabilizer, its anti-proliferative effect is involved in the
inhibition of tubulin polymerization [318]. The cell cycle analysis indicated that after
treatment with SMART-100 the cells were arrested in G2/M phase (Figure 5.7). Since the
destabilization of microtubule dynamics will result in the cell cycle arrest at mitotic phase,
cell cycle analysis experiment further confirmed that the anticancer mechanism of
SMART-100 is through destabilizing microtubule. We also found that after SMART-100
treatment cells in sub-G1 phase were significantly increased (Figure 5.7). The increase in
cell population in sub-G1 phase indicated the induction of cell apoptosis by SMART-100
[330, 331]. The increase in caspase 3 activity is an important marker for cell apoptosis.
Treatment with SMART-100 increased caspase 3 activities in this study (Figure 5.8),
which indicated the occurrence of apoptosis. From the binding of microtubule
destabilizer with the tubulin to apoptosis is a complicated intracellular process, which
involves multiple signal pathways, including the checkpoint of mitotic spindle assembly,
the activation of cyclin-dependent kinases, and the JNK/SAPK [332]. However, these
signal pathways are beyond the scope of this study.
PEG-PLA micelles have been successfully used as a Cremophor EL free formulation for
paclitaxel (Genexol-PM), which is under multicenter phase II clinical trial [333]. Because
of its superior performance as a delivery system for paclitaxel, we used PEG-PLA
micelles to improve the solubility of SMART-100. Due to the high logP value (4.08) of
SMART-100, its aqueous solubility is very low (below the detection limit, 2 ng/mL).
However, the use of PEG-PLA micelles significantly increased its aqueous solubility.
The maximum solubility reached to 213.9 ± 8.1 µg/mL, where SMART-100 solubility
was increased by at least 1.1x105 folds (Figure 5.5). Polymeric micelles are known to
enhance the solubilization of hydrophobic compounds by accommodating them in the
hydrophobic core of polymers. A critical parameters involves in the solubilization
process is polymer-drug compatibility, which could be evaluated by solubility difference
(Δ) and Flory-Huggins interaction parameter (Xsp) [334]. We have calculated the
solubility parameters of SMART-100 and PLA hydrophobic core by Molecular Modeling
Pro Software (ChemSW Inc., Fairfield, CA). The calculated parameters for PLA is 19.7
(δd), 2.48 (δp) and 20.9(δh), while those of SMART-100 is 20.3 (δd), 6.5 (δp) and 9.2
(δh). Thus, the solubility difference (Δ) between PLA and SMART-100 is 12.4. Typically,
a solubility difference value less than 5 is needed to observed good solubility [335].
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Therefore, we plan to design and modify the hydrophobic core of the polymer to make it
more compatible with SMART-100 and further increase the solubility of SMART-100.
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CHAPTER 6. SYNTHESIS AND CHARACTERIZATION OF AMPHIPHILIC
LIPOPOLYMERS FOR MICELLAR DRUG DELIVERY*
6.1.

Introduction

Many anticancer agents are poorly soluble in water, which can cause serious problems for
their clinical application. Dimethyl sulfoxide (DMSO), Ctenophore EL, Tween 80 or
other surfactants are commonly used to solubilize these drugs. However, these
solubilizing agents are harmful to the liver and kidney and cause dose-dependent
hemolysis and acute hypersensitivity reactions [319, 336]. In addition, because of high
critical micelle concentration (CMC) values associated with low molecular weight
surfactant micelles, they are not stable after systemic administration and thus result in the
precipitation of solubilized drugs.
Poly(ethylene glycol)(PEG)-lipid conjugates, such as PEG-phosphatidylethanolamie
(PEG-PE) have been used for micellar drug delivery [337, 338]. The use of PEG-lipid
conjugates for drug delivery are superior to conventional small molecular weight
surfactants, since PEG-lipid conjugates have lower critical micelle concentration (CMC:
around 10-5 M) than conventional surfactants (CMC: around 10-3 M), suggesting PEGlipid conjugate micelles are more stable than those formed by conventional surfactants. A
typical PEG-lipid conjugate structure includes a hydrophilic PEG corona and a
hydrophobic lipid core, which, in turn, is composed of two lipid chains varying from C12
to C18 in chain length. Although we could conjugate PEG with different lipids to make
different PEG-lipid conjugates, the flexibility in the design of hydrophobic core is still
limited.
Alternatively, amphiphilic copolymers have become promising materials for micellar
drug delivery. Pluronic is a triblock copolymer composed of a central hydrophobic chain
of poly (propylene oxide) (PPO) flanked by two hydrophilic chains of poly (ethylene
glycol) (PEG), and has been widely used for drug delivery [339]. It not only increases
drug solubility, but also overcomes drug resistance in cancer [340, 341]. The CMC of
Pluronic copolymers ranges from 5.3 x 10-3 M to 2.8 x 10-6 M depending on the
molecular weight and composition of copolymers [339]. However, the use of Pluronic for
drug delivery is somewhat problematic because they are non-biodegradable. Therefore,
biodegradable copolymers such as PEG-PLLA-PEG were designed to facilitate the
elimination of polymers from the body [342]. In addition, the structure and size of
hydrophobic core block could be properly designed to improve the micelle stability and
drug loading. A significantly reduced CMC (10-6 to 10-7 M) is observed in a diblock
copolymer, which is 10 to 100 folds lower than PEG-lipid conjugates [343]. For
examples, the CMC of PEG5100-PLA4500 was around 3 x 10-6 M as determined by
* Adapted with permission. F. Li, M. Danquah, R.I. Mahato, Synthesis and
characterization of amphiphilic lipopolymers for micellar drug delivery,
Biomacromolecules, 11 (2010) 2610-2620.
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Danquah et al.[321] Similar results were also reported by Yasugi et al.,[339] who showed
that the CMC of PEG5700-PLA5400 was around 3 x 10-7 M. The low CMC of micelles
formed by amphiphilic copolymers indicates that they are more stable than PEG-lipid
conjugate micelles and can maintain the integrity of micelles upon dilution. In addition,
we and others have showed that the drug solubility has been significantly improved by
properly designing the hydrophobic core structure to improve the compatibility between
the hydrophobic core and drugs [344]. For an example, PEG-b-poly(N-alkyl stearate Laspartamide), a lipid conjugated polymer, has been used to improve the solubility of a
hydrophobic drug, amphotericin B, and demonstrated the possibility of using
lipopolymers for solubilization of lipid-like drugs [345, 346].
In this study, we synthesized a novel amphiphilic lipopolymer, poly(ethylene glycol)block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD). The
polymer synthesis procedures were optimized and the properties of polymers were
characterized. PEG-PCD lipopolymers could form micelles and effectively incorporate
embelin and improve its water solubility. PEG-PCD lipopolymers were compared with
similar polymers with different core structures to investigate the effect of core structure
on micelle properties, such as stability, drug loading, particle size and morphology, and
in vitro drug release. In addition, we also investigated the effect of hydrophobic core size
on the properties of PEG-PCD lipopolymer micelles. Finally, the anti-cancer activities of
embelin loaded micelles were determined in vitro with prostate cancer cells.
6.2.

Materials and Methods

6.2.1.

Materials

Hydroxybenzotriazole (HOBT), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),
dodecanol, triethylamine (TEA), stannous 2-ethylhexanoate (Sn(Oct)2), diethyl zinc
(Et2Zn), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 2,2-bis(hydroxymethyl) propionic
acid, methoxy poly(ethylene glycol) (mPEG, Mn = 5000, PDI = 1.03) and all other
reagents were purchased from Sigma Aldrich (St. Louis, MO) and used as received.
6.2.2. Synthesis of poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene
carbonate-graft-dodecanol) (PEG-PCD)
PEG-PCD lipopolymer was synthesized using the following two methods (Figure 6.1):
6.2.2.1. Method I
Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate)
(PEG-PBC) was synthesized with the following procedures. Monomer 2-methyl-2benzyloxycarbonyl-propylene carbonate (MBC) was synthesized as described by
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PEG-PCC

PEG-PBC

MBC
PEG-PCD
MCC

Figure 6.1

MDC

Synthesis of PEG-PCD lipopolymer.

Reaction conditions: (IA) DBU, CH2Cl2, RT, 3 h. (IB) Pd/C (10%), H2 ,
THF/Methanol(1:1), RT, 18 h.(IC) EDC, HOBT,TEA, DMF, RT, 18 h. (IIA) Pd/C
(10%), H2, EtOAc, RT, 3 h. (IIB) EDC, HOBT,TEA, DMF, RT, 18 h. (IIC)
DBU,CH2Cl2, RT, 3h.
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Danquah et al. [344]. Briefly, a mixture of 0.168 mol 2,2-bis(hydroxymethyl)propionic
acid and 0.169 mol potassiumhydroxide was dissolved in 125 mL dimethylformamide
(DMF) by heating to 100 Ԩ for 1 h with stirring. Then, 0.202 mol benzyl bromide was
added drop-wise to the warm solution, and stirred at 100 Ԩ for 16 h. At the end of
reaction, the solvent was removed under reduced pressure. The residue was dissolved in
150 mL ethyl acetate, washed with water, and dried over MgSO4. The solvent was
removed to yield a crude product, which was re-crystallized from toluene to give pure
benzyl 2,2-bis(methylol)propionate. Then, 0.05 mol of benzyl 2,2bis(methylol)propionate was dissolved in 150 mL CH2Cl2 containing 25 mL pyridine,
and the solution was chilled to 78 Ԩ. A solution of CH2Cl2 containing 25mmol
triphosgene was dripped into the solution over 1 h. The reaction mixture was stirred for
additional 2 h at the room temperature before quenched with 75 mL saturated aqueous
NH4Cl. Subsequently, the organic layer was sequentially washed with aqueous HCl (1M,
300 mL), saturated aqueous NaHCO3 (300 mL), dried with Na2SO4, evaporated to give 2methyl-2-benzyloxycarbonyl-propylene carbonate (MBC) as a crude product, which was
further recrystallized from ethyl acetate to give white crystals.
Three methods with different catalysts were investigated in this study to synthesize PEGPBC from copolymerization of mPEG with monomer MBC. (1) Sn(Oct)2 (10 mol%
relative to mPEG) was added to the mixture of given amount of mPEG and MBC
dissolved in anhydrous toluene in a dried polymerization flask under the protection of
nitrogen atmosphere. To optimize the reaction condition, the reaction mixture was heated
to 80 Ԩ for 3 h and 16 h under stirring, respectively. (2) DBU (40 µL) was added to the
mixture of given amount of mPEG and MBC dissolved in 10 ml anhydrous CH2Cl2 and
reacted at RT for 3 h under stirring. (3) Et2Zn (10 mol% relative to mPEG) was added to
the mixture of given amount of mPEG and MBC dissolved in anhydrous toluene in a
dried polymerization flask under the protection of nitrogen atmosphere and reacted at 80
Ԩ for 16 h under stirring. At the end of reaction, the reaction mixture was dissolved in
CHCl3 and the product was precipitated with a large amount of ice-cold diethyl ether and
dried under vacuum at room temperature.
To remove protective benzyl groups, PEG-PBC was subjected to hydrogenation. Briefly,
one gram of PEG-PBC was dissolved in 12 mL of tetrahydrofuran (THF) and methanol
mixture (1:1) containing 200 mg of palladium on charcoal (Pd/C). The reaction flask was
purged with N2 thrice and charged with H2 using a balloon. The reaction was carried out
for 18 h with stirring. At the end of reaction, Pd/C was removed by centrifugation. The
solvent was removed under reduced pressure to get poly(ethylene glycol)-block-poly(2methyl-2-carboxyl-propylene carbonate)(PEG-PCC).
Lipid was conjugated to PEG-PCC as described in the following. For lipid conjugation to
PEG-PCC, 300 mg PEG-PCC, 260 mg dodecanol, 223 mg hydroxybenzotriazole
(HOBT), and 317 mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) were
dissolved in 10 mL DMF and 340 µL of triethylamine (TEA) was then added to the
mixture with stirring. After reaction for 18 h, products were precipitated with a large
amount of cold isopropyl alcohol twice and diethyl ether once, and then dried under
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vacuum at the room temperature to afford poly(ethylene glycol)-block-poly(2-methyl-2carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD).
6.2.2.2. Method II
Firstly, 2-methyl-2-carboxyl-propylene carbonate (MCC) was synthesized by
hydrogenation of MBC as described previously [344]. Briefly, one gram of monomer
MBC was dissolved in 10ml ethyl acetate containing 100 mg of Pd/C. The reaction flask
was purged with N2 three times and charged with H2 to 45 psi. The reaction was carried
out for 3 h. Then, Pd/C was removed by centrifugation. The solvent was removed under
reduced pressure to give MTC-OH as white crystal.
Then, 2-methyl-2-dodecanoxycarbonyl-propylene carbonate (MDC) was synthesized. To
synthesize MDC, 480 mg MTC-OH, 465 mg dodecanol, 506 mg HOBT, and 720 mg
EDC were dissolved in 20 ml DMF and 490 µL of TEA was then added to the mixture
with stirring for 18 h. The reaction mixture was diluted with ethyl acetate (20 mL) and
washed with water and dried over MgSO4. The solvent was removed under reduced
pressure to yield a crude product, which was further purified by column chromatography
to get MDC as white powder.
Finally, PEG-PCD was prepared from copolymerization of mPEG with MDC. DBU (40
µL) was added to the mixture of a given amount of mPEG and MDC was dissolved in
anhydrous CH2Cl2 and reacted under stirring for 3 h. The reaction mixture was dissolved
in CHCl3 and the product was precipitated with a large amount of cold isopropyl alcohol,
diethyl ether, and dried under vacuum at room temperature to get PEG-PCD lipopolymer.
6.2.3.

Polymer characterization

6.2.3.1. Nuclear magnetic resonance (NMR)
1

H NMR spectra were recorded on Varian (500 MHz) using deuterated chloroform
(CDCl3) as a solvent unless otherwise noted. The chemical shifts were calibrated using
tetramethylsilane as an internal reference and given in parts per million.
6.2.3.2. Infrared (IR) spectra
The composition of synthesized polymers was also confirmed with Infra red (IR) spectra
using a Perkin-Elmer IR spectrometer.
6.2.3.3. Gel permeation chromatography (GPC)
The weight (Mw) and number (Mn) average molecular weight and polydispersity index
(PDI) of synthesized polymers were determined by a Waters GPC system equipped with
a GPC column (AM Gel 103/5) and a differential refractive index detector. THF was used
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as an eluent at a flow rate of 1 ml/min. A series of narrow polystyrene standards (700–
40,000 g/mol) were used for calibration.
6.2.3.4. Differential scanning calorimetry
The thermal properties, including glass transition temperature (Tg), melting temperature
(Tm), crystalline temperature (Tc) of the synthesized polymers were determined by
differential scanning calorimetry (DSC) (TA Instrument DSC Q2000 module). Samples
were placed in aluminum pans under nitrogen heated from 25 Ԩ to 100 Ԩ, cooled to -70
Ԩ to remove thermal history and heated from -70 Ԩ to 100 Ԩ at a rate of 5 Ԩ / min.
6.2.4.

Critical micelle concentration

Critical micelle concentration (CMC) was determined with fluorescent spectroscopy
using pyrene as a hydrophobic fluorescent probe, as previously described [347]. Briefly,
forty microliters of pyrene stock solution (2.4 x 10-3 M) in acetone was added to 40 mL
water to prepare a saturated pyrene aqueous solution. Polymer samples were dispersed in
water with concentration ranges from 0.5 to 4.8 x 10-7 mg/mL and mixed thoroughly with
above pyrene solution at a volume ratio of 1:1. The fluorescent intensity was recorded
with a Molecular Devices SpectraMax M2/M2e spectrofluorometer (Sunnyvale, CA)
with a EX = 338 nm (I3) and 333 (I1), Em = 390 nm. The intensity ratio (I338/I333) was
plotted against the logarithm of polymer concentration. The CMC value was obtained as
the point of intersection of two tangents drawn to the curve at high and low
concentrations, respectively.
6.2.5.

Preparation of polymeric micelles

Polymeric micelles were prepared with a film dispersion method as previously reported
with some modifications [348]. Briefly, 15 mg of polymer and given amount of embelin
were dissolved in 0.5 mL CH2Cl2, and then the solvent was removed under reduced
pressure. The resulting film was hydrated in 3 mL PBS (pH 7.4) and sonicated for 1 min.
Then, the residue free drug was removed by centrifugation at 12,000 rpm for 5 min. The
supernatant was filtered using a 0.22 µM filter.
6.2.6.

Drug loading and encapsulation efficiency

To determine drug loading, 10 µL of embelin loaded micelle solution was diluted with
methanol. Then drug concentration was determined using a UV spectrometer at 310 nm
(Thermo Spectronic). Embelin concentration was calculated based the UV absorbance
using a standard curve. Drug loading and encapsulation efficiency were then determined
using the following equations, respectively. Drug loading (%) = ((amount of loaded drug)
⁄ (amount of polymer)) × 100%. Drug encapsulation efficiency (%) = ((amount of loaded

95

drug) ⁄ (amount of drug added)) × 100%. Theoretical loading (%) = ((amount of drug
added) ⁄ (amount of polymer)) × 100%.
6.2.7.

Morphology and particle size

The particle size of polymeric micelles was determined by dynamic light scattering
(Malvern Nano ZS). The intensity of scattered light was detected at 90°. The particle size
measurement was repeated three times and the data were reported as the mean ± SD. The
morphology of polymeric micelles were observed using a transmission electron
microscope (TEM, JEM-100S) using an acceleration voltage of 60 kV. Micelles was
loaded on a copper grid and stained with 1% uranyl acetate. The grid was visualized
under the electron microscope with magnifications of 75,000.
6.2.8.

In vitro drug release

The dialysis technique was employed to determine the release of embelin from polymeric
micelles in PBS (pH 7.4) with 0.1% Tween 80. The micelles used for in vitro release
study have a polymer concentration of 5 mg/mL. Eight hundred microliters of micelles
with 5% drug loading were used to compare the release profiles of PEG-PCD with
different PCD length. In addition, 2 mL micelles with 2% drug loading were also used to
compare the release profiles of PEG114-PCD29 and PEG114-PBC30. Embelin-loaded
micelles were placed into a dialysis tube with a molecular weight cut-off of 3500 Da and
dialyzed against 50 mL release medium in a thermo-controlled shaker with a stirring
speed of 180 rpm at 37 Ԩ. At specified time, 1 mL release medium was withdrawn and
embelin concentration was determined with a UV spectrophotometer based on UV
absorbance at 310 nm. All experiments were performed in triplicate and the data reported
as the mean of the three individual experiments. The release profiles were assessed as
described previously [349] using similarity factor (f2). The percentage of cumulative
drug release was calculated with the following equation: cumulative drug release (%) =
((cumulative amount of released drug) / (total amount of drug added)) × 100%.
6.2.9.

In vitro cytotoxicity of embelin loaded micelles

C4-2 prostate cancer cell line was used to determine the cell growth inhibition ability of
embelin-loaded micelles. Cells were cultured in RPMI 1640 media supplemented with
10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic at 37 Ԩ in humidified
environment of 5% CO2. Cells were seeded in 96-well plates at a density of 5,000 cells
per well 18 h before treatment. Then, cells were treated with drug-loaded micelles or
equivalent amount of blank micelles for additional 72 h. At the end of treatment, cell
culture medium was replaced by 100 μL medium with 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) and incubated for 1 h at 37 °C.
Then the medium was carefully removed and 200 μL of DMSO was added into each well
to dissolve the formazan crystals. The absorbance was measured in a microplate reader at
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a wavelength of 560 nm. Cell viability was expressed as the percentage of control group.
Cell viability (%) = (Atest / Acontrol) × 100%.
6.3.

Results

6.3.1.

Synthesis and characterization of polymers

As summarized in Figure 6.1, the target lipopolymer PEG-PCD was synthesized by two
approaches. In the first approach, PEG was copolymerized with MBC to afford
poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate)
(PEG-PBC). Then, the pendant benzyl group was removed by hydrogenation to expose
carboxyl groups to get poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene
carbonate)(PEG-PCC). Finally, poly(ethylene glycol)-block-poly(2-methyl-2-carboxylpropylene carbonate-graft-dodecanol) (PEG-PCD) lipopolymer was synthesized by
conjugating dodecanol to the carboxyl groups. In the second approach, PEG was
copolymerized with a lipid modified monomer 2-methyl-2-dodecanoxycarbonylpropylene carbonate (MDC). MCC and MDC were characterized with 1H NMR and ESIMS: MCC,1H NMR (500 MHz, DMSO): δ13.35 (s, 1 H), 4.57 (d, 2 H), 4.32 (d, 2 H),
1.18(s, 3 H). MS (ESI) m/z 159 [M-H]-. MCC,1H NMR (500 MHz, CDCl3): δ4.50 (d, 2
H), 4.2 (d, 4 H), 1.65 (m, 2 H), 1.4-1.2(m, 21 H), 0.85 (t, 3 H). MS (ESI) m/z 351 [M +
Na]+. Although we could synthesize the lipopolymers with both approaches, the second
approach involves column purification of MDC which is a time consuming process.
Therefore, the first approach was selected to generate lipopolymer PEG-PCD.
To achieve the optimal polymerization efficiency, three different catalysts were tested for
copolymerization of PEG and MBC as summarized in Table 6.1. Among three catalysts
tested, DBU was the best, as the conversion rate was 80-88% at the molar ratio of
monomer and PEG ranging from 10 to 34. Both Sn(oct)2 and Et2Zn were used at 80 Ԩ
and the degree of polymerization (DP) was increased with prolonged reaction time from
3h to 16 h for Sn(oct)2. However, both of these two catalysts gave less DP under the
reaction conditions described in Table 6.1. Therefore, DBU was selected in the current
study.
The structures of PEG-PBC, PEG-PCC, and PEG-PCD were confirmed by 1H NMR
(Figure 6.2). From Figure 6.2A, the following peaks were observed for PEG-PBC
polymer at δ 1.2 (CH3 in BC unit), δ 3.6 (CH2 in PEG), δ 4.3(CH2 in BC main chain), δ
5.2 (CH2 in BC side group), and δ 7.3 (phenyl ring). All signals are assigned as methoxy
poly(ethylene glycol) (mPEG) and polymerized BC units. In addition, the success of
polymerization was confirmed by the disappearance of signal at δ 4.2 and δ 4.6 in the
MBC monomer and appearance of a new peak at δ 4.3. The degree of polymerization and
molecular weight of the polymers was estimated based on the peak areas of PEG CH2
groups at δ 3.6 and those of CH2 in BC main chain at δ 4.3.
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Table 6.1

a.
b.
c.
d.
e.
f.
g.
h.
i.

Effect of different catalyst on the polymerization of PEG-PBC copolymer.
Catalysta

[MBC]/
[PEG-OH]e

Mn, Targetf

DPMBCg

Mn h

Conversion
(%)i

DBUb
DBUb
DBUb
Sn(oct)2c
Sn(oct)2d
Et2Znd

10
20
34
34
34
20

7500
10000
13500
13500
13500
10000

8
17
30
17
22
6

7000
9250
12500
9250
10500
6500

80
85
88
50
65
30

DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; Sn(oct)2: stannous 2-ethylhexanoate; Et2Zn: diethy zinc.
Reaction condition: RT, 3 h.
Reaction condition: 80 Ԩ, 3 h.
Reaction condition: 80 Ԩ, 16 h.
Molar ratio of monomer (MBC) to PEG in the feed.
Mn, target = [MBC] / [PEG-OH] x Mmonomer unit (250) + MPEG-OH (5000).
DP: Degree of Polymerization, determined by 1H NMR.
Mn = DP x Mmonomer unit (250) + MPEG-OH (5000).
Determine by 1H NMR, Conversion (%) = DP / ([MBC] / [PEG-OH]) x 100%.
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(A) PEG114-PBC30 in CDCl3, (B) PEG114-PCC30 in DMSO, (C) PEG114-PCD29 in CDCl3.
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The benzyl groups were removed via Pd/C catalyzed hydrogenation. The peaks at δ 5.2
(CH2 in BC side group) and δ 7.3 (phenyl ring) disappeared after hydrogenation (Figure
6.2B), which indicates the complete removal of pendant benzyl group. In addition, a peak
at δ 13 was observed, which belongs to the exposed carboxyl group after removing
protective benzyl group. Dodecanol was conjugated onto the polymer backbone using
EDC/HOBT chemistry. The success of dodecanol conjugation to PEG-PCC carboxyl
group was confirmed by the appearance of new peaks at δ 4.1, δ 1.6, δ 1.2-1.4, and δ 0.9,
which could be assigned to different groups in the lipid as shown in Figure 6.2C.
The FTIR of PEG-PBC, PEG-PCC, and PEG-PCD also confirmed the success of the
reaction (Figure 6.3). In FTIR spectra of PEG-PBC, there were peaks at 736 and 696
cm-1, which were due to the CH vibrations of benzyl groups. These two peaks were
absent in the FTIR spectra of PEG-PCC and PEG-PCD, indicating the removal of the
pendant benzyl groups during hydrogenation. In addition, we also observed a broad OH
stretch band, which was centered at 3450 cm-1 and partially overlapped with C-H stretch.
This further confirmed the presence of pendant COOH groups. Besides, we also
observed absorbance bands due to the C = O stretching vibration at 1749 cm-1 (PEGPBC), 1748 cm-1 (PEG-PCC), and 1755 cm-1 (PEG-PCD), respectively. The C-H stretch
band was observed at 2886 cm-1 for PEG-PBC, 2874 cm-1 for PEG-PCC. In addition, 3
bands at 2923, 2889, and 2855 cm-1 were observed for PEG-PCD, indicating the presence
of pendant long alkanes.
The characteristics of PEG-PBC, PEG-PCC, and PEG-PCD polymers are summarized in
Table 6.2. The molecular weight of PEG-PBC and PEG-PCC were calculated based on
the peak areas of PEG CH2 groups at δ 3.6 and those of CH2 in BC main chain at δ 4.3 in
the 1H NMR spectrum. In addition, the percentage of conjugation and molecular weight
of the lipopolymer was calculated by the peak areas at δ 4.3 (belongs to polymer
backbone) and at δ 4.1 (belongs to the conjugated pendant lipid) in the 1H NMR
spectrum. The Mn determine by 1H NMR were 12,500 g/mol for PEG114-PBC30, 9,800
g/mol for PEG114-PCC30, 13,561 g/mol for PEG114-PCD29, 10,248 g/mol for PEG114PCD16, and 6,968 g/mol for PEG114-PCD6, respectively. GPC was also used to determine
the apparent weight (Mw) and number (Mn) average molecular weight of polymers and
their polydispersity index. A good correlation was observed between the molecular
weight estimated from NMR and Mw or Mn determined by GPC. All of the polymers
showed narrow distribution as revealed by the small polydispersity index (1.06 to 1.23).
A representative plot comparing the GPC chromatograms for PEG114-PCC30, PEG114PBC30, and PEG114-PCD29 was shown in Figure 6.4.
DSC was used to determine the thermal properties of the synthesized block copolymers.
The thermograms of diblock copolymers with different core structures are shown in
Figure 6.5. PEG114-PBC30 has a Tg = -35.7 Ԩ, Tc = 6.3 Ԩ, and Tm = 49.5 Ԩ, respectively.
PEG114-PCC30, which is a transparent viscous liquid, showed a Tg of -30.7Ԩ, but no
obvious Tc or Tm. PEG114-PCD29 showed a Tm of -35.7 Ԩ, but no obvious Tg or Tc. The
different thermal properties observed with DSC suggesting different properties of the
copolymers. Only Tg was observed in PEG114-PCC30, indicating it is an amorphous
polymer. PEG114-PCD29 has a high degree of crystallinity, since there was no Tg.
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Figure 6.3

FTIR spectra of polymers.

(A) PEG114-PBC30, (B) PEG114-PCC30, and (C) PEG114-PCD29.
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Table 6.2

Characteristics of PEG copolymers with different core structure.
Polymera

Mn
(NMR)

Mw
(GPC)b

Mn
(GPC)b

PDIb

CMC
(g/L)

CMC
(M)c

Crystallinity

PEG114-PBC30

12500

11140

9703

1.15

4.0x10-4

3.2x10-8

semicrystalline

PEG114-PCC30

9800

7447

6563

1.13

2.2x10-2

2.3x10-6

amorphous

PEG114-PCD29

13561

13342

11636

1.15

3.6x10-4

2.6x10-8

crystalline

PEG114-PCD16

10248

11794

9590

1.23

9.0x10-4

8.7x10-8

crystalline

PEG114-PCD6

6968

6580

6203

1.06

1.4x10-3

2.0x10-7

crystalline

a. PEG-PBC: poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate); PEG-PCD: poly(ethylene glycol)block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol); PEG-PCC: poly(ethylene glycol)-block-poly(2-methyl-2carboxyl-propylene carbonate).
b. Mw and Mn was apparent molecular weight determined by GPC; PDI = (Mw / Mn) x 100%.
c. CMC (g/L) normalized with Mn from 1H NMR.
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Gel permeation chromatography (GPC) of polymers.

(1) PEG114-PCC30 [Mn = 6563 g/mol, Mw/Mn = 1.13]; (2) PEG114-PBC30 [Mn = 9703
g/mol, Mw/Mn = 1.15]; (3) PEG114-PCD29 [Mn = 11636 g/mol, Mw/Mn = 1.15].

103

A
Tg=-35.7Ԩ
PEG-PBC
Tc=6.3Ԩ
Tg=-30.7Ԩ

Tm=49.5Ԩ
PEG-PCC
PEG-PCD
Tm=51.7Ԩ

B
Tm=51.7Ԩ
Tm=53.6Ԩ

n=29
n=16
n=6

PEG114-PCDn
Tm=55.3Ԩ

Figure 6.5

Thermal analysis of polymers by DSC.

(A) Polymers of different core structures: PEG114-PBC30, PEG114-PCC30, and PEG114PCD29. (B) PEG-PCD polymers with different PCD core length: n = 6, 16, and 29.
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The observed Tg, Tc, and Tm in PEG-PBC indicate the existence of both amorphous
domain and crystalline domains in PEG114-PBC30, which is a semi-crystalline polymer.
We also calculated the degree of crystallinity based on the DSC peak areas, which was
57.1%. Different degrees of crystallinity of PEG114-PCC30, PEG114-PBC30, and PEG114PCD29, might be due to the different intermolecular forces among these three polymers
with different hydrophobic core structures. We also determined the effect of hydrophobic
core size on the Tm of PEG-PCD. As shown in Figure 6.5B, the Tm for PEG114-PCD29,
PEG114-PCD16, and PEG114-PCD6 were 51.7 Ԩ, 53.6 Ԩ, 55.3 Ԩ, respectively.
The polymers were further characterized by fluorescence spectroscopy to determine the
CMC (Figure 6.6). PEG114-PBC30 and PEG114-PCD29 had low CMC values of 4.0 x 10-4
g/L and 3.6 x 10-4 g/L, respectively. In contrast, the CMC of PEG114-PCC30 was 2.2 x 102
g/L, which was around 50 folds higher than those of PEG114-PBC30 or PEG114-PCD29.
The low CMC indicates the good stability of micelles prepared from PEG114-PBC30 and
PEG114-PCD29. The effect of hydrophobic core size on PEG-PCD micelle stability was
also determined. The CMC of PEG-PCD micelles decreased significantly from 1.4 x 10-3
g/L to 3.6 x 10-4 g/L, when the DP(n) increased from 6 to 29 (Figure 6.6B).
6.3.2.

Preparation and characterization of micelles

6.3.2.1. Drug loading efficiency
The amount of embelin loaded into polymeric micelles and loading efficiency were
calculated using the equations described in the experimental methods. As demonstrated in
Figure 6.7, PEG-PBC showed 2% drug loading at 5% theoretical loading, which
corresponds to 40% loading efficiency, in contrast, 5% drug loading was achieved by
PEG-PCD with different hydrophobic core lengths, which corresponds to 100% loading
efficiency. Increase in theoretical loading from 5% to 10% showed little effect on the
drug loading of PEG-PBC micelles and the loading efficiency decreased correspondingly.
However, the drug loading increased from 5% to 6% and 7% for PEG-PCD micelles,
when theoretical loading increased from 5% to 10% and 15%, with decrease in loading
efficiency from 100% to 60% and 50%, respectively. There was no significant difference
among three PEG-PCD lipopolymers with different hydrophobic core lengths.
6.3.2.2. Core-shell structure formation
1

H NMR spectroscopy was used to demonstrate the formation of core-shell of PEG-PCD
lipopolymer micelles (Figure 6.8). In CDCl3, peaks from both the hydrophilic PEG block
(3.6 ppm) and the hydrophobic core block (4.3, 4.1, 1.6, 1.2-1.4, and 0.9 ppm) was
observed. In D2O, all the peaks corresponding to the hydrophobic core block were
significantly diminished in contrast to the strong peaks for hydrophilic PEG block (Figure
6.8A). This is consistent with a core-shell structure with a collapsed hydrophobic core. In
addition, we also compared 1H NMR spectra of embelin loaded PEG-PCD lipopolymer in
CDCl3 and D2O. Although the specific peaks for embelin at 6 and 2.4 ppm was observed
when dissolved in CDCl3, they disappeared when they formed micelles in D2O.
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(A) Effect of hydrophobic core structure and length on drug loading and (B) loading
efficiency. Embelin loaded PEG-PBC and PEG-PCD micelles were prepared at 5, 10 and
15% of theoretical drug loading. (C) Encapsulation of embelin by PEG-PCD micelles as
a function of polymer concentration.
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These results indicate that PEG-PCD lipopolymer will form micelles in water with a PEG
hydrophilic shell and a hydrophobic core, and embelin is incorporated into the
hydrophobic core.
6.3.2.3. Physical appearance and particle size distribution
The physical appearance of blank and drug loaded micelles were shown in Figure 6.9A.
Both PEG-PCD and PEG114-PBC30 formed a translucent micelle solution, which was
stable at the room temperature and showed no precipitation on storage at the room
temperature for one week. In contrast, there was a milk-like suspension formation of
PEG114-PCC30 copolymer micelles and precipitation was observed after overnight storage
of these micelles. Also, the drug loaded micelles showed a pink color due to the
solubilized embelin (EM). The color observed in PEG114-PCD29 micelles was darker than
those of PEG114-PBC30 micelles prepared at same theoretical loading (5%). And this was
consistent with the high drug loading in PEG114-PCD29 micelles. We also determined the
particle size and size distribution of blank and embelin loaded micelles by dynamic light
scattering (Figure 6.9B). The blank and embelin loaded PEG114-PCB30 micelles had the
mean particle size of 74 nm and 64 nm, respectively. The particle size of blank and
embelin loaded PEG114-PCD29 micelles was 129 nm and 110 nm, respectively. There was
no increase in the mean particle size after embelin loading. In contrast, micelles formed
by PEG114-PCC30 showed a particle size of 204 nm. We also determined the particle size
of PEG-PCD with different PCD core length, the mean particle size were 129 nm for
PEG114-PCD29, 42.6 nm for PEG114-PCD16, and 25 nm for PEG114-PCD6, respectively.
6.3.2.4. Morphology of micelles
The morphology of micelles formed by PEG-PBC and PEG-PCD was determined by
transmission electron micrography (TEM) (Figure 6.10). PEG-PCD formed micelles with
different morphologies and sizes, depending on the ratio of hydrophobic core (Figure
6.10A-C). PEG114-PBC30 formed spherical micelles (Figure 6.10D). PEG114-PCD29
formed both spherical and cylindrical micelles with a diameter less than 50 nm, and the
cylindrical micelle was the dominant form. The contour length of the cylindrical micelles
ranged from several hundred nanometers to several micrometers. However, PEG114PCD16 and PEG114-PCD6, formed only spherical micelles. We also determined the
morphology of embelin loaded micelles prepared from PEG114-PCD6, PEG114-PCD16,
PEG114-PCD29, and PEG114-PBC30. In addition, the loading of embelin at 5% in PEGPCD and 2% at PEG114-PBC30, had no effect on the morphology of micelles (data not
shown).
6.3.2.5. In vitro drug release
The cumulative percentage of embelin released from PEG-PCD micelles with different
PCD block length was shown in Figure 6.11A. Similarity factors (f2) were calculated to
compare the drug release profiles of micelles with various hydrophobic core lengths. The
similarity factors were 63 (n = 6 Vs 16), 78 (n = 6 Vs 29), and 74 (n = 16 Vs 29),
respectively. Therefore, these micelles showed similar release profiles, since the release
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Physical appearance and particle size of micelles.

(A) Appearance of blank or embelin loaded micelles prepared from polymers with
different core structure and length (polymer concentration 5 mg/mL). (B) Mean particle
size of blank or embelin loaded micelles prepared from PEG114-PCD29, PEG114-PBC30,
and PEG114-PCC30. (C) Mean particle size of micelles prepared from PEG-PCD polymers
with different PCD core length: n = 6, 16, and 29.
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Figure 6.10

Transmission electron microscopy (TEM) of micelles.

Micelles were prepared from (A) PEG114-PCD6; (B) PEG114-PCD16; (C) PEG114-PCD29,
and (D) PEG114-PBC30.
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profiles are considered as the same, when the similarity factors are greater than 50. The
release of embelin from PEG-PCD micelles was fit to a first-order process for the first 24
h .The release half-life was around 12 h. The effect of hydrophobic core on embelin
release was also investigated (Figure 6.11B). The release of embelin from PEG114-PCD30
was significantly slower compared to PEG114-PBC30 with a similarity factor of 38. In
addition, the embelin release half-life from PEG114-PBC30 micelles was 4 h, which was
much shorter than that of PEG114-PCD30.
6.3.2.6. Bio-evaluation of drug loaded micelles
The anticancer activity of embelin loaded PEG-PCD micelles was determined in C4-2
prostate cancer cells. As shown in Figure 6.12, while blank PEG114-PCD29 polymer
showed negligible effect on cell proliferation at polymer concentration up to 0.3 mg/ml,
embelin loaded PEG114-PCD29 micelles showed significant inhibition of C4-2 cell
proliferation in a dose dependent manner, with the IC50 of 10 µM. The free drug
dissolved in DMSO showed similar anticancer effects to micelle formulated embelin
(data not shown). No direct comparison can be made with the results of embelin
formulated in micelles and dissolved in DMSO, as DMSO is known to kill tumor cells
and may not be suitable for in vivo applications. However, this finding is significant,
since the application of polymeric micelles could avoid the use of toxic solubilzing
agents such as DMSO, Cremophore EL and Tween 80.
6.4.

Discussion

Polymeric micelles can serve as a vehicle, which self-assemble into a core-shell structure
with a hydrophobic core capable of loading hydrophobic drugs [350, 351]. The stealth
properties associated with hydrophilic PEG corona of micelles prevent their aggregation,
restrict plasma protein adsorption, prevent recognition by the reticuloendothelial system
(RES), and minimize their rapid elimination from the bloodstream. The small size of
micelles ensures their accumulation preferentially in the tumor via EPR effects [323,
352]. However, successful micellar drug delivery into tumor requires the micelles remain
stable during blood circulation upon systemic administration. The stability of micelles
could be enhanced by crosslinking of the shell, core-shell interface, or the core of the
micelles [353-355]. However, the application of chemical crosslinked micelles is limited
due to the complexity of crosslinking process, possible effects on the structure and
properties of loaded drugs, and problems associated with drug release. Alternatively, the
stability of micelles could also be improved by engineering the structure of hydrophobic
block by introducing aromatic moieties [356, 357].
We have successfully synthesized PEG-PCD lipopolymer with two different approaches
(Figure 6.1). However, the first approach was selected due to the relative simplicity in the
synthesis process, which is critical for its application. In this synthesis approach, PEGPBC was synthesized by ring-opening polymerization of MBC in the presence of PEG
carrying a hydroxyl end group with one of the following catalysts: DBU, Sn(oct)2, and
Et2Zn (Table 6.1). Relatively lower reaction efficiency was observed with Sn(oct)2, and
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Et2Zn, this is due to the high reaction temperature and long reaction time required for
these two catalysts, which is usually associated with the potential polymer degradation
due to transesterification or backbiting side reaction [356, 358]. In addition, the use of
these metallic catalysts is also associated with safety issues due to the presence of trace
metal residue in the polymer. Therefore, DBU was used in the current study, which is
purely organic and suitable for the synthesis of biomaterials. Besides, the reaction was
carried out in solution and at room temperature, which is superior to bulk reaction that
usually results in broad polydispersity due to the inefficient mixing of reactants. To
optimize the reaction time, molecular weight of the polymer was monitored during the
reaction. We found that the reaction was almost completed after 3 h and the DP of
polymerization decreased after reaction for 24 h. This may be due to the occurring of
transesterification of polymer which becomes dominant when monomer is consumed
[358]. Therefore, the reaction time was set to 3 h to achieve optimal polymerization
efficiency and polydispersity. Subsequently, the benzyl groups in the PEG-PBC were
removed via hydrogenation to expose COOH function group. This reaction was also
carried out under at the room temperature to avoid the potential degradation of polymer
backbone, while still maintaining the high reaction efficiency to completely remove
benzyl groups. The dodecanol was conjugated to the COOH groups in the polymer
backbone through EDC/HOBT coupling chemistry with conjugation efficiency of around
95%. This is much higher than the previous report, where less than 70% of conjugation
efficiency was achieved in conjugating fatty acids to poly(ethylene glycol)-block-poly(βbenzyl-L-aspartate) through a link molecule [359]. Because of the commercial
availability of starting materials, simple synthesis procedure, and high reaction
efficiency, this synthesis procedure will have a broad application in the drug delivery and
bioengineering.
PEG-PCD lipopolymer synthesized in the current study has the polycarbonate backbone
and dodecanol was conjugated to this backbone with an ester bond. Therefore, this is a
biodegradable polymer, which is expected to degrade in vivo through hydrolysis of the
ester linkages. The hydrolysis of polycarbonate backbone was facilitated at the presence
of esterase such as lipase or cholesterol esterase [360, 361]. In addition, the final
degradation product was CO2, dual alcohol, dodecanol, and PEG5000, which have less
effect on pH change in vivo compared to poly(D,L-lactide) and thus are less likely to
cause inflammation [362]. These degradation products are non-toxic and could be
eliminated from the body.
PEG-PCD lipopolymer has multiple dodecanol lipid chains attached to the polycarbonate
backbone, which mimics the structure of interface crosslinked PEG-lipids (Figure 6.13)
and could enhance the hydrophobic interaction among the hydrophobic cores. Because
the crosslinking of micelles are known to improve stability, it is not surprising to observe
significantly reduced CMC values for PEG-PCD lipopolymer compared to conventional
PEG-lipid conjugates. Due to its low CMC value (~10-8 M), the concentration of PEGPCD in the bloodstream is expected to be much higher than the CMC value of PEG-PCD
after systemic administration, which indicates its good in vivo stability. Therefore, PEGPCD lipopolymer micelles can serve as an alternative to cross-linked PEG-lipid micelles
for in vivo drug delivery.
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Figure 6.13

Structure of PEG-lipid and lipopolymer PEG-PCD.
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Among PEG-PCD series, we found that the CMC decreased with increasing the number
of lipid in the hydrophobic core (Figure 6.6B). This is due to the increased length of
hydrophobic block, which is known to enhance the hydrophobic interaction among the
core block [363]. The effects of core structure were also investigated and the results
showed that the CMC of PEG-PCD or PEG-PBC was around 50 folds lower than
corresponding PEG-PCC (Figure 6.6A). This is because of the presence of hydrophobic
aromatic rings in PEG-PBC and lipid chains in PEG-PCD, which will all facilitate the
hydrophobic interaction within the core of micelles and promote the self-assembly of
polymeric micelles. However, PEG-PCC has a higher CMC due to the presence of
COOH group which significantly reduced the hydrophobicity of the core block.
Comparable CMC values were observed for PEG-PBC and PEG-PCD, though the
structure of PBC and PCD are significantly different (Figure 6.6A). Since the backbone is
the same for PEG-PBC and PEG-PCD, the close similarity in CMC values are due to
comparable contributions by the pedant phenyl rings in the PBC and the pedant
dodecanol carbon chain in PCD to the core block hydrophobicity.
Spherical, cylindrical, and vesicular assemblies are three commonly observed
morphologies of micelles prepared from amphiphilic block copolymers. Recently,
interest has shifted from spherical to cylindrical micelles, due to their longer systemic
circulation time compared to spherical micelles [364-366]. The cylindrical micelles
prepared from poly(ethylene glycol)-b-poly(caprolactone) (PEG-PCL) showed
significantly longer circulation time than that of spherical micelles prepared from the
same polymer and was persistent up to several days after intravenous injection [364]. In
addition, paclitaxel loaded cylindrical micelles were more effective to induce apoptosis
and reduce the tumor size in tumor bearing mice [365, 366]. Several approaches have
been investigated to control the morphology of micelles, including kinetic control [367],
the use of interfacial instability [368], aromatic oxidation [369], and the use of nanopore
extruder [370]. The most important parameter that determines the morphology and
architecture of micelles is the copolymer composition and volume ratio between
insoluble and soluble blocks. Sumeet et al. have studied the effect of molecular size and
composition using poly(ethylene glycol)-b-poly(1,2-butadiene)(PEG-PB) as a model
diblock copolymer. These authors found that PEG-PB form spheres, cylinders, and
bilayers in water, sequentially, with decreased ratio of PEG block [371]. This could
explain the transition from spherical to cylindrical micelles with the increased
hydrophobic length of PEG-PCD. In the current study, the use of PEG-PCD29 with a PEG
ratio of 0.37 produced cylindrical micelles, while PEG-PCD6 (PEG ratio: 0.49) and PEGPCD16 (PEG ratio: 0.72) produced only spherical micelles. Although PEG-PCD29 formed
cylindrical micelles, PEG-PBC30, a polymer with similar hydrophobic core length did not
form cylindrical micelles but spherical micelles (Figure 6.10). This indicates that not only
the PEG ratio but also the structure of hydrophobic core determines the morphology of
micelles. Thus the morphology of micelles can be controlled by changing the length and
structure of hydrophobic core of polymer. The preparation of micelles of different
morphologies will help us to understand the effect of micelles morphology and their in
vivo biodistribution and bioactivities.
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The compatibility of core-forming block and the drug to be loaded is critical for drug
loading capacity [344]. One objective of this study was to design an engineered
polymeric micelle for improved solubilization and delivery of embelin based on the
polymer-drug compatibility. PEG-PCD showed significantly high embelin loading
capacity compared with PEG-PBC (Figure 6.7), although these two polymers have
similar CMC value and comparable thermodynamic stability. The compatibility is highly
dependent on the three-dimensional arrangement and conformation of different groups in
the structure of drug and polymer core [357]. Figure 6.14 illustrates the structure of
embelin and the repeating units of PEG-PBC and PEG-PCD hydrophobic core block. In
contrast to PEG-PBC, the structure of the repeating unit of PEG-PCD is similar to that of
embelin. A similar finding was reported previously, where the attachment of cholesterol
to the poly(caprolactone) block of a poly(ethylene glycol)-b-poly(caprolactone)
copolymer significantly improved the loading of cucurbitacin I, which is similar to
cholesterol in the structure [357]. Our previous data also showed that the introduction of
carbonate moiety into a PEG-PLA copolymer significantly increased the micellar
solubility and loading of bicalutamide into micelles [344]. In this study, we also found
that PEG-PCD lipopolymers with different core block length (repeating unit number
ranges from 6 to 29) did not show significant difference in the drug loading (Figure 6.7).
Although an increased drug loading efficiency was observed with increased length of
PCL blocks in PEG-PCL polymer [372], this may not be applicable for PEG-PCD, which
has a highly branched structure in contrast to the linear structure of PEG-PCL. In fact, a
good drug loading was observed in PEG-lipid conjugates with much shorter hydrophobic
core length [337], indicating that the further increase in hydrophobic length might not be
able to improve the drug loading of lipopolymers with similar structure as PEG-PCD.
Similarly, we also observed there was no significant difference in the in vitro drug release
profiles among these PEG-PCD polymers with different block lengths (Figure 6.11A).
The drug release profiles of polymeric micelles are influenced by several factors
including strength of the interaction between drug and hydrophobic core, physical state of
the core, the amount of drug loaded, the length of hydrophobic core, and the location of
drug inside the micelle core [363]. In addition, the highly branched structure in the
hydrophobic core of PEG-PCD may have contributed to the observation in this study. We
also found that the release of embelin from PEG-PCD was much slower than that from
PEG-PBC (Figure 6.11B). This might due to the fact that the interaction between PEGPCD and embelin was stronger than those of PEG-PBC and embelin.
6.5.

Conclusion

We have successfully synthesized a novel lipopolymer poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate–graft-dodecanol) (PEG-PCD) for
delivery of a hydrophobic anticancer drug, embelin. PEG-PCD lipopolymer could form
micelles in water through self-assembly and significantly improved embelin solubility by
loading drugs inside its hydrophobic core. The drug loading and encapsulation efficiency
were dependent on the length and structure of polymer hydrophobic core block. The
CMC of PEG-PCD micelles was around 10-8 M and decreased with increasing the length
of hydrophobic block, indicating good thermodynamic stability of PEG-PCD micelles.
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Structure of embelin and repeating unit of hydrophobic core.
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The particle size and morphology of micelles were also dependent on the structure and
length of hydrophobic core. Embelin loaded PEG-PCD micelles showed significant
inhibition of C4-2 prostate cancer cell proliferation in a dose dependent manner, while no
obvious cellular toxicity was observed with blank micelles themselves. Thus, these
lipopolymer have the potential to be used as vehicles for anticancer hydrophobic drug
delivery.
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CHAPTER 7. PACLITAXEL AND LAPATINIB LOADED LIPOPOLYMER
MICELLES OVERCOME MULTIPLE DRUG RESISTANCE IN PROSTATE
CANCER
7.1.

Introduction

Prostate cancer is the second common male cancer in the United States. More than
186,000 American men learn are diagnosed to have prostate cancer each year
(http://www.cancer.gov/cancertopics/wyntk/prostate). Although the majority of patients
respond well to androgen ablation therapy, chemotherapy, and radiotherapy at the
beginning, many patients relapse over time and become resistant to chemotherapy [373,
374]. This is mainly due to the over-expression of multiple drug resistant (MDR)
transporters in prostate cancer cells (Figure 7.1). These transporters, such as P-gp, breast
cancer resistance protein (BCRP), and multiple drug resistance protein (MRP), increase
drug efflux and reduce drug accumulation in tumor cells [375, 376].The prognosis of
patients with MDR cancer is poor, due to the lack of effective clinical interventions.
Thus, there is an urgent need for effective therapies for MDR prostate cancers. Several
strategies have been used to overcome MDR, including developing of novel anticancer
agents [348], using novel delivery systems, such as liposomes [377], solid lipid
nanoparticles [327], polymer-drug conjugates [324], and the use of MDR transporter
inhibitor [378].
Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor 2 (Her-2) tyrosine kinases, was approved by the FDA
for the treatment of advanced breast cancers [379]. Studies indicate that lapatinib can
inhibit the function of ATP-binding cassette (ABC) transporters, and thus sensitize MDR
cancer cells to chemotherapeutic agents (Figure 7.1) [380-382]. Lapatinib has also been
reported to decrease the percentage of cancer stem cells and improved the long term
survival of patients [383]. Therefore, the combination of lapatinib and paclitaxel provides
a new regimen for treating MDR cancers [380].
Polymeric micelle is a recently developed drug delivery system and prepared from
amphiphilic diblock copolymers. It forms a core-shell structure by self-assembly. The
hydrophobic core of micelles is capable of loading hydrophobic drugs, and thus avoids
the use of toxic solubilizing agents in the delivery of poorly soluble anticancer drugs
[350, 351]. The stealth properties associated with hydrophilic PEG corona of micelles
prevent their aggregation, restrict plasma protein adsorption, prevent recognition by the
reticuloendothelial system (RES), and minimize rapid elimination from the bloodstream.
The small size of micelles ensures their accumulation preferentially in the tumor via EPR
effects [323, 352]. In order to targeted deliver drugs into tumors, the micelles need to be
stable in the blood circulation. The stability of micelles can be improved through the
engineering of the hydrophobic core. In our previous study, we designed a lipopolymer
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graftdodecanol) for micelle drug delivery. This lipopolymer showed significantly improved
stability and good drug loading for many poorly soluble drugs [384] .
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In the current study, we used lipopolymer PEG-PCD micelles to formulate lapatinib and
paclitaxel. Firstly, we optimized the micelle formulation and characterized the
formulation with analytical and biophysical methods. Then, the anticancer effects of
lapatinib and paclitaxel micelle formulations were determined with in vitro cell-based
assays, focusing on their effects on overcoming MDR in prostate cancers. We also tested
their abilities to inhibit of MDR growth in vivo with athymic mice xenograft tumor
models established with the MDR prostate cancer cells.
7.2.

Materials and Methods

7.2.1.

Materials

Hydroxybenzotriazole (HOBT), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),
dodecanol, triethylamine (TEA), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 2,2bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG, Mn = 5000,
PDI = 1.03) and all other reagents were purchased from Sigma Aldrich (St. Louis, MO)
and used as received. DU145-TXR cells were provided by Professor Evan T. Keller of
the University of Michigan.
7.2.2. Synthesis of lipopolymer poly(ethylene glycol)-block-poly(2-methyl-2carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD)
Lipopolymer PEG-PCD was synthesized as described by Li et al. [384]. Firstly,
poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate)
(PEG-PBC) was synthesized through a ring-opening polymerization from monomer
MBC, using mPEG as macro imitator and DBU as a catalyst. Then, protective benzyl
groups in PEG-PBC was removed by hydrogenation to get poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate) (PEG-PCC). Finally, lipopolymer PEGPCD was obtained after conjugation of dodecanol lipid pendant groups to PEG-PCC.
Lipopolymers and intermediate polymers were characterized with following methods. (1)
Nuclear magnetic resonance (NMR). 1H NMR spectra were recorded on Varian (500
MHz) using deuterated chloroform (CDCl3) as a solvent unless otherwise noted. The
chemical shifts were calibrated using tetramethylsilane as an internal reference and given
in parts per million. (2) Gel permeation chromatography (GPC). The weight (Mw) and
number (Mn) average molecular weight and polydispersity index (PDI) of synthesized
polymers were determined by a Waters GPC system equipped with a GPC column (AM
Gel 103/5) and a differential refractive index detector. THF was used as an eluent at a
flow rate of 1 mL/min. A series of narrow polystyrene standards (700 – 40,000 g/mol)
were used for calibration.
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7.2.3.

Preparation and characterization of lipopolymer micelles

7.2.3.1. Preparation of lipopolymeric micelles
Lipopolymer micelles were prepared with a film dispersion method as previously
reported with some modifications [348]. Briefly, 30 mg of polymers and given amount of
drugs were dissolved in 0.5 mL CH2Cl2, and then the solvent was removed under reduced
pressure. The resulting film was hydrated in 3 ml saline (0.9%) and sonicated for 1 min.
Then, the residue free drug was removed by centrifugation at 12,000 rpm for 5 min. The
supernatant was filtered using a 0.22 µM filter.
7.2.3.2. Drug loading and encapsulation efficiency
To determine drug loading, 10 µL of drug loaded micelle solution was diluted with
acetonitrile. Then drug concentration was determined using a reverse phase high
performance liquid chromatography (RP-HPLC, Waters, Milford, MA) with UV detector
at 227 nm. A C18 column (250 mm 4.6 mm, Alltech, Deerfield, IL) was used. The
mobile phase was composed of 50:50 V/V water and acetonitrile at 1 mL/min. Lapatinib
and Paclitaxel concentration was calculated based on peak area.
7.2.3.3. Measurement of particle size
The particle size distribution of micelles was determined by dynamic light scattering with
Malvern Nano ZS. The intensity of scattered light was detected at 90 °.
7.2.4.

MTT assay

Drug resistant prostate cancer cell DU145-TXR was used to determine the cell growth
inhibition ability of drug-loaded micelles. Cells were cultured in DMEM media
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic at 37 ℃
in humidified environment of 5% CO2. Cells were seeded in 96-well plates at a density of
5,000 cells per well. At the end of treatment, cell culture medium was replaced by 100 μL
medium with 0.5 mg/mL MTT (3-(4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide and incubated for 1 h at 37 °C. Then medium was removed and 200 μL of
DMSO was added into each well to dissolve the formazan crystals. The absorbance was
measured in a microplate reader at a wavelength of 560 nm. Cell viability was expressed
as the percentage of control group. Cell viability (%) = (Atest ⁄ Acontrol) × 100%.
7.2.5.

Calcein AM assay

Cells were seeded into a black wall clear bottom 96-well plate at a density of 20,000 cells
per well one day before experiment. After treating cells with various concentration of test
compounds in 50 μL DPBS for 20 min at 37 ℃, 50 μL Calceim AM (10 μM) in DPBS
were added to each well and incubated at 37 ℃ for additional 20 min. Fluorescence
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intensity in each well were determined using a SpectraMax M2/M2e spectrofluorometer
(Sunnyvale, CA) at the excitation wavelength of 494nm and emission wavelength of 517
nm.
7.2.6.

Propidium iodide staining and cell cycle analysis

Cells were cultured in a 24-well plate to 90% confluence and then treated for 24 h. Cells
were trypsinized and fixed in 70% ice-cold ethanol. After washing with PBS, cell pellet
was re-suspended in 5 µg/mL propidium iodide staining solution for 15 min at room
temperature. Cell cycle distribution was measured by flow cytometry (Becton, Dickinson,
NJ). Results from 10,000 fluorescent events were obtained for analysis.
7.2.7.

TUNEL assay

TdT-mediated dUTP Nick End Labeling (TUNEL) assay was performed using DeadEnd
Fluorometric TUNEL System (Promega, Madison, WI). Briefly, DU145-TXR cells were
grown on Lab-tek chamber slide and treated with lapatinib, paclitaxel, and their
combination for 24 h. At the end of treatment, cells were fixed with -20 °C acetone for 10
min, washed with PBS, and equilibrated with buffer at RT for 10 min. Then, it was
incubated with staining agent composed of nucleotide and rTdT, in a humidified chamber
at 37 °C for 1 h and protected from light. The reaction was terminated with 2 X SSC
buffer and washed with PBS to remove unincorporated fluorescein-12-dUTP. The
washed specimens were then counterstained with DAPI and visualized with Zeiss
AxioVision fluorescent microscope.
7.2.8.

In vivo anticancer efficacy study

All animal experiments were performed in accordance with NIH animal use guidelines
and the protocol approved by the Animal Care and Use Committee at the University of
Tennessee Health Science Center. Xenograft flank tumors were established in 8 week old
male athymic nude mice (Charles River) by subcutaneously injection of five million
DU145-TXR prostate cancer cells suspended in 1:1 media and matrigel. When tumors
reached approximately 100 mm3, mice were randomized assigned to different treatments.
Drugs were administrated through tail vain injection. Tumors were measured with a
caliper prior to each injection, and their volumes were calculated using the formula:
(width2 × length) / 2. At the end of study, tumor tissue was excised from the mice and
weighted.
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7.3.

Results and Discussion

7.3.1.

Effect of lapatinib and paclitaxel on MDR prostate cancer cells

We determined whether lapatinib could reverse MDR in prostate cancer cells. Paclitaxel
resistant prostate cells DU145-TXR were treated with the combination of paclitaxel and
lapatinib. As shown in Figure 7.2, the IC50 of paclitaxel was 2069 ± 597 nM in the
absence of lapatinib, indicating DU145-TXR cells were resistant to paclitaxel. However,
the IC50 of paclitaxel decreased to 79 ± 29 nM, at lapatinib concentration of 1 µM, and to
15 ± 8 nM at lapatinib concentration of 5 µM. Fold of reversal was 26.2 and 138 at the
lapatinib concentration of 1 µM and 5 µM, respectively. The results showed that lapatinib
can reverse the sensitivity of DU145-TXR to paclitaxel. This study proved the feasibility
of using lapatinib and paclitaxel combination to overcome MDR in prostate cancers.
7.3.2. Preparation of paclitaxel and lapatinib loaded PEG-PCD lipopolymer micelle
formulations
7.3.2.1. Synthesis and characterization of PEG-PCD lipopolymer
PEG-PCD lipopolymer were synthesized according our previous developed methods. The
synthesized PEG-PCD lipopolymer were characterized with 1H NMR, GPC. The Mn
calculated based on 1H NMR is 11560. We also used GPC to determine the apparent Mn
and Mw of lipopolymer PEG-PCD, which was 10800 and 14986, respectively.
7.3.2.2. Preparation and characterization of drug loaded lipopolymer formulations
A film dispersion method was used to prepare lipopolymer micelles. The paclitaxel and
lapatinib drug concentration in the formulations were determined with a HPLC method.
Due to the different retention time for paclitaxel (4.7 min) and lapatinib (7.1 min), we can
simultaneously determine the concentration of these two drugs (Figure 7.3A). We first
tested the ability of lipopolymer PEG-PCD micelles to load a single drug of paclitaxel or
lapatinib. As shown in Figure 7.3B and C, both paclitaxel and lapatinib can be effectively
loaded into lipopolymer micelles. For both of these two drugs, the final drug
concentrations in the formulation increase from around 0.5 to 2 mg/mL with increased
theoretical loading (weight ratio of initial drug/polymer) from 5% to 20%. The drug
loading efficiency were around 100%, indicating all the drugs can be effectively loaded
into micelles at this range. Based on above findings, we developed several lipopolymer
micelle formulations to simultaneously load paclitaxel and lapatinib. As shown in Figure
7.3D, we could simultaneously load both paclitaxel and lapatinib into lipopolymer
micelles and reach final drug concentration to at least 1 mg for each drug. The drug
loading efficiencies were also around 100% for both drugs in all of these three
formulations. We also determined the particle size of lipopolymer micelles with or
without drug. The particle size was around 60 nm for all the tested formulations and the
incorporation of drugs had almost no effect on particle size.
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concentration in paclitaxel and lapatinib co-loaded lipopolymer micelles.
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7.3.3. Inhibition of MDR prostate cancer cell proliferation by paclitaxel and lapatinib
loaded lipopolymer micelles
The anticancer effect of paclitaxel and lapatinib loaded lipopolymer micelles were first
tested in vitro with MDR prostate cancer cells DU145-TXR (Figure 7.4). No obvious
toxicity was observed in cells treated with blank micelles, lapatinib (2 µM), or paclitaxel
(0.5 µM) alone for 48 h, while the combination of lapatinib (2 µM) and paclitaxel (0.5
µM) significantly reduced cell viability to around 23% of the control group. In addition,
the combination of lapatinib (1 µM) and paclitaxel (0.25 µM) also showed significant
inhibition of DU145-TXR cell proliferation. (Cell viability was around 35% of the
control group). This study further confirmed the lapatinib and paclitaxel loaded
lipopolymer micelles formulation can overcome MDR in prostate cells and effectively
inhibit the proliferation of resistant prostate cancer cells in vitro.
7.3.4.

Inhibition of P-gp activity in MDR cancer cells by lapatinib

To understand the mechanism that lapatinib overcomes MDR in cancer cells, we
performed a calcein AM assay. Calcein AM assay was used to determine the effect of
lapatinib on P-gp activity [348]. The intracellular accumulation of calcein, which is a Pgp substrate with fluorescence, was observed with a fluorescence microscope and also
quantitatively determined by a spectrofluorometer. As shown in Figure 7.5A, lapatinib
treatment led to dose-dependent increase in intracellular calcein fluorescence. The
fluorescence intensity increased with increased lapatinib concentration from 0 to 20 µM.
We also quantitatively determined the fluorescent intensity with a spectrofluorometer
(Figure 7.5B). In the absence of lapatinib the fluorescence intensity was very low (around
50 RFU), however, it increased to around 800 RFU at a lapatinib concentration of 20 µM.
In contrast, treatment with blank PEG-PCD lipopolymer micelles showed neglectable
effect on intracellular accumulation of calcein fluorescence. Since calcein AM is a P-gp
substrate, the observed results indicate that lapatinib works as an inhibitor of P-gp,
reduces the P-gp substances efflux, and thus increases the intracellular accumulation of
P-gp substances (Such as paclitaxel).
7.3.5. Effect of paclitaxel and lapatinib loaded micelles on cell cycle and apoptosis of
MDR prostate cancer cells
We also determined the effect of lapatinib and paclitaxel loaded lipopolymer micelles on
DU145-TXR cells by analyzing cell cycle distribution and cell apoptosis with a flow
cytometry. Cells were treated with different formulations for 24 h before analysis. As
shown in Figure 7.6, the treatment of lapatinib (2 µM) or paclitaxel (0.5 µM) alone had
no effects on the cycle distribution, in contrast, their combination showed significant
effects on cycle distribution and cell apoptosis. The treatment of lapatinib (2 µM) +
paclitaxel (0.5 µM) caused cells in G0/G1 phase decreased from 29.0 ± 2.1 % in control
group to group to 4.7 ± 0.2 % in the combination group. Meanwhile, cells in G2/M phase
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Anticancer effect of paclitaxel and lapatinib combination on MDR
DU145-TXR cells.
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Effect of paclitaxel and lapatinib combination on cell cycle and
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were increased from 50.7 ± 4.0 % in control group to 61.1 ± 1.2 % in the combination
group. In addition, the apoptotic subG1 phase cells increased from 0.4 ± 0.2 % in the
control group to 25.1 ± 2.5 % in the combination group. These results indicated that the
cells treated with above combination therapy were failed to undergo mitosis. This is
consistent with the anticancer mechanism of paclitaxel, which is a microtubule inhibitor
and can cause the arrest of the cell cycle at mitotic phase. The increased cell population
in subG1 phase indicated that apoptotic cells were increased after treating with
combination therapy [332332]. We also used TUNEL assay to further confirm that the
combination of paclitaxel and lapatinib induced apoptosis in DU145-TXR cells. TUNEL
is a method for detecting DNA fragmentation by labeling the terminal end of nucleic
acids. As shown in Figure 7.7, neither paclitaxel (0.5 µM) nor lapatinib (2 µM) alone
caused apoptotic cell death in DU145-TXR cells, while the combination of paclitaxel (0.5
µM) and lapatinib (2 µM) induced significant cell apoptosis.
7.3.6.

Lapatinib and paclitaxel loaded lipopolymer micelles overcome MDR in vivo

Encouraged by the in vitro anticancer effect of lapatinib and paclitaxel loaded
lipopolymer micelles in MDR prostate cancer cells. We decided to test their ability to
overcome MDR in vivo using athymic nude mice xenograft model established with
DU145-TXT MDR prostate cancer cells. When tumors reached approximately 100 mm3,
mice were randomized assigned to two groups of four mice. Mice were treated with tail
vain injection of lipopolymer micelle formulations at a dose of paclitaxel (10 mg/kg) in
monotherapy group or paclitaxel (5 mg/kg) + lapatinib (5 mg/kg) in combination therapy
group, respectively. In contrast to paclitaxel monothearpy, the lapatinib and paclitaxel
combination therapy significantly inhibited in vivo tumor growth (Figure 7.8A). We also
determined the weight of tumor at the end of the study, which also showed that the
weight of tumors in combination group were significantly less than those in the paclitaxel
monotherapy group (P < 0.05, Figure 7.8B). In addition, we did not observe any mortality
and significant decrease body weight in mice after drug administration, indicating the
neglectable toxicity of lipopolymer micelle formulations used in this study (Figure 7.8C).
7.4.

Summary and Conclusion

Paclitaxel and lapatinib loaded lipopolymer micelle formulations were developed, which
showed high drug loading efficiency. These lipopolymer micelle formulations have a
particle size of around 60 nm and narrow size distribution. In vitro cell-based studies
showed that paclitaxel and lapatinib loaded lipopolymer micelles can overcome MDR in
prostate cancers. The paclitaxel (0.5 µM) and lapatinib (2 µM) combination effectively
inhibited DU145-TXR cell proliferation in vitro, induced cell cycle perturbation and cell
apoptosis. In contrast, monotherapy with paclitaxel (0.5 µM) or lapatinib (2 µM) alone
showed almost no effect on DU145-TXR cells. Effect of combination therapy was further
investigated in vivo with athymic nude mice xenograft tumor model established with
MDR prostate cancer cells. Similar to in vitro study, paclitaxel (5 mg/kg) + lapatinib (5
mg/Kg) combination therapy significantly inhibited tumor growth in vivo compared with
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Paclitaxel and Lapatinib combination induced cell apoptosis in DU145-TXR Cells.
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paclitaxel 0.5 µM + lapatinib 2 µM. After 24 h treatment, cells were subject to TUNEL
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In vivo anticancer effect of paclitaxel and lapatinib loaded
lipopolymer micelles on xenograft MDR prostate tumors.
MDR xenograft athymic tumor models were established with DU145-TXR prostate
cancer cells. When the tumor size reaches 100 mm3, mice were given intravenously
injection of lipopolymer formulations on day 0, 3, and 4, respectively. The dose was 10
mg/Kg paclitaxel for paclitaxel monotherarpy group, 5 mg/kg each of lapatinib and
paclitaxel in combination therapy group. Tumor growth was measured with a caliper and
tumor size was calculated using the formula: (width2 × length)/2 (A). At the end of study,
tumor tissue was excised from the mice and weighted (B). Meanwhile, the body weight
of mice were also determined (C). Points are mean tumor size (n = 4); bars, SE. *, p <
0.01, **, p < 0.05.
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high dose paclitaxel (10 mg/kg) monothearpy. These studies indicate that the paclitaxel
and lapatinib loaded PEG-PCD lipopolymer micelle formulations could be used to treat
MDR prostate cancers.
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